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1. Preface and objectives 
The main subject of this PhD thesis belongs to the use of nanostructured carbon material for different 
goals. Graphene oxide (GO) and oxidized multiwalled carbon nanotubes (CNTs) have been exploited for 
covalent and adsorption decoration to achieve systems profitable in several areas, such as 
nanomedicine or organocatalysis. GO and CNTs represent good platform thanks to their deep versatility, 












Figure 1. Different applications of CNTs and GO  
In the first part of my PhD I have been involved in a project concerning the design and synthesis of a 
Drug Delivery System.1 This system was based on short oxidized multiwalled carbon nanotubes, as a 
device suitable for cancer treatment. A multimodal approach was chosen, targeting both metabolism 
and proliferation of tumor cells with two different drugs, in such a way to address cells of different sub-
populations of the tumor: proliferative and staminal cancer cells (stem cells).  
The synthetic approach, exploiting the chemical flexibility of carbon nanotubes, was planned in a way 
to decorate the delivery system with the highest quantities of two different drugs (metformin and 
doxorubicin), and a targeting component, a small molecule reported to increase tumor uptake (biotin). 
(Figure 2) Then, with minor changes to the synthetic protocol, the system was modified to study the 
pharmacokinetic in tumor bearing mice models The biological properties of these systems were studied 
thanks to the collaborations with the Department of Clinical and Experimental Biomedical Sciences, 
which carried out in vitro studies, and with the University of Texas MD Anderson Cancer Centre for the 

















Figure 2. Structure of the designed DDS. 
The first cytotoxic drug, doxorubicin, was loaded on DDS exploiting the supramolecular chemistry, due 
to formation of π-π stacking interaction between the anthracycline moiety of doxorubicin and the π-
system on the CNTs. Another chemical approach was exploited to load metformin. The drug was 
covalent bund to CNTs by exploiting the carboxyl groups on nanostructured material after their 
activation.  
The major limitation observed for the described system consisted in the lack of metformin release after 
the internalization into cell, which caused a no combined effect.  
To overcome this problematic two DRUG DELIVERY SYSTEM MODELS based on CNTs and GO were 
designed and synthesized. In these MODELS one or more cytotoxic drugs will be covalent attached on 
carbon material through disulfide linkers, labile in intracellular environment. These systems will afford 
a modulated release of molecular fragments (drugs) attached on CNTs or GO through the linkers. To 
verify the correct internalization into cells of our DDS and the efficiency in the use of disulfide linker we 
synthesized a MODEL SYSTEM decorated with two BODIPY dies, different in conjugation, one of which 









Figure 4: Structure of model of DDS 
BODIPY probes represent excellent substrates both for their fluorescence and for the possibility to 
modify their structure to achieve different purposes. We performed the modification of BODIPY dye 
through first amino acids conjugation, then peptides addition, such as the conjugation with RGD 
sequence. The final goal will be the use of BODIPY-PEPTIDES as selector for DDS, increasing the uptake 
of the system into cancer cells, and, at the same time, exploiting the fluorescence properties of BODIPY. 













Figure 5: BODIPY conjugated with RGD sequence covalent bund on CNTs/GO. 
In addition to the use of a linker to bind the drug, an alternative possibility to overcome the lack of 
metformin release observed for our first DDS (Figure 2) may be a change in the chemical approach to 
decorate CNTs. Metformin could be adsorbed on CNTs instead of covalent bund to the material. To 
increase the interaction of drug with the carbon platform, the organic molecule should be modified, to 







Figure 6: Biguanide derivative adsorbed on CNTs. 
The activity of the derivative will be studied and compared to metformin activity. 
CNTs should be the base of our ARTIFICIAL SPONGES consisting of CNTs decorated with polycationic 
molecules able to form stable complexes with proteoglycans, inhibitory substrates for the regeneration 
of injured spinal cord tissue. These nano-platforms could be the channel to remove proteoglycans from 
the medium, thanks to the addition of magnetic nanoparticles the entire systems may be moved away 







Figure 7: Representation of nano-sponges. 
Nanostructured carbon material, as previously presented, could be profitable support for DDS, useful 
in nanomedicine, but also versatile substrate for different purposes. The covalent decoration of CNTs 
with organophosphorus moieties afforded catalysts for chemical reactions in HETEROGENEOUS phase, 












Figure 8: Example of catalysts based on CNTs decorated with organophosphorus moieties 
The FUNCTIONALIZATION of GO should be performed in liquid phase, as previously presented for DDS 
based on GO, but also by mechanical chemistry via Ball Milling. This procedure allowed to avoid the use 

























2. Fluorescent probes linked to carbon nanotubes and 
graphene oxide through a disulfide bridge: viability 
study for drug delivery 
 
2.1 OBJECTIVES OF THIS CHAPTER (2) 
This project has two main objectives that aim to design and synthesize two model systems for a viability 
studies for drug delivery systems. In particular, the first one is to develop a multifunctionalization 
procedure on oxide carbon nanotubes (CNTs) for future biomedical application. In addition to chemical 
strategies to reproduce the same designed system, but on graphene oxide (GO) have been investigated 
as second goal.  
In Figure 1 was reported the desired system. 
. A central backbone consisted in a nanostructured carbon material: oxidized carbon nanotubes (CNTs) 
for the first part of the project, GO for the second one. 
. A BODIPY dye, with a maximum adsorption at 640 nm. This probe will be essential to verify the effective 
internalization of the system into cell. 
. A BODIPY dye with a disulfide linker reactive in intracellular environment, due to the high 
concentration of endogenous thiols in cancer cells, such as glutathione. Maximum adsorption of the 
modified dye at 529 nm. 
. Polyethylene glycol chain to improve cells uptake.  
 
Figure 1. Model system for DDS. 
The first goal of this model system is to demonstrate that in the environment melanoma cancer cells, 
the molecular fragment attached through a disulfide bond could be released. This study represents a 
viability study to build systems of drug delivery (Figure 2) in which the drug is anchored to the 
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nanostructured material with a covalent bond that can only be broken after a cellular internalization. 
PEG chain will be bund to a specific selector, such as a peptide, useful to increase cell uptake of drug. 
Due to the interest in their applications as drug nanocarriers, CNTs and GO were chosen.  Their ability 
to cross cell membrane is independently of the kind of chemical groups on carbon surface, as well as 
the cell type selected.2 
 
Figure 2. Future DDS. 
The second goal is a comparison of the preliminary models for DDS made of CNTs or GO. The loading 
degree of BODIPY dye and BODIPY-linker on nanostructured carbon material were investigated and 
compared. 
2.2 INTRODUCTION 
2.2.1 CARBON NANOMATERIAL 
Difficulties in overcoming the limited control over biophysical and biochemical characteristics in 
traditional biomaterials have hampered their use in biomedical applications.3 This pushed the research 
of novel materials showing multiple properties that allow advanced functionalities. In this respect, 
carbon nanostructures (CN) thanks to the multiple uncommon properties, have had an impressive 
impact on scientific research with important technological implications. Carbon is one of the prototypal 
elements showing an organization in different allotropic forms (as sketched in Figure 3), carbon 
nanostructures (CN) consist of sp2 carbon atoms with different spatial arrangements:4  from the zero-
dimension fullerenes and carbon quantum dots, to the one dimensional CNTs, to the two-dimensional 
graphene atomic sheet, to the 3D bulk graphite or diamond crystals where atoms are pure sp2 or sp3 





Figure 3. Carbon allotrpes 
 
Thanks to electrical, chemical, and mechanical properties of these systems, have led to a number of 
different types of applications. Concerning biology and biomedicine, the big potential of carbon 
nanomaterials is the possibility to tune the CNS dimensions, the capability to functionalize the surface, 
and the high chemical stability coupled to the optical and biomimetic properties. As an example, CNTs 
and fullerenes soon after their discovery have been studied for biosensing, drug delivery, and 
bioimaging. Recently they experienced a revival for their application in the regenerative medicine,5 
cancer therapy, and theranostic applications.6 
 
2.2.2 CARBON NANOTUBES (CNTs) 
Carbon Nanotubes (CNTs) are one kind of carbon allotrope which has a seamless hollow cylindrical 
shape. Like carbons in graphene, carbon atoms in CNTs are also bonded with three neighboring carbon 
atoms in a sp2 configuration forming the hexagonal units. Conceptually, CNTs are considered as rolled-
up graphene sheets in certain directions. The rolling up of single-layer graphene and multi-layer 
graphene form single-wall CNTs (SWCNTs) and multi-wall CNTs (MWCNTs), respectively. Their structure 
makes them suitable for a wide variety of applications ranging from electronics to biomedical.7,8 
 
A list of properties of this carbon nanostructured material was reported below: 
I. The high surface area and the hollow structure make CNT suitable for drug loading, but 
also as nano-adsorbents for the scavenging of metallic ions and organic compounds from 
aqueous solutions.  
II. The ease functionalization of CNTs allow their modification and tailoring for several 
different applications.9–11 
III. The excellent conductive profile offers a unique platform for the development of sensors 
and biosensors10 as well as a large number of applications in electronic devices.  
IV. Their mechanical strength has promoted them as reinforcement additives in polymeric 




The most preferred technique to produce CNTs was represented by chemical vapor deposition (CVD). 
This process involves the pyrolysis of hydrocarbons, or other carbon feedstock carried out in a stream 
of inert gas into a chamber with a metal catalyst (Ni, Fe and Co). Numerous parameters influence CVD; 
the control of these variables (temperature, gas pressure, presence of inert gas) allows to modify some 
CNTs feature such as diameter, length and alignment. Catalytic decomposition of methane at 680°C for 
120’, using nickel oxide–silica binary aerogels as catalyst was exploited to achieve MWCNTs. The 
diameter of synthesized CNTs was found to be dependent on the temperature; as the temperature 
increased, the diameter also increased.  Essential is to remove metal catalyst impurities which could 
influence material’s properties. 8 It is difficult to separate single CNTs and make stable biocompatible 
solutions in most solvents, especially not possible in water. Surface functionalization has provided 
efficient solutions to solve this problem. 
 
Functionalization is fundamental to provide material suitable for widespread applications thanks also 
to the possibility to remove residues of metallic catalyst.  
 
2.2.3 FUNTIONALIZATION OF CARBON NANOTUBES  
Thanks to their unique properties, CNTs are expected to be versatile nanomaterials for biomedical 
application. As previously mentioned surface functionalization could also provide efficient intracellular 
uptake and increase the possibility of the attachment of different functional groups onto the surface of 
CNTs for biomedical applications.13 CNTs functionalization can be generally divided into two groups: 




The covalent functionalization process involves several chemical reactions, through which covalent 
chemical bonds are formed between CNTs and the entities for functionalization. They can be divided 
into two categories: (i) oxidation and end/defect functionalization, and (ii) side wall covalent 
functionalization. 
 
The first step in the functionalization of CNTs is the oxidation of the material. This process cuts tubes 
into short pieces and removes impurities inside CNTs, such as amorphous carbon and metallic catalysts. 
At the same time, it opens the tube ends of CNTs and brings in tube-end oxygen functional groups, such 
as carboxylic acid, ketone, alcohol, and ester groups. Meanwhile the oxidation process generates 
defects on the tube wall, for example holes with oxygenated functional groups.14 
A chemical method to achieve oxidized material is the addiction of an acid mixture (HNO3/H2SO4).15 
(Figure 4) Successive modifications were reported in Figure 4 through four reaction pathways. The first 
decoration consisted in the formation of CNTs-carboxylate zwitterion.16,17 The second modification is 
the amidation reaction exploited to graft R-NH2 on to CNTs. Before the synthesis of amide an activation 
of carboxyl groups is required by using SOCl2 or coupling reagents. Lastly through an esterification 






Figure 4. Different chemical reactions for end functionalization of CNTs.4 
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Side wall covalent functionalization of CNTs usually involves the breaking of sp2 bonding networks to 




Several techniques have been established for graphene synthesis. However, mechanical cleaving 
(exfoliation),18 chemical exfoliation19, chemical synthesis,20 and thermal chemical vapor deposition 
(CVD)21 synthesis are most commonly used methods today. Some other techniques are also reported 
such as unzipping nanotube22 and microwave synthesis; however, those techniques need to be explored 
more extensively. An overview of graphene synthesis techniques is shown in the flow chart in Figure 5. 
In 1975, few-layer graphite was synthesized on a single crystal platinum surface via chemical 
decomposition methods, but was not designated as graphene due to lack of characterization techniques 
or perhaps due to its limited possible applications.23  
 
Figure 5. Graphene synthesis methods. 
In 1999, mechanical cleaving of highly ordered pyrolytic graphite (HOPG) by atomic force microscopy 
(AFM) tips was first developed in order to fabricate graphene from a few layers down to a mono-atomic 
single layer.24 Nevertheless, mono-layer graphene was first produced and reported in the year 2004, 
where adhesive tape was used to repeatedly slice down the graphene layers on a substrate.18 This 
technique was found to be capable of producing different layers of graphene and is relatively easy to 
fabricate. Mechanical exfoliation using AFM cantilever was found equally capable of fabricating few-
layer graphene, but the process was limited to producing graphene of a thickness 10 nm, which is 
comparable to 30-layer graphene. Chemical exfoliation is a method where solution-dispersed graphite 
is exfoliated by inserting large alkali ions between the graphite layers. Similarly, chemical synthesis 
process consists of the synthesis of graphite layers. Similarly, chemical synthesis process consists of the 
graphite oxide, dispersion in a solution, followed by reduction with hydrazine. Like carbon nanotube 
synthesis, catalytic thermal CVD has proved to be one of the best processes for large-scale graphene 
fabrication. Here, thermally dissociated carbon is deposited onto a catalytically active transition metal 
surface and forms a honeycomb graphite lattice at elevated temperature under atmospheric or low 
pressures. When the thermal CVD process is carried out in a resistive heating furnace, it is known as 
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thermal CVD, and when the process consists of plasma-assisted growth, it is called plasma enhanced 
CVD or PECVD. As a whole, all the above techniques are standard in their respective fields. However, all 
synthesis methods have their own advantages as well as disadvantages depending upon the final 
application of graphene. For example, the mechanical exfoliation method is capable of fabricating 
different layers of graphene (from monolayer to few-layer), but the reliability of obtaining a similar 
structure using this technique is quite low. Moreover, large-area graphene fabrication using mechanical 
cleaving is a serious challenge at this moment. From monolayer to few-layer graphene can easily be 
obtained by the adhesive tape exfoliation method, but extensive method, but extensive research is a 
prerequisite for further device fabrication, which limits the feasibility of this process for 
industrialization. Furthermore, chemical synthesis process (that involve the synthesis of graphite oxide 
and reducing it back to graphene in a solution dispersal condition) are low temperature processes that 
make it easier to fabricate graphene on various types of substrates at ambient temperature, particularly 
on polymeric substrates (those exhibit a low melting point). However, homogeneity and uniformity of 
large-area graphene synthesized from reduced graphene oxides often causes incomplete reduction of 
graphite oxide (which exhibits insulator characteristics) and results in the successive degradation of 
electrical properties depending on its degree of reduction. In contrast, thermal CVD methods are more 
advantageous for large-area device fabrication and favorable for future complementary metal-oxide 
semiconductor technology by replacing Si.25 Epitaxial graphene, thermal graphitization of a SiC surface, 
is another method, but the high process temperature and inability to transfer on any other substrates 
limit this method’s versatility. In this context, the thermal CVD method is unique because a uniform 
layer of thermally chemically catalyzed carbon atoms can be deposited onto metal surfaces and can be 
transferred over a wide range of substrates. However, graphene layer controllability and low-
temperature graphene synthesis are challenges for this technique.  
 
2.2.4 GRAPHENE OXIDE FOR BIOMEDICAL APPLICATION 
Chemistry, material science, biology, medicine and nanotechnology are fields of applications of 
graphene and graphene oxide (GO). Brodie discovered in 1859 GO, but only recently its properties 
started to be fully exploited and studied. Later different procedures emerged to obtain GO from 
graphite thanks to the studyes of Staudenmaier and Hummers.26 
GO is a two dimensional material made of sp2 and sp3 hybridized carbon atoms arranged in a hexagonal 
honeycomb pattern and of oxygen atoms present in the form of different functional groups (Figure 6). 
The type and amount of oxygenated species is still highly discussed today. This is due to a lack of 
sufficiently sensitive analytical techniques and to the amorphous and berthollide character of this 
material.27 
 
Figure 6. Schematized representation of GO 
GO’s sheets are irregular. Modulating the size of this material is possible through an accurate post-




GO is a very hydrophilic material thanks to their oxygenated functional groups. This carbon material, 
compared to non-oxidized form graphene, is more chemically reactive due to the presence of defects. 
The mechanical properties of GO are lower, but it shows a higher optical transmittance.  
Exploiting their hydrophilic aspects, GO finds many applications in the biomedical field. The large 
surface area allowed a high drug loading. Drugs and molecules can be covalently attached or can be 
adsorbed onto the surface of GO. GO proved to be an excellent structure for DDS or for combined 
strategies of targeting and imaging. Numerous studies were performed by using GO as delivery for 
anticancer drugs.29  
The graphene surface with delocalized π electrons can be utilized for effective loading of aromatic 
anticancer drugs such as doxorubicin (DOX) via π- π stacking and hydrophobic interactions. The 
extremely large surface area of graphene, with every atom exposed on its two sides, is allowed for ultra-
high drug-loading efficiency. 30 
 
CPT, a cytotoxic quinoline alkaloid, has been proved to be effective against a broad spectrum of tumors 
by inhibiting the DNA enzyme topoisomerase I (Topo1).31 But CPT has a low bioavailability due to its 
poor water solubility which limits its clinical applications. The functionalized GO as a nanocarrier can 
help improving not only its solubility but also its cellular uptake by enhancing its ability to go across the 
target cell membrane. Dai and collaborators explored for the first time functionalized nanoscale GO 
(NGO) as a novel and efficient nanocarrier for delivery of SN38, a CPT analog into cells.32 
 
Apart from cancer drugs, presently GO-based drug delivery is elaborated to other drugs for non-cancer 
diseases treatment. Rana et al. synthesized chitosan-functionalized graphene oxides (FGOCs) and 
studied the delivery of an anti-inflammatory drug, IBU.33 The IBU drug was released up to ~ 19% in PBS 
from FGOCs. They showed that there was no serious toxicity of the CEM cell line for various 
concentrations of FGOCs GS without drug loading, which suggested that FGOCs sheets had a very good 
biocompatibility. But FGOCs/IBU samples showed higher cell killing effect compared with FGOCs. 
 
2.2.5 STRUCTURAL PROPERTIES OF GRAPHENE OXIDE AND MAIN SYNTHESIS PROCEDURES 
Brodie developed the first production procedure of this material: the treatment of graphite with an 
oxidation mixture made of potassium chlorate and fuming nitric acid. A modification in chemical 
procedure was introduced in 1898 by Staudenmaier who added to the oxidation mixture concentrated 
sulfuric acid, reduced the oxidation cycles to only one and introduced a two-step protocol.26 This 
protocol thanks to Hummers and Offeman was improved obtaining a time-efficient synthetic route. 
New reagents were introduced such as potassium permanganate to oxidize substrates, with the 
cooperate effect of sodium nitrate and sulfuric acid. Later, due to the toxic gases produced by the 
oxidation, Tour et al proposed the use of phosphoric acid instead of sodium nitrate, removing the 
dangerous gases. Eigler et al. understood the importance of temperature during the synthesis process, 
decreasing from 45°C to 10°C. This method allowed to achieve a better quality GO, called oxo-G.34 
 
Surface composition of GO was influenced by synthetic process, such as the oxidation reagent or the 
mentioned adopted temperature. Eng. et al investigated by using voltammetry analysis on GO material, 
obtained by adding permanganate or chlorate oxidation mixture. The results revealed that the use of 
permanganate mixture involved a majority of ortho-quinones followed by ketones. A small amount of 
carboxyl groups was found. Epoxides represent the major contribution on GO surface followed by a 
minor number of hydroxyl groups.35 Chlorate oxidation mixture contributes to have a more uniform 
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distribution, but with a lower amount of oxygenated functional groups, ketones represent the major 
contribution. Carboxyl acids were not detected.  
Because of the complexity of GO and difficulty in analytical techniques for characterization, many 
models to represent GO were proposed in literature. The first models, dated in the forties, suggested 
repeating groups of 1,2-epoxide or 1,3-epoxide and hydroxyl groups. Later ketones functional groups 
were introduced, such as quinones. Phenolic groups are mentioned to explain the acidity of GO.36 All 
these improvements were provided by different analyses: magic angle spinning (MAS), transmission 
electron microscopy (TEM), elemental analyses, Fourier Transform (IR).  
Today one of the plausible model was introduced by Tour and coworkers.37 They proposed an 
unconventional view of GO chemistry and developed the corresponding “dynamic structural model” 
(DSM). In contrast to previously proposed models, the DSM considers GO as a system, constantly 
changing its chemical structure due to interaction with water. Using potentiometric titration, 13C NMR, 
FTIR, UV-vis, X-ray photoelectron microscopy, thermogravimetric analysis, and scanning electron 
microscopy we showed that GO did not contain any significant quantity of preexisting acidic functional 
groups, but gradually generates them through interaction with water. This model explained also the 
reduction of GO under strong alkaline conditions, resulting in the formation of CO2 and vacancies.  
In spite of all the suggested models, until today the definitive structure of GO is till unknow. 
2.2.6 FUNCTIONALIZATION OF GRAPHENE OXIDE 
GO, without any surface functionalization, usually has sheet dimensions of hundreds of nm and tends 
to aggregate in physiological solutions with salts and proteins due to screening of electrostatic charges 
and non-specific binding of proteins. As a result, size control and individual separation are necessary for 
GO to suitably interact with a biological system in vitro and in vivo. As well, rational functionalization is 
essentially needed to offer GO with better compatibility and stability in the physiological environment.38 




Numerous oxygenated functional groups on GO allowed many possibilities of derivatization of this 
nanostructured material, but many side reactions could occur, hindering an easy selectivity degree. For 
this reason performing control reactions in the same conditions, but without an essential reagent is 
required.  
The functional groups more exploited for covalent decorations of GO are epoxides, carboxyl groups and 
hydroxyl groups. Hydroxyl groups are localized on the core surface of GO, they were reacted through 
silanization,39 etherification,40 phosphorylation41 and Ritter reaction.42   
Silanization is a two-steps reaction: first the hydrolysis of the trialkoxy groups of the silane followed by 




Scheme 1. Silanization reaction on GO. (The reaction has been drawn only on one functional group for clarity 
reasons. Side reactions were not considered). 
 
Phosphorylation was performed by mixing GO with concentrated phosphoric acid at 50°C. Scheme 2 
 
Scheme 2. Phosphorylation of GO. (The reaction has been drawn only on one functional group for clarity reasons. Side 
reactions were not considered). 
 
Ritter reaction: carbocations produced on the basal plane of GO underwent a nucleophilic attack by the 
nitrogen of a nitrile.  After hydrolysis an amide is formed. This reaction has been performed with sulfuric 
acid and acetic acid at 70°C, conditions that brought to the reduction of GO to restore the conductivity 
of this material. (Scheme 3) 
 
 
Scheme 3. Ritter reaction on GO. (The reaction has been drawn only on one functional group for clarity reasons. 
Side reactions were not considered). 
 
Epoxide groups are manly located on the basal plane of GO, the rings could be opened by addition of 
amine-terminated molecules or sodium azide (Scheme 4). Graphene azide could be synthesized from 




Scheme 4. Opening of epoxide ring on GO. (The reaction has been drawn only on one functional group for clarity 
reasons). 
After the activation of carboxyl acids located mainly at the edges of GO, esterification or amidation 
process could be performed.  The activation was achieved by adding oxalyl chloride or thionyl chloride. 
However, these reagents can cause side reactions. (Scheme 5) 
 
Scheme 5: Esterification and Amidation approaches on GO. Side reactions were not considered. 
2.2.7 CITOTOXICITY OF GO: BIOCOMPATIBILITY AND BIODEGRADATION 
The cytotoxicity of GO and its derivatives must be extensively investigated in vitro and in vivo if they are 
employed as drug nanocarriers. Several research groups have deliberatively explored this critical issue.30 
Most of the in vitro experimental results to date have suggested that as-prepared GO was a safe 
material at low concentrations in a variety of cells such as human fibroblasts,43 HeLa cells,44 L929 cells,45 
human hepatoma HepG2 cells46  and A549 human lung cancer cells.47 
 
On the other hand, in vivo studies indicated severe chronic toxicity associated with GO, especially at a 
high dose. Zhang et al. systematically studied the distribution and biocompatibility of GO in mice by 
using radiotracer technique and a series of biological assays.27 When mice were exposed to 1 mg/kg 
body weight of GO for 14 days, no pathological changes were observed in examined organs, indicating 
that GO might be non-toxic and suitable for biomedical applications at a low injection dose. However, 
it is revealed that GO at a relatively higher injection dose (10 mg/kg) showed dominant accumulations 
in the lungs after being intravenously injected into rats or mice and were hardly excreted for long 
periods of time, leading to serious toxic effects and significant pathological changes, such as 
inflammation cell infiltration, pulmonary edema and granuloma formation. 
 
GO biocompatibility depends on the synthesis procedure and on the starting graphite used. The surface 
of GO plays an important role in the biological interaction of nanomaterial. A fundamental factor is the 
number of layers of material which is closely connected to the flexibility of GO. Multilayer GO could 
acquire the behavior of a rigid block interacting with cells. Many aspects are influenced by lateral 
dimension size such as uptake, renal clearance, blood brain barrier transport, cell internalization 




The interaction with proteins in blood could determine the half-lives and biodistribution of the 
nanoparticles. Their hydrodynamic size could be influenced and improved. This effect facilitates 
recognition and clearance by macrophages and phagocytes. Interaction with proteins may also impact 
on the targetability of nanomedicines. Protein corona formation is a phenomenon consisting in serum 
protein adsorption onto the surface of GO. Proteins (albumin, apolipoprotein, immunoglobulins, 
complement, and fibrinogen) adsorb on various nanomaterial (polymeric nanoparticles, iron oxide 
nanoparticles, gold nanoparticles, liposomes, GO and CNTs) surfaces exhibit structural changes in the 
bloodstream (bioactivity). PEG is used to limit non-specific protein adsorption.48 
 
A good dispersibility of GO can influence also the biodegradation of this material.49 
 
Toxicity can derive also from some residues due to the production process of GO, such as from oxidation 
mixture previously mentioned. Considering that until now there are only a lot of studyes performed 
with different kinds of GO, without any standard, the analysis of the results of toxicity studyes is still 
inconclusive.  
 
2.2.8 DISULFIDE LINKER 
The final goal of this project is the synthesis of two models for a DDS based on the use of CNTs and GO 
which allow the release of the molecular fragment bound through the disulfide linker. 
A DDS for the treatment of tumors should not exhibit systemic toxicity: the linker must be stable in the 
bloodstream, but in cell internalization the disulfide bridge should be broken to release the drug. For 
this purpose a simple molecule has been synthesized (Figure 7).  
 
               
Figure 7: linker that binds the drug to the CNT. In red the disulfide bridge cleaved into intracellular environment. 
 
The structure shows a stable disulfide bridge in the blood, but potentially cleavable from endogenous 
thiols typical of the intracellular environment of tumors, such as glutathione. (Figure 8) 
 
 
Figure 8: Glutathione. 
 
GSH levels in cancer cells have been shown to be> 1000 higher compared to the amount in the blood 
plasma.50 The presence of glutathione leads to the cleavage of disulfide bridge by forming a 5-
membered thiolactone, releasing the drug free.  
In this work any drug has been not used, but a BODIPY dye linked to CNTs via the linker. The 
internalization of the system can be monitored. 
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2.2.9 FLUORESCENT PROBES 
Fluorescent probes are molecules that absorb light of a specific wavelength and emit light of a different, 
typically longer, wavelength (a process known as fluorescence), and are used to study biological 
samples. The molecules, also known as fluorophores, can be attached to a target molecule and act as a 
marker for analysis with fluorescence microscopy.  
Experimentally they are used in different areas of interest such as in medical care, biochemistry, clinical 
diagnostical environment. Thanks to a remarkable advancement of imaging techniques, many of the 
previous technical-practical limits were overcome. The affirmation of confocal microscopy is now able 
to obtain images, even of complexes samples, with high contrast and resolution.    
DESIGN CRITERIA 
Design criteria include numerous parameters simultaneously required to ensure the effectiveness of 
the probe itself: 
 
i. High selectivity and high fluorescence response for the desired analyte, without 
competitive reactions with other analytes in the same chemical environment; 
 
ii. Probe’s robustness to chemical agents and light; 
 
iii. The fluorescence must be as intense as possible, requiring wide values of ε (λ) at the λ 
wavelength of excitation and quantum yield Φ very high; 
 
iv. The associative-dissociative mechanism between receptor and analyte must be fast, such 
as to carry out a real-time investigation of the concentration (in the case of time-
dependent response); 
 
v. The fluorescence signal generated by the “starting/lighting” of the probe (e.g. 
fluorescence enhancement or length shifts wave of excitation and / or emission, must be 
favored on response of the type "shutdown" (for example, quenching of fluorescence), 
with a concomitant signal-to-noise ratio lower; 
 
vi. The use of indicators that absorb and emit light in the visible or near infrared NIR (650-
900 nm) was preferred, choosing this region numerous advantages, compared to UV 
region, were achieved: such as the absence of quartz optical equipment and less light 
scattering. 
 
Primarily light-induced damage to the biological sample should be minimized, for this reason NIR (Near 
Infrared) is more used. In this wavelength interval, biological samples have a low fluorescence 
background, which consequently produces a high signal/noise ratio; furthermore, in this band, Rayleigh 
and Raman scatterings are reduced, allowing an important capacity penetration of light into biological 
tissues and cells. In biological environment, a certain water solubility, a permeability of membrane 
(closely connected to pH) and minimal toxicity towards samples are also required.   
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BODIPY dyes represent an important class of fluorescent probes. These compounds found many 
applications such as an imaging probes51 or in chemosensing.52 We decide to synthesize and modify the 
structure of this probe thanks to its versatility and its properties.  
Many types of BODIPY are not soluble in water and only a few of these structures have been modified 
to increase their solubility. On the other hand, however, they are relatively insensitive to the polarity 
and pH of the environment, exploiting their related stability in physiological conditions. BODIPY 
represents an excellent investment as building block, although not meeting all the previously mentioned 
requirements. 
2.2.10 BODIPY 
STRUCTURE AND PROPERTIES 
The basic structure, also called “core”, is shown in Figure 9. This structure is fundamental for the 
synthesis of the most complex BODIPY dyes. 
                         
Figure 9: BODIPY’s structure. 
The pyrrole protons of the BODIPY Core, especially those in position 5 and 7, are relatively acidic and 
this leads to electrophilic attack, reason why this compound, without any substituent, has never been 
isolated. Analogously for the other two systems: dipyrrometene, for example, decomposes at 
temperatures above -40 °C.53,54 
The most basic structure of BODIPY is shown in Figure 10; compounds B and C are not presented in 
literature due to the synthetic limits: 
 
Figure 10. BODIPY 3,5 Dimethyl substituted A. EtOH, φ=0.81; λMax Abs=506 nm, λMax Emis= 520 nm; B e C not isolated. 
 
The synthesis of tera-, esa-, epta- substituted compounds Figure 11 reveled a shift of fluorescence close 




Figure 11. D, EtOH, φ = 0.80; λMax Abs= 505 nm, λMax Emis= 516 nm; E, EtOH, φ= 0.56; λMax Abs= 528 nm, λMax Emis=535 
nm; F, EtOH, φ=0.70; λMax Abs= 517 nm, λMax Emis= 546 nm. 
 
The substitutions in meso position are not associated with relevant change in absorption or emission 
wavelength, but considerable variation in quantic yields (φ) are collected, as shown in Figure 12. 
 
Figure 12. G, MeOH, φ= 0.19; λMax Abs= 508 nm, , λMax Emis= 519 nm; H, MeOH, φ=0.65; λMax Abs= 498 nm, , λMax Emis=508 
nm. 
 
The difference in quantic yields between the compounds in FIGURE are associated to a major rigidity 
due to the presence of methyl groups in position 1 or 7 which prevent the free rotation of phenyl group. 
Less energy was lost from excited states (via non-radiative). Aromatic rings substituted in orto show 
analogous properties.  
 
2.2.11 SYNTHESIS OF BODIPY 
The synthetic procedures of this class of compounds are widely described in literature to obtain various 
derivative of the BODIPY Core. 
SYNTHESIS FROM CARBOXYL ACIDS AND PYRROLES 
BODIPY meso-substituted are synthesized from condensation of acidic chlorides and pyrroles Figure 13 
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As synthetic intermediates dipirromethene chloridites constituted instable compounds. These salts, 
although they are easier to treat and purify, are generally never isolated during the process synthesis 




Figure 13. Synthesis of BODIPY starting from acidic chloride and pyrroles.  
 
Otherwise, anhydrides can be used as an alternative to chlorides, as shown in Figure 14, in which 
derivative 4 is synthesized starting from glutaric anhydride.56 
 

















SYNTHESIS FROM ALDHEIDE AND PYRROLES 
 
Figure 15. Aromatic aldehyde was reacted with pyrrole to achieve dipirromethane, after a condensation process. 
The consecutive oxidation and complexation process allow to obtain the final BODIPY product.  
 
3-iodobenzaldehyde forms with pyrrole, by acid-catalyzed condensation, the substituted 
dipyrromethane. If unsubstituted pyrrole is used, the reaction should be carried out using the pyrrole 
as solvent to avoid polymerization. In Scheme 3 2-Methylpyrrole doesn't have any polymerization as 
competitive reaction, therefore it doesn't need to be in large excess. 57 
BODIPY compounds are sensitive to light, to air and acids, it must be immediately used for subsequent 
oxidation. This latter step occurred by using both para-chloroanile and 2,3-Dicloro-5,6-Diciano-p-
benzochinone, to achieve dipirrometene. Many examples are presented in literature describing 
aromatic aldehydes, but any synthesis exploiting no aromatic aldehydes were reported. Finally this 
substrate reacted with a tertiary amine and BF3EtO2 to obtain the final product, in high yield. 
 
CHANGES ON BODIPY’s STRUCTURES 
The family of BODIPY, thanks to its versatility in structural changes, is a molecule of relevant interest. it 
is an excellent building block, different positions that lead BODIPYs to nucleophilic or electrophilic 




Figure 16. Modifications of BODIPY structure. 
 
The structure shows that the two pyrrole rings are aromatic electron-poor systems resulting in the 
relative acidity of the two methyl groups (3 and 5 positions) providing excellent positions for 
electrophilic attacks, such as for Knovenagel Condensation with aromatic aldehydes (Figure 17). Usually 
the reaction is carried out under inert atmosphere (N2), with the presence of a buffer, or by using a 
base-catalyzed system. Although the ease chemical procedure, the collected yields are often low with 
electron-poor aldehydes.  
 
 
Figure 17. Condensation of 3,5-dimethyl-BODIPY and aromatic aldehydes; changing the equivalents the synthesis 
produces mono- or di- substituted.  
 
The condensation process allows to increase the conjugation of BODIPY core. Electron donor 
substituents on aromatic aldehydes shift the absorption and emission wavelengths towards the red or 
even in the NIR. The substituents in 3 and 5 positions modify the properties of BODIPY, both for the 
spectra and fluorescence quantum yield of product. 11 
 
The above mentioned positions, thanks to their poverty of electrons, are excellent sites for aromatic 




Figure 18. Synthetic pattern to obtain BODIPY 
 
The versatility of reaction of substitution allows to synthesize both mono- and di- substituted, 
modifying/stressing reaction conditions. Additional flexibility derives from a wide range of nucleophiles 
with different structures and properties, such as amines, alkoxides, thiolates etc. Cross-coupling 
reactions metal catalyzed on positions 3 and 5 are possible. Different reagents bring to various products, 
as shown in Figure 19. 
 
 
Figure 20. Functionalization of BODIPY-3-halogenated metal catalyzed.  
 
Recalling Figure 16, focusing on position 6 (or Beta) reaction Pd catalyzed occurred, exploiting a new 
bond C-C. (Figure 21). A direct functionalization of BODIPY is possible without resort to halogenated or 




Figure 21. Functionalization Palladium catalyzed of C-H (EWG=CO2Me). 
 
As show in Figure 21 two products could be obtained: mono- and di- substituted with different 
spectrophotometric properties, Tab 1. 
 
 Solvent λMax Abs λMax Em φ 
E MeOH 527 nm 549 nm 0.73 
F EtOAc 559 nm 580 nm 0.51 
Tab 1 
 
An additional reaction concerning BODIPY in position 6 is the electrophilic aromatic substitution, such 
as sulfonation, nitration and halogenation. Changing the reaction condition displayed in Tab 2, the 
synthesis provides numerous products.59,60  
 
 
   
 





2.3 RESULTS AND DISCUSSION-fCNTs 
2.3.1 OXIDATION OF CARBON NANOTUBES 
The synthetic work started with the preparation of the carrier: pristine MWCNT needed to be treated 
to increase the water dispersibility of the material and to remove all impurities, like residues of the 
metallic catalysts and amorphous carbon. Such feature can be obtained through an oxidation process 
where CNTs are chopped at defect sites and oxygenated functionalities are created on their sidewall 
and edges. This process requires harsh conditions: concentrated oxidant acids, high energy sonication 
for prolonged time or heating at high temperatures.61 To guarantee the highest purity and water 
dispersibility,  
 
MWCNT (diameter 6-9 nm and 5 μm length) were treated with a refluxing 3:1 mixture of concentrated 
sulfuric acid and nitric acid for 30 minutes. (Scheme 6)  
 
Scheme 6. Oxidation process to obtain compound 2. 
Accordingly to a previous procedure, oxidized material was recovered after quenching with 
demineralized water, two centrifugation cycles (replacing the supernatant with fresh water) and 
filtration followed by washing with water until the filtrated solvent was neutral.11 The OxMWCNTs 
obtained have an average length ranging from 50 to 1000 nm and are dispersible in water. Considering 
that, as mentioned above, shorter OxCNTs are more biocompatible than longer ones, and are believed 
to be more easily internalized by tumor cells, we harvested the shortest fraction using a series of 
centrifugation cycles (Figure 23), (see experimental part for details). 





G -H - 492 nm 504 nm 0.95 
Ha -
SO3Na 
1.ClSO3H, DCM, 50°C 
2. NaOH 
492 nm 533 nm 0.73 (H2O) 
Hb -NO2 HNO3, 0°C, 15’ - - - 
Hc -Br Br2, DCM, 25°C 516 nm 546 nm 0.45 
(DCM) 
Hd -I I2, HNO3 EtOH, H2O, 60°C, 
20’ 




Figure 23:. Schematic representation of the separation process.  
 
The procedure allows to collect a fraction with highly oxidized short multi-walled CNTs (from now on 





Figure 24.TEM images of CNTs bulk material on the left, collected short fraction on the right.  
 
2.3.2 DECORATION OF CNTs WITH 4-AZIDOANILINE 
The nanostructured support chosen to realize the DDS model was oxidized carbon nanotubes (CNTs). 
The first kind of functionalization was the introduction of 4-azidoaniline through Tour reaction (Scheme 
7). This radical process allowed to exploit an aniline to covalent bind a substrate with an azido group.  
 
Scheme 7. Functionalization of CNTs (2) with 4-azidoaniline (3). 




2.3.3 GO FUNCTIONALIZATION via PEG 
 
Scheme 8: PEG functionalization of GO  
A two steps process allowed to introduce PEG chains (5) covalent bound to CNTs by using 2-(N-
morpholino)ethanesulfonic acid Buffer and EDC to activate carboxyl acids on carbon nanotubes, 
followed by an addition of PEG in dry DMF. After a filtration process the material was recovered as a 
black powder. 
 
2.3.4 SYNTHESIS OF BODIPY CORE 
The first part was the synthesis of BODIPY Core, which may be functionalized to bring two different 
fluorescent probes. The first synthetic pathway was presented in literature. 62 During the 
mechanochemical synthesis 4-Nitro benzaldehyde was reacted with 2,4-dimethylpyrrole in the 
presence of trifluoroacetic acid (TFA), with an excess of p-chloroanyl for the oxidation of meso carbon 
(Scheme 9)  
Numerous extractions were required to obtain compound 7 (BODIPY-Nitro) due to the formation of 
triethyl amine salts, nevertheless after chromatography purification the yield was low. 1H-NMR 
spectrum of compound 8 was synthesized in Scheme 9. and compared to 1H-NMR of compound 7, 
collected before the complexation process with BF3Et2O.  
 
 
Scheme 9: Synthesis of BODIPY Core 
Moving from compound 7 to compound 8 by adding boron to bridge the two pyrrole rings, a shift of the 
signals to higher ppm was showed: 
. The signal of the methyl protons has a shift of 0.22 ppm; 
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. The signal of the pyrrole hydrogens has a shift of 0.12 ppm; 
. The signal of methyl hydrogens is shifted by 0.10 ppm; 
. The signals of the protons of the benzene ring are essentially unchanged. 
  
Figure 25. 1H-NMR Spectrum of compound 7. 
  
Figure 26. 1H-NMR Spectrum of compound 8. 
These two mentioned steps were limiting in yields. A different synthetic approach allowed to improve 




Scheme 10. Synthesis of BODIPY Core 
The adopted synthetic approach provided compound 8 through the reaction of 4-Nitro benzoic acid and 
thionyl chloride, followed by pyrrole addition and BF3Et2O complexation. This procedure was preferred 
compared to the previous mentioned.  
The reduction of -NO2 to -NH2 group occurred by using Fe powder, H2O and HCl in MeOH for 2.5 h in 
reflux condition. 
1H-NMR spectrum (Figure 12) showed: 
. Signal at 6.90 ppm: dd of hydrogen atoms of benzene; 
. Singlet at 5.97 ppm of pyrrole hydrogens; 
. Signal of amino protons at 3.83 ppm; 
. Two singlets of methyl hydrogens at 2.54 ppm and 1.29 ppm. 
 
Figure 27: 1H-NMR spectrum of compound 9. 
A part of product 9 was modified by introducing an alkyne group thanks to a coupling with 4-pentynoic 
acid to introduce a triple bond to allow the grafting onto nanomaterial. Subsequently the extension of 
the conjugation in position 3 and 5 has been extended. The reaction was carried out on reflux, under 
nitrogen atmosphere and controlled by TLC. After 40’ the reaction was stopped. The products of 
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reaction were mono and disubstituted compounds. (Scheme 11) Thanks to a chromatography column 
BODIPY-disubstituted was collected.  
Scheme 11. Coupling Reaction and Knovenagel Reactio. 
In 1H-NMR the appereance of signal at 2.07 ppm confirmed the occurred reaction, due to the presence 
of an alkyne proton.  
 
Figure 28: 1H-NMR spectrum of compound 10. 
The synthesis of BODIPY-disubstituted was showed in Scheme 11  
. At 8.65 ppm a doublet that integrates two protons, which are those of pyridine adjacent to the N atom; 
. Signal centered at 8.05 ppm, a doublet which integrates 2 protons, belonging to double bond that 
binds pyridine to BODIPY; 
. A multiplet is included in the aromatic zone between 7.75 ppm and 7.65 ppm which integrates 7 
protons of which 2 belong to the two pridiles, 4 belong to the benzene ring in the meso position of the 
BODIPY and the last is the H amide; 
. A signal centered at 7.35 ppm is a doublet that integrates 2 belonging protons to the double bond 
between pyridyls and BODIPY; 
. A signal centered at 7.27 ppm there is a doublet that integrates 2 belonging protons to pyridyls; 
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. A signal centered at 7.20 ppm a triplet integrates two protons belonging to the system of pyridyls; 
. A signal centered at 6.69 ppm a singlet integrating 2 protons indicates the presence of 2 equivalent 
hydrogens of pyrroles; 
 
Figure 29: 1H-NMR spectrum of compound 11. 
2.3.5 SYNTHESIS OF THE LINKER 
To synthesize the disulfide linker a known synthetic pattern was followed.50 
SYNTHESIS OF tri-tert-butylsilyl 3-(pyridin-2-yldisulfanyl)propanoate 
The first step is an exchange reaction between the 2,2-dipyridyl disulfide and the 3- acid 
mercaptopropionic, which occurred in methanol at room temperature. After 1:50 h a TLC analysis did 




Scheme 12. Synthetic pattern to obtain compound 13.  
Although 1H-NMR spectrum of the crude showed overlapping signals of by products it presented also 
the signals of desired product 12.  
The obtained acid (12) was protected with TIPSCl, slowly added under nitrogen atmosphere at 0°C, in 
dry DCM in the presence of TEA dry. Such protection was necessary for a subsequent reaction, the 
selective reactivity of a carboxyl group is required. 
The crude product 12 was washed with a saturated aqueous solution of NH4Cl; then the product was 
further purified by flash chromatography with eluent EP-EtOAc (20: 1), obtaining a product with 65% of 
yield. 
A 1H-NMR spectrum of 12 was recorded, showing typical TIPS signals: a doublet at 1.06 ppm (18H) and 




Figure 30. 1H-NMR of product 13. 
SYNTHESIS OF 2-(2-mercaptophenyl)acetic acid 
The synthesis of compound 14 was achieved through the synthetic pathway shown in Scheme 13. 
Benzo[b]thiophen-2-ylboronic acid was reacted with H2O2 in ethanol at room temperature for 5h to 
obtain a thiolactone 14 (90% yield) 
 
Scheme 13: Synthesis of compounds 14, 15. 




Figure 31. 1H-NMR of compound 14. 
Several overlapping signals are observed due to the protons of the benzene ring, centered at 7.33 ppm, 
which integrate 4 hydrogens. Finally, there is a singlet centered at 4.04 ppm connected with 2 protons, 
adjacent to carbonyl group. The spectrum confirmed the desired product. 
The thiolactone was subsequently hydrolyzed with LiOH in H2O and THF for 16 h at 60°C, to obtain a 
carboxylic acid 15 with a yield of 97%. 1H-NMR spectrum confirmed the presence of 2-
mercaptophenylacetic acid (Figure 32): 
 
Figure 32: 1H-NMR of compound 15. 
. The signal at 10.65 ppm suggested the successful transformation into carboxylic acid; 
. Two multiplets were generated at 7.20 ppm and 7.50 ppm (4 protons) connected with benzene ring of 
product; 
. At 3.88 ppm a singlet (2 protons), diagnostic signal of 2 aliphatic hydrogens 
. At 3.57 ppm there is a singlet, a proton, typical of the -SH of aromatic thiols; 
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SYNTHESIS OF 2-(2-((3-oxo-3-((tri-tertbutylsilyl)oxy)propyl)disulfanyl)phenyl)acetic acid (16) 
In the following synthetic step, the desired disulfide linker was achieved through the reaction between 
compounds 11 and 13 previously prepared. The reaction was carried out in dry Et2O under nitrogen 
atmosphere, for 48 hours, at -7 C° with the aid of a thermostat.  
 
Scheme 14. Synthetic path to achieve compound 16. 
Through chromatography column byproducts were removed and the final compound was characterized 
by 1H-NMR. (Figure 33) 
 
 
Figure 33. 1H-NMR of compound 16. 
. Typical TIPS signals were localized between 1.0 ppm and 1.5 ppm; 
. Two triplets centered at 2.82 ppm and 2.98 ppm (4 protons), confirmed the presence of the two 
aliphatic -CH2- adjacent to the disulfide bridge; 
. A singlet at 3.95 ppm (2 protons), indicates the presence of the 2 aliphatic hydrogens between -Ph and 
-COOH; 
. The multiplet ranging from 7.20 ppm to 7.30 ppm and the doublet centered at 7.77 ppm, are correlated 
to the protons bound to the benzene ring  
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2.3.6 COUPLING OF BODIPY WITH LINKER 
 
Scheme 15. Coupling of BODIPY Core with Linker 
This reaction allowed to bind the newly synthesized linker (compound 14) to the reduced BODIPY 3,5-
dimethyl substituted (compound 8), by forming an amide. EDC was used as a coupling agent, to activate 
the carboxyl group. The reaction was carried out under nitrogen atmosphere for 24 h.  
1H-NMR showed signals confirming the presence of the BODIPY amide: 
. Typical TIPS signals between 0.9 ppm and 1.30 ppm;  
. Centered at 1.45 ppm and 2.47 ppm there are two singlets, due to the methyl groups of the BODIPY; 
. At 2.74 ppm and 2.93 ppm two triplets, connected to 2 protons each, diagnostic of aliphatic hydrogens 
between S-S and -CO2TIPS; 
. A singlet (2 protons) at 3.99 ppm associated with the two protons between the amide group and the 
benzene ring; 
. A singlet centered at 6.05 ppm which suggested the presence of the two hydrogens of pyrrole; 
. The multiplet ranging from 7.20 ppm to 7.50 ppm and the doublet centered at 7.80 ppm, due to 4 
protons connected to the benzene ring of the BODIPY in meso position and to the 4 protons of the 




Figure 34. 1H-NMR Spectrum of compound 17 
DEPROTECTION OF BODIPY AMIDE 
The consecutive step was the deprotection of carboxyl group of the BODIPY amide to re-establish its 
reactivity. TIPS was removed by using TEA 3HF, at room temperature.  
 
Scheme 16. TIPS deprotection to afford compound 18 
1H-NMR spectrum was recorded. The occurred deprotection process was confirmed thanks to the lack 




Figure 35. 1H-NMR Spectrum of compound 18 
COUPLING BODIPY-LINKER 
To attach the final system on CNTs the introduction of an alkyne group was required to exploit CuAAC 
chemistry. The introduction of propargylamine occurred by adding EDC HCl and HOBt to increase the 
reaction yield. After a purification through chromatography column a 1H-NMR was showed in Figure 36. 
 





Figure 36. 1H-NMR Spectrum of compound 19 
In this synthetic step the fluorescent probes 9 and 17 were bund on CNTs surface. The nanotubes are 
already functionalized with azide group and PEG chain. The azide groups on CNTs and the alkyne groups 
on the fluorescent probes were exploited to conduct a Cu (I) catalyzed cycloaddition reaction. CuIP 




Scheme 18. Functionalization of CNTs with fluorescent probes. 
At the end of reaction functionalized CNT were filtered on nylon and washed several times with water 
and methanol. The collected workup waters were analyzed by UV spectroscopy to evaluate the 
complete removal of two dyes not bund on functionalized carbon material. 
In Figure 37 a UV Spectrum of 20 was reported. The absorption profile of synthesized compound 
suggested the occurred reaction. showing the two characteristic absorbance signals connected with the 
fluorescent molecules. In orange with maximum of absorption at 510 nm (BODIPY-Linker, 19) and in 




Figure 37. UV adsorption of compounds 20 (black), 11 (blue) and 19 (orange). 
Confocal microscopy images analysis performed on functionalized carbon nanotubes were acquired by 
using a laser with two wavelengths (Figure 38) 
 
Figure 38. Images of functionalized CNTs provided by confocal microscope.  
First two columns of Figure 38 showed the single fluorescence of two probes, confirming the occurred 
functionalization. The last column revealed the merge of the images of two dyes. 
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2.3.7 IN VITRO BIOLOGICAL ASSAYS 
The desired model for DDS was objective of study about its cancer cells internalization. This study was 
carried out in cooperation with Professor Paolo Paoli. at Dipartimento di Scienze Biomediche 
Sperimentali e Cliniche dell’Università di Firenze.  
Confocal microscopy images were acquired of both isolated models of DDS and models of DDS 
incubated for different period of time in melanoma cancer cell cultures (A375). The images showed the 
presence of both fluorescent probes by using two lasers with different wavelengths (488 nm and 570 
nm). The two different fluorescence were connected to the two probes.  
Different images were collected after 0 minutes, 5 minutes, 30 minutes, 6 hours and 24 hours of 
incubation. (Figure 39, 40, 41, 42, 43). 
After 6 hours (Figure 42) the collected images showed small areas with a lack of a perfect overlapping 
of two fluorescence, suggesting a possible release of a BODIPY due to the break of disulfide bridge. This 
hypothesis was confirmed thanks to the images recorded after 24 hours: extended are 
as with only green fluorescence were showed in Figure 43. The compound appears suitable for our 
proposal.  
 
0’ A375 Melanoma cells 
 
Figure 39. A375 cells incubated with product 18 at 0’. In A only the cell nucleus (DAPI dye). In B fluorescence of the 





5’ A375 Melanoma cells 
 
Figure 40. A375 cells incubated with product 18 at 5’. In A only the cell nucleus (DAPI dye). In B fluorescence of the 

















30’ A375 Melanoma cells 
 
Figure 41: A375 cells incubated with product 18 at 30’. In A only the cell nucleus (DAPI dye). In B fluorescence of the 

















6h A375 Melanoma cells 
 
Figure 42: A375 cells incubated with product 18 at 6h. In A only the cell nucleus (DAPI dye). In B fluorescence of the 


















24h A375 Melanoma cells 
 
Figure 43: A375 cells incubated with product 18 at 24h. In A only the cell nucleus (DAPI dye). In B fluorescence of 
the probe S-S-linker (product 17). In C fluorescence of product 9. In D the merge of the two fluorescence. 
2.4 CONCLUSION AND PERSPECTIVES OF CNTs-MODEL OF DDS 
This project was focused on the viability study of a drug delivery system. The drug was bund to multi 
walled carbon nanotubes through covalent bonds divisible in intracellular environment. The prepared 
system showed functionalized CNTs with two fluorescent probes of BODIPY family; the first BODIPY 
(maximum of absorption at 623 nm) directly to nanostructured material, the second BODIPY dye 
(maximum of absorption at 510 nm) through a disulfide bridge. This bond resulted cleavable in the 
environment of cancer cells, due to the higher concentration of endogenous thiols.  
The ability of nanotubes to cross cell membranes and the selective release mechanism are interesting 
properties for a drug vectorization system (especially in the chemotherapy field, the lack of selectivity 
is one of the main problems). Since this project was a viability study, instead of a drug, a fluorescent 
probe was anchored to the CNTs.  
One of the two dyes was then modified to form an amide bond with the linker disulfide molecule, 
previously synthesized. The other BODIPY conjugation was extended by Knoevenagel condensation, to 
modify also the emission frequency. 
The functionalization of CNTs with these described molecules was carried out through a click-chemistry 
reaction catalyzed by a complex (CuIP (OEt) 3), exploiting the azide groups on nanotubes. 
In collaboration with Professor Paolo Paoli, microscopy images of cell cultures (A375) incubated for 
different periods of time were acquired by confocal microscope. These analyses revealed a double 
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fluorescence of the tumor cells after the incubation and therefore the internalization of the model of 
DDS. The collected images suggested the release of the BODIPY dye. Future studies could quantify the 
release of compound bonded to carbon nanotubes via disulfide bridge. 
2.5 RESULTS AND DISCUSSION-fGO  
As previously showed in chapter 2.2, a similar approach was exploited to achieve a model to build a DDS 
based on GO instead of CNTs. The synthetic approach was the same, first the decoration with a PEG 
chain which will exploit to bind a selector, later the introduction of a substrate with an azido group to 
anchor the fluorophores.  
Thanks to Dr. Alberto Bianchi (Institut de biologie moleclulaire et céllulaire, Strasbourg) we have 
decided to extend the study by substituting carbon nanotubes with an other nanostructured carbon 
material such as graphene oxide since the higher biocompatibility and low toxicity compared to carbon 
nanotubes. 
The first step allowed the introduction of PEG chain by exploiting the epoxide ring opening at room 
temperature in water. (Scheme 19).  
 
Scheme 19. Functionalization of GO via Epoxide Rings Opening. 
Few milligrams of compound 22 were used to remove BOC protecting group through an acidic reaction 
Scheme 20 
 
Scheme 20: BOC Deprotection of amine. 
To functionalize graphene oxide, amino-terminated chains were chosen because they can be easily 
functionalized for other purpose, such as bonds with selectors. Moreover, the presence of a primary 
amine makes it possible to evaluate the amount of molecules introduced on GO using a colorimetric 
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test, namely the Kaiser test (material methods). Kaiser test result revealed an amount of amine equal 
to 34 µg/g of material. 
 
Scheme 21: Functionalization of GO via esterification 
Our strategy involved the addition of 5-azidopentanoic acid to introduce an azido group. This fragment 
allowed to bind the two dyes previously synthesized. (Scheme 21) 
A control reaction was done, to verify if 5-azidopentanoic acid was adsorbed onto GO surface. This 
reaction was performed in the same conditions of Scheme 21, without adding the coupling reagents.  
 
Scheme 22. Deprotection of BOC. 
Elemental analysis on GO of control reaction didn’t establish any absorption of 5-azidopentanoic acid 
onto GO; consequently the organic molecule was covalent bound onto carbon material.  
From these results, we can conclude the occurred functionalization of GO in two steps.  
Once obtained the decorated system (25), a strategy of multifunctionalization was developed. Mild 
conditions were used to avoid the reduction of GO. In the presence of copper sulfate and sodium 





Scheme 23. CuAAC reaction to introduce fluorescent dyes. 
To evaluate the loading degree of two fluorophores, ICP (S, B) analyses were done to establish an 
amount of compound 11 equal to 0.42 mmol/g and 19 equal to 0.37 mmol/g.  
Comparing the loading degree collected for the first described model, based on CNTs, to the second 
one, built with GO, 26 three times higher values for the second model (GO) were collected as compared 
























2.6 CONCLUSION AND PERSPECTIVES OF GO-MODEL OF DDS 
A system made of functionalized GO was achieved. The previously synthesized BODIPY 11 and BODIPY-
Linker 19 were covalent attached onto GO. A similar approach was carried out to bind PEG chain onto 
nanostructured carbon material.  
Our hypothesis plans to exploit the properties of disulfide bridge to release the dye with a maximum 
adsorption at 510 nm.  
In conclusion all the studyes mentioned used CNTs and GO samples with different characteristics, thus 
drawing a real conclusion appears to be a difficult task. A good functionalization of carbon materials has 
been possible. Analogous studyes with confocal microscope and in vitro studyes for the compound 26 
will be done by reproducing the same experiments previously adopted for compound 20.  
2.7 MATERIAL AND METHODS 
 OXIDATION OF MULTIWALLED CARBON NANOTUBES 2 
Pristine nanotubes (500 mg) were dispersed in a 3:1 mixture of 95% sulfuric acid and 65% nitric acid (30 
mL) and heated at 100°C under stirring for 30 minutes. The mixture was cooled at room temperature 
and quenched with 130 mL of MilliQ water, the obtained solution was centrifuged at 1500 rcf (relative 
centrifugal force) for 30 minutes, the supernatant was removed, and the precipitate dispersed with 
milliQ water (130 mL) and centrifuged again. The CNT slurry recovered from centrifugation (still acidic) 
ICP analyses S, B: 
BODIPY 11: 0.15 mmol/g 





was filtered on a 0.2 μm polycarbonate membrane and washed with water until neutral pH of the 
filtered solution. The process provided 200 mg of oxidized material, elemental analysis: C 79.1%, N 
0.15%, H 0.62% and O 20.3%. FT-IR showed the C=O absorption peak at 1700 cm-1. 
SEPARATION OF OXIDE CARBON NANOTUBES BY LENGHT 
Bulk oxidized CNT (140 mg) were dispersed using ultrasound bath in milliQ water (280 mL) to obtain a 
0.5 mg/mL solution. The solution was centrifuged at 10k rcf for 1h and supernatant and precipitate were 
collected. The supernatant was centrifuged again at 15k rcf for 1h providing a new precipitate and a 
new supernatant. The procedure was repeated using the supernatant other 3 times using different G 
force (20, 25 and 30 K rcf) as reported in the figure 6. The supernatant of the 30 k rcf centrifuge was 
dried and 65 mg of material 2 were obtained, the length was measured with TEM (Figure 45) giving an 
average value of 130 nm. 
 
Figure 45. TEM image of short oxidized carbon nanotubes 
 
SYNTHESIS OF 4-azidoaniline- 3 
 
4-azidoaniline was synthesized from 4-bromoaniline in quantitative yield following a procedure 
reported in the literature.63 




CNTs (2) (20 mg) was dispersed in dry DMF (2 mL) and sonicated for 15 minutes, then 4-azidoaniline 
(61.5 mg, 0.46 mmol) and isoamylnitrite (38.6 mg, 0.33 mmol) were added and the mixture stirred at 
60°C under nitrogen for 24 h. CNT 5 was recovered by filtration on a 0.2 μm nylon membrane, washing 
with DMF until a colorless solution obtained and then with methanol to remove the unreacted 
materials. FT-IR peak at 2100 cm-1 confirmed the azide decoration (Figure 46). 
 
 
Figure 46. IR of compound 4 
SYNTHESIS OF N3-CNTs-PEG 6 
 
N3CNTs (4) (15 mg) were dispersed in MES (50 mL) and sonicated for 15 minutes, then EDC-HCl (90 mg, 
0.47 mmol) and N-Hydroxysuccinimide (375 mg, 3.26 mmol) were added and the mixture stirred at 
room temperature for 90’. Functionalized CNTs were recovered by filtration on a 0.2 μm nylon 
membrane, washing with water. The recovered material (12.7 mg) was dispersed in dryDMF (2.5 mL). 
100 mg of PEG 2K (5)were added and the mixture stirred at 45°C for 24h. CNTs (6) were filtered on a 0.2 








SYNTHESIS OF BODIPY Core-7  
 
P-nitrobenzaldehyde (790 mg, 5 mmol, 1 eq.), 2,4-dimethylpyrrole (952 mg, 10 mmol, 2 eq.) were 
mechanical reacted with mortar and pestle; about 20 drops of TFA were added. DCM and p-chloroanyl 
(1844 mg, 7.5 mmol, 1.5 eq.) were added and homogenize with the pestle; the color of the substance 
varied from orange to dark purple. The product obtained was diluted with 250 mL and transferred in a 
separating funnel. The solution was washed with 200 mL of a saturated solution of Na2CO3 and then 
with 200 mL of BRINE. Each aqueous phase is then washed again with 100 mL of DCM to recover as 
much product as possible. The combined organic layers were anhydrified with Na2SO4, filtered on cotton 
and dried. 2.810 g of crude product were obtained. 
1H-NMR (CDCl3, 200 MHz) _(ppm): 8.31 (AA’BB’, 2H, Ha); 7.51 (AA’BB’, 2H, Hb); 5.89 (s, 2H, Hd); 2.33 
(s, 6H, He); 1.25 (s, 6H, Hc)  
 
SYNTHESIS OF BODIPY Core-8  
 
Product 7 (1606 mg, 5 mmol, 1 eq.) was put into a two-necked flask, under nitrogen atmosphere, diluted 
in 50 mL of anhydrous DCM and subsequently added first, fresh distilled TEA (6 mL, 42.9 mmol, 8.6 eq.), 
than BF3 (previously distilled under a flow of N2) at 0°C. After 12 h at room temperature the organic 
phase were diluted with 55 mL of DCM and washed with 3x50 mL of Na2CO3 and 3x50 mL of BRINE.Thn 
the organic layers were dried on Na2SO4  The crude product was purified through a flash 
chromatography column (EtP: DCM 1:1). 943 mg of product, or a yield of 37%. 
1H-NMR (CDCl δ 200 MHz) (ppm): 8.37 (AA’BB’2H, Ha); 7.52 (AA’BB’2H, Hb); 6.01 (s, 2H, Hd); 2.55 (s, 
6H, He); 1.35 (s, 6H, Hc)  
2.5 g (0.015 mmol, 1eq) of 4-Nitrobenzoic acid were dissolved in 3.3 mL (0.045 mmol, 3 eq) of thionyl 
chloride at 80°C for 1h, under nitrogen atmosphere. 75 mL of dichloromethane were added into the 
flask. Then 15 mL of fresh distilled triethyl amine and 15 mL of BF3 Et2O were added. At the end of 
reaction several extractions with waters were repeated after the dilution with dichloromethane (50 
57 
 
mL). The crude product was purified through a flash chromatography column (PEt: DCM 1:1). 1.73 g of 
product, or a yield of 68%. 
SYNTHESIS OF BODIPY-amine-9 
 
In a flask equipped with a magnetic stirrer, under N2 atmosphere, compound 7 (500 mg, 1.35 mmol, 
1eq) was placed with MeOH (21 mL). A solution of HCl in MeOH (0.4 mL of HCl 37% in 10 mL of MeOH) 
was added. The resulting mixture was heated to reflux, 8 mL of water were added and the reaction was 
monitored via TLC (Rf: 0.55, 4:1 DCM: Pet. E.). After 2.5 h the product was synthesized. After cooling to 
room temperature, the reaction mixture was diluted with dichloromethane and filtered to remove Fe. 
The mixture was washed with a solution of Na2CO3, the organic layers were combined, dried over 
anhydrous MgSO4 and evaporated. Yield: 250 mg, 55%, solid red compound.  
 
1H-NMR (CDCl3, 200Hz) δ (ppm): 7.03 (AA’ of a system AA’-BB’, 2H, J=8.0Hz, Ha); 6.78 (BB’ of a system 
AA’-BB’, 2H, J=8.0Hz, Hb); 5.97 (s, 2H, Hc); 3.88 (bs, 2H, Hd); 2.53 (s, 6H, He); 1.48 (s, 6H, Hf). 
 
SYNTHESIS OF BODIPY-alkyne-9 
 
100 mg of product 8 (0.29 mmol, 1eq) were put in a flask. 4-Pentynoic acid (29 mg, 0.29 mmol, 1eq), 
Dicyclohexylcarbodiimide (87 mg, 0.44 mmol, 1.5 eq), 4-(Dimethylamino)pyridine (3.7 mg, 0.03 mmol, 
0.1 eq) were added to the flask with 5.5 mL of dry dichloromethane. After 24h at room temperature 
the reaction was completed. The crude product was washed with 30 mL of 0.1M HCl solution (x3), 30 
mL of a saturated solution of Na2CO3 (x3), 30 mL of a BRINE solution (x2). The crude product was purified 
by a flash chromatography column (DCM:Pet.Et. 4:1). 108 mg were collected with a yield of 91%. 
1H-NMR (CDCl3, 200 MHz) δ (ppm): 7.96 (bs, 1H, Hi); 7.70 (dd, 2H, He); 7.20 (dd, 2H, Hf ); 5.97 (s, 2H, 





SYNTHESIS OF -BODIPY disubistuted-11 
 
Compound 10 (80 mg, 0.19 mmol, 1 eq.) was put in a flask under nitrogen atmosphere in anhydrous 
CH3CN and brought to reflux temperature.2-pyridincarboxaldehyde (102 mg, 0.95 mmol, 5 eq.), 
pyrrolidine (82 mg, 1.14 mmol, 6 eq.) and acetic acid (56 µL, 0.95 mmol, 6 eq). After 1 h of reaction the 
crude product was diluted with 50 mL of DCM. The organic phase was washed with 2x30 mL of Na2CO3, 
then 2x30 mL with MilliQ water and finally 2x40 mL with BRINE and dried on Na2SO4. The obtained 
compound was purified by flash chromatography with eluent PetEt-EtOAc (2: 1). 79.4 mg of BODIPY-
disubstituted were recovered with a yield of 70%. 
1H-NMR (CDCl3, 200 MHz) δ (ppm): 8.65 (d, 2H, Ho); 8.05 (d, 2H, He); 7.75-7.65 (m, 7H, Hm + Ha + Hb + 
Hf); 7.36 (d, 2H, Hk); 7.27 (d, 2H, H1); 7.20 (t, 2H, Hn); 6.69 (s, 2H, Hd); 2.66 (s, 4H, Hg + Hh); 2.11 (s, 1H, 
Hi); 1.50 (s, 6H, Hc). 
 
SYNTHESIS OF (tert-butyl)-2,2,4,4-tetramethylsiletan-1-yl 3-(pyridin-2yldisulfanyl)propanoate-13 
 
3-mercaptopropionic acid was added in a flask (130 µL, 1.49 mmol, 1 eq.) And it is solubilized in 1.4 mL 
of MeOH. Add the 2-2'-dipyridyldisulfide (503 mg, 2.29 mmol, 1.5 eq.) under magnetic stirring. After a 
reaction time of 4 h at room Temperature a 1H-NMR spectrum of the crude is acquired to ensure the 
absence of 2-2'-dipyridyl disulfide. 
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To protect the carboxylic group TIPSCl was used. 
The obtained crude (325.1 mg, 1.52 mmol, 1 eq.) was solubilized in a flask with 8.12 mL of dry DCM 
under nitrogen atmosphere, dry TEA (420.9 µL, 3.02 mmol, 2 eq.) was slowly added to the flask. At 0°C 
TIPSCl (387.7 µL, 1.81 mmol, 1.2 eq) was added drop by drop in 10’ of time. 6mL of aqueous solution of 
NH4Cl was used to wash the organic layers. The crude is purified by flash chromatography. Eluent Pet.Et-
EtOAc (20: 1). 362.3 mg of product 11 were recovered with a yield of 65%. 
1H-NMR (CDCl3, 200 MHz) δ (ppm): 8.46 (d, 1H, Ha); 7.75-7.61 (m, 2H, Hb+Hd); 7.08 (t, 1H, Hc); 3.03 (t, 
2H, He); 1.40-1.13 (m, 3H, Hg); 1.13-0.90 (d, 18H, Hi) 
 
SYNTHESIS OF (2-mercaptophenyl)acetic acid-15 
 
Benzo-b-thiophen boronic acid was added to a flask (417 mg, 2.34 mmol, 1 eq) and solubilized in 5 mL 
of EtOH; therefore 930 µL of H2O2 at 30% were added under magnetic stirring. After 5 h. the reaction 
mixture was diluted with 12 mL of H2O milliQ, 12.5 mL of dichloromethane were used to perform three 
extractions. The combined organic layers were anhydrified on Na2SO4.  
1H-NMR spectrum is acquired which reveals the formation of thiolactone (yield = 90%). 
The synthesized thiolactone (317 mg, 2.11 mmol, 1 eq.) was solubilized in 12.6 mL of H2O and in 12.6 
mL of THF into a flask. LiOH (303.2 mg, 12.66 mmol, 6 eq.) was put into a flask equipped with a magnetic 
stirring for 16 h at 60°C. 345 mg of crude product were collected  
1H-NMR (CDCl3, 200 MHz) δ (ppm): 10.65 (bs, 1H, Hg); 7.50-7.20 (m, 4H, Ha+Hb+ Hc+Hd); 3.88 (s, 2H, Hf 
); 3.57 (s, 1H, He). 
 
SYNTHESIS OF (2-((3-oxo-3-((tri-tert-butylsilyl)oxy)propyl)disulfanyl)phenyl)acetic acid 16 
 
 
Product 13 (362.3 mg, 0.97 mmol, 1 eq.) was solubilized under nitrogen atmosphere with 15 (244.7 
mg, 1.455 mmol, 1.5 eq.) in Et2O, inside a tube equipped with a magnetic stirrer. The reaction was 
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carried out at -7°C for 48 h, thanks to the use of a thermostat. The purification process occurred 
through a flash chromatography by using Et2O as eluent, obtaining 103 mg of product 14 (yield = 25%). 
1H-NMR (CDCl3, 200 MHz) δ (ppm): 7.77 (d, 1H, Hd); 7.30-7.20 (m, 3H, Ha+Hb+Hc); 3.89 (s, 2H, Hg); 
2.91 (t, 2H, He); 2.76 (t, 2H, Hf ); 1.35-0.9 (m, 21H, Hl + Hh)  
 
COUPLING OF linker 16 with BODIPY 9 to obtain 17 
 
Products 18(103 mg, 0.240 mmol, 1 eq.) and compound 9 (90 mg, 0.264 mmol, 1.1 eq.) were dissolved 
in dry DCM, under nitrogen atmosphere. EDC hydrochloride (74.5 mg, 0.36 mmol, 1.5 eq.) was added 
to the flask for 24 h at room temperature. The crude product was purified by flash chromatography, a 
mixture of hexane-dichloromethane (1:1) was prepared as eluent. 103 mg were obtained (yield = 57%).  
1H-NMR (CDCl3, 200 MHz) δ(ppm): 7.82-7.21 (m, 8H, Hc+Hd+He+Hf+Hi+Hj); 7.40-7.20 (m, 6H, 
Hc+Hd+He+Hf+Hi); 6.05 (s, 2H, Hl); 3.98 (s, 2H, Hg); 2.91 (t, 2H, Hb); 2.65 (t, 2H, Ha); 2.48 (s, 6H, Hk); 
1.45 (s, 6H, Hm). 
 
DEPROTECTION OF TIPS-GROUP FROM COMPOUND 18 
 
The synthesized amide (product 16) was dissolved in dry THF into two Eppendorf (103 mg, 0.137 mmol, 
1 eq.), and 33.6 µL (0.206 mmol, 1.5 eq.) of TEA fluoride. After 24 h at room temperature, an additional 
7 µL of TEA fluoride were introduced in each Eppendorf. After 24h the reaction mixture was washed 
with BRINE, the same procedure was repeated after the addition of EtOAc and anhydrified on Na2SO4.  
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1H-NMR (CDCl3, 200 MHz) δ(ppm): 7.82-7.21 (m, 8H, Hc+Hd+He+Hf+Hi+Hj); 7.40-7.20 (m, 6H, 
Hc+Hd+He+Hf+Hi); 6.05 (s, 2H, Hl); 3.98 (s, 2H, Hg); 2.91 (t, 2H, Hb); 2.65 (t, 2H, Ha); 2.48 (s, 6H, Hk); 
1.45 (s, 6H, Hm). 
 
SYNTHESIS OF COMPOUND 19 
 
Product 18 (86 mg, 0.145 mmol, 1.6 eq.) was solubilized in 8 mL of dry DCM, under nitrogen 
atmosphere. Then 15 µL (1.6 eq.) of propargylamine, 45.4 mg (1.6 eq.) of EDC hydrochloride and 32.4 
mg (1.6 eq.) of 
HOBt. The reaction was carried out for 48 h at r.t. Subsequently the crude product was purified by flash 
chromatography, using dichloromethane: ethyl acetate (20: 1) as eluent mixture. 
 
1H-NMR (CD3OD, 200 MHz) _(ppm): 7.81-7.27 (m, 8H, Hc+Hd+He+Hf+Hi+Hj); 6.17 (s, 2H, Hl); 3.94 (s, 2H, 
























SYNTHESIS OF CNTs-BODIPY-BODIPYLINKER 20 
 
Nitrogen flow was bubbled for 2 hours in dry DMF, where compound 6 was dispersed (5.3 mg, 0.0084 
mmol, 0.75 eq.). Substrate 17 (5.3 mg, 0.0084 mmol, 0.75 eq.), DIPEA (5.65 µL, 0.0324 mmol, 2.9 eq.) 
and CuIP (OEt)3 (1.3 mg, 0.0028 mmol, 0.25 mmol) were added. After 24h the functionalized carbon 
nanotubes were filtered and washed with fresh DMF and methanol. 4.8 mg of material were collected. 
 
OPENING OF EPOXIDE GO WITH LONG CHAIN OF PEG 22 
 
To a suspension of GO 21 (20 mg) in MilliQ water (20 ml) sonicated in a water bath for 20 min, PEG (80 
mg, 0.32 mmol) was added. The reaction mixture was stirred for 1 day. To 21, milliQ water was added 
and the sample was dialyzed in milliQ water for 5 days. fGO 22 was kept in solution and obtained as a 










To a solution of Boc protected-f-GO (10 mg) 22/24 in 1,4-dioxane (5 ml), sonicated in a water bath for 
10 min, was added a solution of 4M HCl in 1,4-dioxane (5 ml). The reaction mixture was stirred 
overnight. The reaction mixture was centrifuged at 1400 rcf for 15’ at 0°C. The precipitate was dispersed 
in fresh DMF, sonicated in a water bath for few minutes and centrifuged. This workup sequence was 
repeated twice with DMF, twice with MeOH and twice with DCM. 
The precipitate was dried under vacuum to obtain Boc-deprotected f-GO. 
Quantitative Kaiser Test –  
 
Three solutions were prepared separately: 
- 10 g of phenol dissolved in 20 ml of ethanol (solution I) 
- 2 ml of KCN 1 mM (aqueous solution) dissolved in 98 ml of pyridine (solution II) 
- 1.0 g of ninhydrin dissolved in 20 ml of ethanol (solution III) 
 
An amount of approximately 200 μg of GO conjugates was carefully weighted and then the following 
solutions were carefully added into the test tube: 75 μl of solution I, 100 μl of solution II and 75 μl of 
solution III. As blank solution, the three solutions were mixed in a test tube without GO. The test tube 
was sonicated in a water bath for 5 minutes, heated at 110°C for 5 minutes and then cooled rapidly in 
an ice bath to stop the reaction. 2.75 ml of 60% ethanol were added and the suspension was mixed. A 
UV-Vis cuvette was filled with the blank solution to collect the baseline. The absorbance of each sample 
was measured at 570 nm. The calculation of the amine loading was made using the Equation V.1. 
 
The result was expressed as micromole of amino group per gram of material. The test was performed 














ESTERIFICATION REACTION ON CARBOXYLIC ACID –GO-24 
 
 
To a suspension of 23 (10 mg) in MilliQ water (10 ml), sonicated in a water bath for 20 min, were added 
EDC (15 mg, 0.10 mmol), DMAP (20 mg, 0.16 mmol) and 5-azidopentanoic acid (31 mg, 0.16 mmol). The 
reaction mixture was stirred for 2 days at room temperature. To 24, milliQ water was added and the 
sample was dialyzed in milliQ water for 7 days. 24 was kept in solution and obtained as a powder after 
freeze drying only for characterization. 
 
CONTROL REACTION OF GO_CONT 
 
To a suspension of 22 (10 mg) in MilliQ water (10 ml), sonicated in a water bath for 20 min, 5-
azidopentanoic acid (31 mg, 0.16 mmol) was added. The reaction mixture was stirred for 2 days at room 
temperature. To reaction product, milliQ water was added and the sample was dialyzed in milliQ water 
for 7 days. The material was kept in solution and obtained as a powder after freeze drying only for 
characterization. 
 




To fGO (2.4 mg) 25 in milliQ H2O (0.15 ml) under nitrogen a solution of BODIPY amine 11 (3.1 mg, 1.44 
μmol) and BODIPY LINKER 19 ( 3.1 mg, 1.44 μmol ) in milliQ H2OtBuOH (2:1, 2.4 ml) was added. 
Afterwards CuSO4 (92 μg, 0.576 μmol) and sodium ascorbate (0.1 mg, 0.57 μmol) were added. The 
reaction mixture was stirred for 24h at room temperature. To fGO, milliQ water was added and the 
sample was dialyzed in milliQ water for 7 days. fGO 26 was kept in solution and obtained as a powder 
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3. Amino acids/Peptide functionalized BODIPY 
fluorescent probes  
 
3.1 OBJECTIVES OF THIS CHAPTER (3) 
BODIPY Core showed an azido group 27 which could be exploited for Click Chemistry reactions (CuAAC- 
Copper catalyzed Alkyne-Azide Cycloaddition) to obtain cycloaddition products which presented 
functionalized BODIPYs as fluorescent probes of CNTs. 
One of the goal of this project consisted in the extension of BODIPY’s conjugation to connect amino 
acids or a dipeptides to the fluorescent dye as showed in Figure 47 . The applied strategies could be 
two: 
. 1. First the Coupling of the linker to the selected amino acid, therefore the Knövenagel Reaction with 
the methyl groups connected to pyrroles of BODIPY. 
. 2. First the Knövenagel Reaction involving the linker and the methyl groups of pyrroles, therefore the 
Coupling Reaction of BODIPY-Linker molecule with the chosen amino acid. 
 
Figure 47.Pattern of amino acids coupled to BODIPY azido 27 .  
The second part of the project concerned the design of a system based on BODIPY-azido previously 
synthesized, connected to RGD peptide (Arg-Gly-Asp) thanks to an aldehyde linker, as showed in Figure 
48. The biological role of the peptide is fundamental both for the properties of pharmacophore, and for 
the direct interaction with cell adhesion molecules (integrins). The integrins recognize the specific 




Figure 48: Final product due to the coupling of BODIPY dye and RGD sequence.  
 
3.2 INTRODUCTION 
3.2.1 RGD SEQUENCE 
Arginylglycylaspartic acid (RGD) is the most common peptide motif responsible for cell adhesion to 
extracellular matrix (ECM). Many cell adhesion proteins placed in ECM and into blood include Arginine-
Glycine-Aspartic Acid as cellular recognition site. RGD sequence of cell adhesion proteins are identified 
from at least one member of transmembrane receptors family, such as integrins, which are 
heterodynamic proteins with two subunits. The development of new biomaterials was inspired by the 
recent progresses65 concerning interactions between peptides containing RGD sequence (Gly-Arg-Asp) 
and cellular receptors. Understanding the molecular bases of RGD-integrins bond allowed the 




Integrins are heterodimeric membrane proteins, which constitute one family of evolutionary ancient 
cell adhesion receptors. Integrins play an important role in physiological and pathological processes, 
such as neo-angiogenesis and tumor dissemination. As shown in Figure 43 integrins are obligate 
heterodimers, meaning that they have two subunits: α (alpha) and β (beta). Integrins are made up of 





Figure 49. On the left an inactive integrin; on the right an integrin suitable to interact with a lingand through α and 
β subunits. http://www.nature.com/nrm/journal/v11/n4/images/nrm2871-i1.jpg 
 
The cytoplasmatic domain regulates activity and function of integrins, monitoring their affinity state 
and their activity as bridge with extracellular matrix. In addition to the cytoplasmatic domain promotes 
the cellular responses demanded by binding with extracellular ligands.  The bond with their extracellular 
ligands (inside-outside signaling pathway) activates integrins and causes different conformations 
depending on individual responses.  
 
Since integrins lack intrinsic kinase activity, they require the formation of complexes with other signaling 
and adaptor proteins of cytoplasm. These systems produce macromolecular dynamic structures 
generally called adhesion complexes, promoting the cell survival and proliferation, thanks to integrins 
activation.  Tumor growth and metastasis process are connected to integrins, generally overexpressed 
in cancer cells, reason why they are considered important drug targets in the treatment of tumor. 
 
The antagonist of integrins allows to inhibit both cancer cells and their associated cells. Several methods 
aimed at inhibiting integrins have been carefully studied to treat pathologies actively involving integrins. 
Synthetic peptides and peptidomimetics, as well as blocking antibodies are antagonist of integrins. The 
most studied class of synthetic peptides, which mimic the structural of natural ligands of integrins, 










As presented in numerous studies, peptides including RGD sequence, may bind to integrins of 
membrane of cancer cells, hindering their interactions with natural ligands. When an integrin of a cancer 
cell interacts with RGD, its functionality was inhibited, as well as the cellular metabolism, proliferation 
and metastasis. The ability of integrins to connect to extracellular proteins or to cytoskeleton is 
compromised. An isolation of cancer cell occurred, due to the inhibition of all types of information 
exchange.  
The interaction RGD-integrin, as show in Figure 51, consists of:  
I. An electrostatic interaction: carboxylate group of the peptide interacts with a metal ion 
positively charged (usually Mg2+) associated with the subunit β of integrin.66 
 
II. Different interactions between acid residues of the α subunit and the basic part of the 
peptide chain, that is Arginine.  
 
 
Figure 51. Principal characteristics of the binding sites of RGD sequence.67  
Peptides containing the RGD sequence, consequently, represent a family of potential drugs with anti-
thrombotic, anti-angiogenic and antimetastatic activity.67 
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The final product of this work would to exploit a combined effect derived from biological role of the 
RGD, and the activity of BODIPY probes, for future imaging studies. 
3.3 RESULTS AND DISCUSSION 
The first part of the project was the synthesis of BODIPY Core Scheme 23 . The final goal consisted in 
the transformation of -NO2 in -N3. This synthetic step allows to exploit the azido group to bond BODIPY 
molecules to nanostructured materials, thanks to Click chemistry for the decoration of CNTs or GO.  
 
 
Scheme 23. Synthesis process to achieve BODIPY Core. 
Starting from 4-Nitrobenzaldehyde and 2,4-dimethylpirrole, compound 27 was obtained in two distinct 
steps. A first synthetic step was represented by using 2,3,5,6-tetrachlorocyclohexane-1,4-dione as 
oxidation reagent and then the addition of BF3 for a complexation procedure.  
The first step was a mechanochemistry reaction type, with a catalytic amount of TFA and an oxidation 
reagent. The workup consisted in hard extractions with DCM-Na2CO3. 62,68 
The second step was the addition of fresh distilled BF3∙Et2O and TEA to the flask containing Y to achieve 
the coordination of -BF2 to 2N of pyrroles.  
These two mentioned steps were limiting in yields. A different synthetic approach allowed to improve 
the yields and the ease workup. 
The reduction of -NO2 to -NH2 group occurred by using Fe powder, H2O and HCl in MeOH for 2.5 h in 
reflux condition. 
1H-NMR spectrum showed: 
. Signal at 6.90 ppm: dd of hydrogen atoms of benzene; 
. Singlet at 5.97 ppm of pyrrole hydrogens; 
. Signal of amino protons at 3.83 ppm; 




Figure 52. 1H-NMR spectrum of compound 9. 
The second step expected the chemical transformation of -NH2 in -N3 by using tert-Butyl nitrite and 
TMS-N3 (trimethylsylil azide). 
1H-NMR spectrum showed: 
. The shift of chemical shift of benzene’s protons due to the presence of azido group instead of amino 
group; 
. The disappearance of protons of amino signals at 3.90 ppm; 
 Smaller separation of aromatic signals. 
 
Figure 53: 1H-NMR spectrum of compound 27. 
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3.3.1 STRATEGY 1 TO BIND BODIPY AND AMINO ACIDS 
As showed in Scheme 24 the first synthetic strategy to bind an azido-BODIPY to an amino acid consisted 
of  
. synthesize as linker 4-aminobenzaldehyde;  
. glycine with BOC protecting group as amino acid.  
This synthesized molecule was reacted with methyl groups of BODIPY Core through a Knövenagel 
reaction. 
 
Scheme 24. Synthetic Pattern to obtain compound 31 
The coupling reaction between 28 and 29 expoiting as coupling reagents: EDC∙HCl, TEA and DMAP bases 
in DCM afforded 30.69 A problem was the poor solubility of p-aminobenzaldehyde 28 in solvents such 
as DCM, EtOH, MeOH, Et2O, H2O at room temperature. This was the limiting factor in yield (18%). During 
the reaction, the solution changed from amber to opaque orange. The purification of the product 
required two columns to remove the starting material. 
1HNMR spectrum showed: 
. a shift of benzene signals due to the action of the amide group instead of amine group; 
. the disappearance of signals due to amine protons and the appearance of a signal due to the amide 
proton at 5.38ppm; 
. the disappearance of mobile acid proton; 




Figure 54. 1H-NMR spectrum of compound 30. 
 
Figure 55: 13C-NMR spectrum of compound 30 
A small amount of product after the coupling, implicated to perform the Knövenagel Condensation to 
obtain the monoadduct, using only 2 aldehyde equivalents. The reaction was carried out in inert 
atmosphere (N2), in the presence of a secondary amine, pyrrolidine, and AcOH in CH3CN at reflux (80°C). 
By lengthening the conjugation of BODIPY Core, the color of the product should change. After 2h the 
reaction was concluded, but the desired product was not achieved. A possible cause could be due to 
the poor stability of the -Boc group in these conditions (base + acid at 80°C). This hydrolysis allows to 
have a free amino group which hinders the reaction. 
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3.3.2 STRATEGY 2 TO BIND BODIPY AND AMINO ACIDS 
 
Scheme 25. Synthetic pattern to obtain fluorescent dye 35 
The 2nd strategy consisted in a coupling reaction exploiting a disubstituted BODIPY and 4-formyl benzoic 
acid as linker (Scheme 25).  From previously experiments Knövenagel Condensation carried out directly 
with deprotected aldehyde causes a difficult purification process, reason why the used strategy involved 
a first protection of carboxyl groups, the coupling with BODIPY, a deprotection of carboxyl groups to 
proceed with a second coupling with protected amino acid.70 
Knövenagel Condensation was focus on obtain the substituted adduct by using 5 equivalents of 




. the disappearance of aldehydic proton signal; 
. the disappearance of the BODIPY methyl proton signal;  
. the appearance of the two protons of double bond at 7.80 and 7.26ppm; 
. the appearance of the t-butyl signal at 1.61ppm;  
. the symmetry of signals. 
 




Figure 56. 1H-NMR spectrum of compound 34. 
 
Figure 57. 13C-NMR spectrum of compound 34. 
The symmetry of the signals confirmed that the product was the bi-adduct. 
This reaction was carried out for 3 times varying some parameters such as reaction time, aldehyde 

















5 0.21 6 1h Flask 27 
10 0.21 6 50’ Flask / 
5 0.41 6 30’ Pyrex vial 82 
Tab 3 
Deprotection of carboxyl group from t-butyl occurred by using 4M HCl in dioxane. This product showed 
low solubility in DCM and MeOH, due to their two carboxyl groups. 
1H-NMR was presented below: 
. the disappearance of t-butyl signal; 
. the appearance of acidic protons signal at 13ppm. 
. a shift of aromatic signals to higher ppm. 
 
Figure 58: 1H-NMR spectrum of compound 39. 
Before the coupling, the carboxyl group of glycine was protected by using t-Butyl group. A first approach 
to obtain the product consisted in a reaction with H2SO4 in MTBE,71 but the product was not achieved. 
A second strategy involved the use of HClO4 (70%) in tert-butyl acetate. The yield of reaction was 10%, 
due to the high number of extractions, the glycine distributed in water phase, numerous extractions 
with saturated NaCl aqueous solution and organic solvents were required.72  
Coupling reaction occurred to synthesize two BODIPY adducts:  
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. the first molecule derived from mono-deprotection of compound 34 before the coupling with 33 (lack 
of symmetry in 1H-NMR spectrum).; 
. the second product 35 derived from a complete deprotection of compound 34 and a consequently 
coupling with 33 (symmetry in 1H-NMR spectrum). 
1H-NMR of fraction S showed: 
- The disappearance of the signals of acidic proton at 13 ppm; 
- The shift of sp2 no aromatic proton signals; 
- The appearance of amide proton signal (t at 6.73 ppm); 
- Signal appearance of 2 protons of glycine at 4.16ppm; 
- The appearance of the t-butyl signal at 1.51ppm. 
 
Figure 59. 1H-NMR spectrum of compound protected 35.  
The deprotection of the two t-butyl groups was performed with the same strategy previously 
mentioned for product 34.(4M solution of dioxane HCl). 
Of this compound UV-Vis absorption and fluorescence measurements were made (by excitation of the 
sample at 600nm) at different concentrations using MeOH as solvent. Starting from a 10-6M solution 




Figure 60. Uv-Vis Absorbum spectrum of compound 30 at different concentrations (M) in MeOH (λAss.Max= 
629nm). 
 
Figure 61. Fluorescente mission spectrum of compound 31 at different concentrations (M) in MeOH, excited 
wavelenght 600nm (λEmis.Max= 636nm). 
In addition, from the measurements of UV-Vis, the molar extinction coefficient (ε) was dated back to 
the wavelength that had maximum absorption, 629nm. 
 




3.3.3 STRATEGY 3 TO BIND BODIPY AND AMINO ACIDS 
 
Scheme 26: Synthetic pattern for fluorescent probe 38. 
Following the previously mentioned synthetic path, glycyl-dipeptide L-phenylalanine (Gly-L-Phe) was 
synthesized. Scheme 26. Design and synthesis of the dipeptide with a free amino group on glycine side 
was the first step of the project, then the coupling with 36. Glycine-Boc (36) was reacted with L-
phenylalanine-t-butyl through a coupling reaction using EDC HCl, DMAP, Tea and HOBt (anti-
racemizing)73 in dry DCM.74 
1H-NMR spectrum showed: 
. the disappearance of amide acid proton signals at 6.48 and 5.06ppm; 
. the appearance of a d to 6.48ppm due to amide proton of Phe; 
. the appearance of a dd at 4.75ppm due to the proton in α of Phe; 





Figure 63: 1H-NMR spectrum of product 37 protected.  
 
TFA 20% (w/w) solution was used to remove -Boc from a 0.1M solution of 36 in DCM. 2 eq of anisole75 
as Scavenger, were added to reaction mixture, to avoid that tert-butyl cation reacted with nucleophiles 
in the chemical environment. 76,77 
1H-NMR spectrum showed: 
. the disappearance of the -Boc signal; 
. the disappearance of the amide proton signal from Gly; 
. the shift of the amide proton of Phe from 6.48 to 7.56 ppm. 
 
Figure 64. H-NMR spectrum of compound 37. 
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Finally, the coupling reaction of compounds 39 and dipeptide 37 were performed adopting the 
conditions used previously.  
. Compound 39 was activated after the addition of EDC HCl and DMAP at room temperature for 1h; 
. compound 37 was added in two moments, spaced out 24h from each other; during the second 
addition 3eq of DMAP and 4eq of EDC HCl were introduced into the flask. 
1H-NMR revealed: 
- the disappearance of the acid proton signal at 13.0 ppm; 
- the change of the chemical shift of aromatic signals; 
- the change of the positions of the 2 protons in α of the Gly, from 3.40 to ≈ 4.00ppm; 
- the shift of the amide proton of Phe from 7.56 to 7.08 ppm. 
 




Figure 66.13C-NMR of product 38. 
Uv-Vis absorption and fluorescence measurements were carried out for this compound (exciting the 
sample at 600nm) at different concentration using MeOH as solvent. 
The starting 10-6M solution was gradually changed. 100μL of starting solution were gradually replaced 
with 100μL of MeOH. 
 




Figure 68. Fluorescence emission graph of product 38 at different concentrations (M) in MeOH, exciting at 600nm 
(λEmis.Max = 637nm) 
Furthermore, from the measures of UV-Vis ass, the molar extinction coefficient (ε) was extracted at the 
maximum absorption wavelength, 630nm. 
 
Figure 69. Absorption graph (at 630nm)-Concentration of product 34 in MeOH to calculate ε (ε630= 57995 M-1cm-1) 
Performed a synthesis to obtain a BODIPY-core conjugated with an amino acid or a peptide, was the 
foundation to the next goal to connect BODIPY dye with a more complex peptide, such as RGD 
sequence. 
3.3.4 SYNTHESIS PLAN OF RGD SEQUENCE 
To achieve the final RGD sequence, the synthetic pattern involves the realization of two dipeptides, 
which were reacted in a conclusive coupling.78 
SYNTHESIS OF DIPEPTIDE ONE 
The first step, as shown in Chart 11, was the protection of Serine with tert-Butyl acetate and perchloride 




Scheme 27. Synthetic pattern to synthesize Asp-Ser dipeptide. 
As shown in 1H-NMR spectrum we observed: 





Figure 70. 1H-NMR spectrum of compound 41. 
In the 2nd step of coupling the protected Serine (compound 41) was reacted with Fmoc-Asp(OtBu)-OH 
(compound 42 ) in dichloromethane, by adding EDC.HCl and HOBt at 0°C. 
1H-NMR spectrum of compound 43 showed: 
. a signal connected to aromatic hydrogens of Fmoc; 
. an additional signal due to protecting group of aspartic acid; 
. the disappearance of signals connected to amino protons of serine.  
 
Figure 71. 1H-NMR spectrum of compound 43. 
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The removal of protecting group (Fmoc) of aspartic acid with 10% solution of DEA in CH3CN (N2 
atmosphere, 1.5 h). 
1H -NMR of compound 44 revealed: 
. signals of aromatic protons of Fmoc. 
 
 
Figure 72. 1H-NMR spectrum of compound 44. 
SYNTHESIS OF DIPEPTYDE TWO 
The protection of Glycine occurred both by using tert-butyloxycarbonyl protecting group to protect 




Scheme 28: Synthetic pattern to synthesize Arg-Gly dipeptide. 
1H-NMR showed: 
. CH3 singlet of tert-butoxycarbonyl in the first synthetic step; 




Figure 73. 1H-NMR spectrum of compound 29 and 45 
 
In third step tert-Butyloxycarbonyl protecting group of 45 was removed by using a solution 4M of HCl 
in dioxane for 2h. 
1H-NMR of 47 compound revealed: 




Figure 74. 1H-NMR spectrum of compound 46 
Compound 46 was reacted with Fmoc-Arg(Pbf)-OH (47) in dichloromethane by adding EDC HCl and 
HOBt at 0°C. 
1H-NMR of compound 48 showed: 
. signals of aromatic protons regarding Fmoc and benzyl group; 
. singlet of -CH2 of benzyl group centered on 5.10 ppm; 
. -CH3 singlet of Pbf protecting group; 
 





Figure 76. 13C-NMR spectrum of compound 48 
Pd(OH)2 and H2 were used in methanol to remove benzyl groups. 
1H-NMR of compound 49 was shown below: 
. the disappearance of previously mentioned singlet at 5.10 ppm; 
. the disappearance of signals concerning aromatic protons. 
 




Figure 78. 13C-NMR spectrum of compound 49 
SYNTHESIS OF TERAPEPTIDE 
 
Scheme 29. Synthetic pattern to obtain RGD tetrapeptide. 
The first step concerned the coupling reaction of dipeptide 44 and dipeptide 45 in dichloromethane, by 
adding EDC HCl and HOBt at 0°C. 
1H-NMR of compound 50 revealed signals connected to all protecting groups: 
. tert-butyl around 1.5 ppm; 
. methyl groups of Pbf around 2-2.5 ppm; 





Figure 79. 1H-NMR spectrum of compound 50. 
 
Figure 80. 1H-NMR spectrum of compound 50. 
The second step consisted in the removal of amine’s Fmoc, protecting group of arginine, achieved by a 
treatment of a solution 10% DEA in anhydrous CH3CN. This step is fundamental in the consequently 
coupling to synthesize compound 51. 1H-NMR revealed that: 
. the disappearance of signals concerning aromatic protons of Fmoc group around 8-7 ppm; 




Figure 81. 1H-NMR spectrum of tetrapeptide RGD-Ser 51. 
 
Figure 82. 1H-NMR spectrum of tetrapeptide RGD-Ser 51. 
 
FUNCTIONALIZATION OF BODIPY 
The first functionalization step was Knövengel Condensation focused on achievement of double adduct, 
by using 5 eq of 36, pyrrolidine and acetic acid in anhydrous CH3CN. The reaction was carried out at 
90°C. After 10’ a relevant change of color solution occurred: from red to blue. The reaction was 





Scheme 30: Synthetic Pattern for BODIPY functionalization. 
The consecutive step was a coupling reaction concerning tetrapeptide 53 and functionalized Bodipy 34 
in dichloromethane with the addition EDC HCl and HOBt at 0°C. 1H-NMR spectrum showed: 
. aromatic protons of Bodipy between 7 – 8 ppm; 
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. the signal of pyrrolic hydrogen at 6.78 ppm; 
. the methyl signals of Pbf and tetrabuthyl of Boc. 
 
Figure 83. 1H-NMR spectrum of compound 53. 
 
Figure 84. IR spectrum of compound 53. 




Figure 85. Uv-Vis absorption graph of compound 53 at different concentrations (M) in MeOH (λAss.Max= 632nm). 
 
The removal of all protecting groups, Pbf and Boc, occurred after the reaction of peptide 53 with a 
solution of TFA/H2O/triisopropylsilane 90/5/5 at a temperature higher of 30°C for 2h, as shown in Chart 
15. Compound 54 was purified by C18 reversed-phase chromatography column. 
 
Scheme 31. Deprotection of compound 53 to afford compound 54 
3.4 CONCLUSION AND PERSPECTIVES 
The goal of this project was the design and synthesis of BODIPY dye derivatives for biological 
applications. Compound 40 was partially characterized thanks to a first purification. 
Future outlooks: 
. improvement in yields; 
. studies of biological and spectrophotometric of BODIPY dyes with different aminoacidic chains; 




3.5 MATERIALS AND METHODS 
 
SYNTHESIS OF BODIPY Azide 27 
 
In a 25 mL flask compound 20 (250 mg, 0.73 mmol, 1 eq) was dissolved in dry CH3CN (10 mL). t-buthyl 
nitrite (113 mg, 0.13 mL, 1.10 mmol, 1.5 eq) and TMS-N3 (102 mg, 0.12 mL, 0.88 mmol, 1.2 eq) were 
added to the mixture in an ice-water bath. The reaction was stirred overnight at room temperature. At 
the end of reaction TLC showed a new spot with Rf: 0.43 (P.Et.:DCM 1:2). The flask was washed with 
dichloromethane and dried on rotavapor. The crude product was purified on flash chromatography 
column (2 cm, Pet.E.:DCM 1:4 -> 1:1). Yield: 176mg (66%). Red-pink solid. 
 
1H-NMR (CDCl3, 200Hz) δ (ppm): 7.27 (AA’ of a system AA’-BB’, 2H, J=7.6Hz, Ha); 7.17 (BB’ of a system 
AA’-BB’, 2H, J=8.2Hz, Hb); 5.99 (s, 2H, Hc); 2.56 (s, 6H, Hd); 1.42 (s, 6H, He). 
 
SYNTHESIS OF of p-amino benzaldehyde 28 
 
In a 100ml flask p-nitrobenzaldehyde (500mg, 3.3mmol, 1eq) was dissolved in EtOH (45mL). SnCl2 ·2H2O 
(3750mg, 16.6mmol, 5eq) was added and the mixture refluxed for 4h. At the end of the reaction a yellow 
spot is noted in TLC (2: 1 E.Pet:AcOEt, Rf: 0.52). A saturated solution with NaHCO3 was added up to 7-8 
pH of the solution. The organic phase were extracted with EtOAc, washed with water and then with 
Brine. The organic phase was dried over Na2SO4 and the solvent was evaporated. Yield: 325mg (85%). 
The product is a yellow-orange scaly compound 
1H-NMR (CDCl3, 400Hz) δ (ppm): 9.78 (s, 1H, Ha); 7.70 (Part AA 'of an AA system' - BB ', 2H, Hb); 6.70 
(Part BB 'of an AA'-BB' system, 2H, Hc); 4.22 (bs, 2H, Hd) 
SYNTHESIS OF BOC-Glycine 29 
 
A 50 mL flask equipped with a stirring bar was charged with Glycine (26) (1.5g, 20 mmol), Boc2O (6.5g, 
30 mmol, 1.5eq), MeOH (20.6 mL) and TEA (1.65g, 2.28 mL, 16.4 mmol, 0.82eq). The system was heated 
to reflux for 30’. At the end of reaction, 60 mL of 0.1 M HCl solution were added in an ice-bath, checking 
pH solution up to 3.  The organic layer was extracted with EtOAc, washed with brine and anhydrified on 
Na2SO4 and dried to achieve a white solid compound. Yield: 1.4g (50%). White solid. 
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1H-NMR (CDCl3, 200Hz) δ (ppm): 3.95 (dd, 2H, Hc); 1.45 (s, 9H, Hd) 
SYNTHESIS OF compound 30 
 
In a 50ml flask p-aminobenzaldehyde (300mg, 2,47mmol, 1eq) and DCM (20mL) were placed. EDC HCl 
(947mg, 4.94mmol, 2eq), TEA (375mg, 0.515mL, 3.7mmol, 1.5eq), DMAP (30mg, 0.247mmol, 0.1eq) and 
finally glycine-Boc (435mg, 2.47mmol, 1eq) were added. After 24 hours under stirring the solution 
gradually became opaque orange. At the end of the reaction. After a TLC check (40: 1 DCM: MeOH, Rf: 
0.33) the crude was purified by flash chromatography (column of 5, 50: 1 DCM: MeOH → 5: 1). Yield: 
128mg (19%). Pale yellow compound 
1H-NMR (CDCl3, 200Hz) δ (ppm): 9.91 (s, 1H, Ha); 7.85 (Part AA 'of an AA system'- BB ', 2H, J = 8.6Hz Hb); 
7.70 (Part BB 'of an AA'-BB' system, 2H, J = 8.6Hz, Hc); 5.38 (bs, 1H, Hd); 3.97 (d, 2H, J = 6.0Hz, He); 1.48 
(s, 9H, Hf) 
13C-NMR (CDCl3, 400Hz) δ (ppm): C10 191.1, C5 168.6, C3 156.7, C6 143.4, C8 132.2, C9 131.0, C7 119.4, 
C2 80.8, C4 45.4, C1 28.3 
 
SYNTHESIS OF t-buthyl-4-formylbenzoate 32  
 
In a 500ml flask, p-formylbenzoic acid (2000mg, 13.3mmol, 1eq) was solubilized in t-BuOH (200mL). 
Boc2O (3292mg, 15.06mmol, 1.13eq) and DMAP (1080mg, 8.84mmol, 0.66eq) were added. The reaction 
was monitored by TLC (1: 1 Pet Et: EtOAc, Rf: 0.88). At the end of reaction, after 16h, the reaction 
mixture was diluted with DCM (300mL), the organic phase was washed with a saturated solution of 
Na2CO3 (2x100mL) and then with 0.1M of HCl solution (2x120mL). After the addition of Brine (150mL). 
It was dried on Na2CO3 and dried. Yield: 984mg (36%) of a white solid. 
1H-NMR (CDCl3, 200Hz) δ (ppm): 10.16 (s, 1H, Ha); 8.20 (Part AA 'of an AA'-BB' system, 2H, J = 7.8Hz, 
Hb); 7.99 (Part BB 'of an AA'-BB' system, 2H, J = 8.2Hz Hc); 1.68 (s, 9H, Hd) 




Compound 27 (45mg, 0.12mmol, 1eq) and compound 32 (126mg, 0.61mmol, 5eq) were placed in a 
pyrex tube. 3 mL of dry CH3CN were used to solubilize the solid. Pyrrolidine (52mg, 0.060mL, 1.02mmol, 
6eq) and the Acetic acid (43mg, 0.041mL, 1.02mmol, 6eq) were added, the mixture refluxed (80-90 ° C). 
After 10’ a change in the color of the solution from red to dark blue was observed. The reaction was 
monitored by TLC (2: 1 DCM: Pet.Et., Rf: 0.47). After 30 'the reaction was blocked. 
The mixture was diluted with 40mL of DCM. The organic phase was washed with H2O (4x25mL) and 
Brine (2x30mL), dried on Na2SO4 and finally evaporated. The resulting crude is then purified by flash 
chromatography column (1: 1 DCM: Pet.Et  3: 1) Yield: 75mg (82%). Compound Dark Blue 
1H-NMR (CDCl3, 400Hz) δ (ppm): 8.01 (Part AA 'of an AA'-BB' system, 4H, J = 8.0Hz Has); 7.80 (d, 2H, J = 
16.4Hz Hb); 7.65 (Part BB 'of an AA'-BB' system, 4H, J = 8.4Hz Hc); 7.31 (Part AA 'of an AA'-BB' system, 
2H, J = 8.4Hz, Hd); 7.26 (d, 2H, J = 16.4Hz, He); 7.18 (Part BB 'of an AA'-BB' system, 2H, J = 8.4Hz, Hf); 
6.64 (s, 2H, Hg); 1.62 (s, 18H, Hh); 1.50 (s, 6H, Hi) 
13C-NMR (CDCl3, 400Hz) δ (ppm): C3 165.4, C10 152.4, C19 142.3, C16 141.2, C7 140.2, C8 138.5, 135.4, 
133.81, 131.9, 131.3, 130.0, 129.9, 127.2, C12 121.0, C11 119.8, C9 118.3, C2 81.1, C1 28.2, C13 15.0 
 
SYNTHESIS OF tert-Butyl-glycine 33 
 
In a 100mL flask, glycine (1000mg, 13.3mmol, 1eq) was suspended in tert-Butyl acetate (50mL). Placed 
the flask in the ice bath under stirring and drop to drop 70% HClO4 (3034mg, 1.8mL, 20mmol, 1.5eq). At 
room temperature the reaction proceeded for 40h. The reaction was monitored via TLC (1: 1 MeOH: 
EtOAc, Rf: 0.45). The reaction mixture was washed with H2O (125mL) and then with a 1M HCl solution 
(75mL). The aqueous phase was treated with a 10% (w / w) solution of K2CO3, until up to pH 9 (≈250mL) 
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and then the aqueous phasewere extracted with DCM (300mL). Part of the product remained in the 
aqueous phase, more extractions were required first with hexane and then with Et2O. The organic phase 
was dried over Na2SO4. Yield: 180mg (10%) of an oil. 
1H-NMR (CDCl3, 200Hz) δ (ppm): 3.31 (s, 2H, Ha); 1.46 (s, 9H, Hb) 
SYNTHESIS OF compound deprotected 34 
 
Compound 34 (34mg, 0.046mmol, 1eq) was placed in a Pyrex tube. Then 4M HCl solution in dioxane 
(0.5mL) was add. The reaction occurred at room temperature for 5.5h and it was monitored via TLC 
(DCM, Rf: 0). Various aliquots of 4M HCl in Dioxane (for a total of 1.2mL) were added. Once the reaction 
was finished, the mixture was diluted with DCM (10mL) and dried. Yield: 28mg (Quantitative). 
1H-NMR (DMSO, 400Hz) δ (ppm): 13.01 (s, 2H, Ha); 8.00 (Part AA 'of an AA'-BB' system, 4H, J = 8.0Hz, 
Hb); 7.95 (d, 2H, J = 16.4Hz, Hc); 7.72 (Part BB 'of an AA'-BB' system, 4H, J = 8.0Hz, Hd); 7.64 (d, 2H, J = 
16.4Hz, He); 7.49 (Part AA 'of an AA'-BB' system, 2H, J = 8.0Hz, Hf); 7.32 (Part BB 'of system AA'-BB', 2H, 
J = 8.4Hz, Hg); 7.05 (s, 2H, Hh); 1.48 (s, 6H, Hi). 
SYNTHESIS OF protected compound 35 
 
In a 25mL single-neck flask compound deprotected 34 (24mg, 0.038mmol, 1eq) was dissolve in DCM 
(6mL). The flask was placed in an ice bath and added DMAP (14mg, 0.114mmol, 3eq) and EDC · HCl 
(22mg, 0.114mmol, 3eq), then the mixture was stirred at room temperature for 1h. Compound 29 
(15mg, 0.114mmol, 3eq) was dissolved in 0.5mL of DCM. After 24h at room temperature additional 6eq 
of EDC HCl (44mg, 0.228mmol), 3eq of DMAP (14mg, 0.114mmol) and 3eq of compound 29 (15mg, 
0.114mmol) were placed in the flask in 0.5mL of DCM. The reaction was monitored via TLC (Rf: 0.21, 2: 
1 Pet.Et.:EtOAc). Then the mixture was diluted with DCM (10mL), washed with H2O (2x10mL) and then 
with a 5% (w / w) solution of NaHCO3 (20mL). 
Re-extractrion of aqueous phase with DCM was required. Then washed with Brine (30mL), dried over 
Na2SO4. The crude was purified by flash chromatography column 15: 1 Pet.Et : EtOAc → EtOAc Yield: 
11mg (34%) of a dark blue product 
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1H-NMR (CDCl3, 400Hz) δ (ppm): 7.84 (Part AA 'of an AA'-BB' system, 4H, J = 8.4Hz, Ha); 7.79 (d, 2H, J = 
16.4Hz, Hb); 7.67 (Part BB 'of an AA'-BB' system, 4H, J = 8.4Hz, Hc); 7.32 (Part AA 'of an AA'-BB' system, 
2H, J = 8.4Hz, Hd); 7.27 (d, 2H, J = 16.0, He); 7.18 (Part BB 'of an AA'-BB' system, 2H, J = 8.4Hz, Hf); 6.73 
(t, 2H, J = 4.8Hz, Hg); 6.68 (s, 2H, Hh); 4.16 (d, 4H, J = 4.8Hz, Hi); 1.51 (s, 18H, H1); 1.49 (s, 6H, Hm) 
SYNTHESIS OF compound 35 
 
In a 10mL flask compound protected 35 (11mg, 0.013mmol) was placed. After the addition of 4M HCl 
solution in dioxane (1.5mL) the mixture was stirred at room temperature for 48h. The reaction was 
controlled by TLC (Rf: 0, 1: 1 EtOAc:Pet.Et.). At the end of reaction the solvent was evaporated.  
SYNTHESIS OF compound 37 
 
Glycine-Boc  (1000mg, 5.71mmol, 1.2eq), Lt-Bu-phenylalanine HCl (1225mg, 4.75mmol, 1eq), EDC HCl 
(1094mg, 5.71 mmol, 1.2eq), HOBt (772mg, 5.71mmol, 1.2eq) and DMAP (29mg, 0.24mmol, 0.05eq) 
were placed in a 50 mL flask. With dry DCM (15mL) to solubilize the substrates. At 5 ° C distilled TEA 
was added. The reaction was monitored via TLC (1.25: 1 EtOAc:Et.Pet, Rf: 0.58. The crude mixture was 
washed with a saturated solution of NH4Cl (70mL). The organic phase was extracted, while the aqueous 
layers were rewashed with DCM (3x50mL). The combined organic phases, were treated with Brine 
(2x50) and H2O (70mL). Dried over Na2SO4. The product was purified for flash chromatography (500mg 
of crude, 1.25: 1 EtOAc:Pet.Et, the product was collected. Yield: 493 g  
1H-NMR (CDCl3, 400Hz) δ (ppm): 7.29-7.13 (m, 5H, Ha); 6.48 (d, 1H, J = 7.6 Hz, Hb); 5.06 (bs, 1H, Hc); 
4.75 (dd, 1H, J = 13.6, 6Hz, Hd); 3.84 (dd, 1H, J = 16.8, 5.6Hz, He); 3.74 (dd, 1H, J = 16.8, 5.6Hz, Hf); 3.08 





SYNTHESIS OF compound protected 38 
 
In a 50mL flask, compound 39 (62mg, 0.098mmol, 1eq) was dissolved in DCM (15mL). EDC HCl (75mg, 
0.392mmol, 4eq) and DMAP (36mg, 0.294mmol, 3eq) were added. The reaction was stirred at room 
temperature for 1h. In the meantime, compound 37 (155mg, 0.55mmol, 5.6eq) was dissolved in 6mL of 
DCM and 3mL of the solution were added to the reaction flask, at room temperature. Other 4eq of EDC 
HCl, 3eq of DMAP and the remaining solution of compound 33 in DCM, then leave to stir for another 
24h. The reaction is monitored by TLC (Rf: 0.29, 2: 1 AcOEt: hexane). The mixture was diluted with DCM 
(20mL) and washed the organic phase with H2O (2x25mL), with a 5% (w / w) solution of NaHCO3 (50mL) 
and with Brine (70mL). The product in solution was dried. The crude was purified by Flash 
Chromatography (column of 2 cm, 15: 1 hexane: EtOAc → 20: 1 EtOAc: hexane.  Yield: 45mg (40%) of a 
dark blue scaly compound. 
1H-NMR (CDCl3, 400Hz) δ (ppm): 7.80 (Part AA 'of an AA'-BB' system, 4H, J = 8.4Hz, Ha); 7.73 (d, 2H, J = 
16.4Hz, Hb); 7.55 (Part BB 'of an AA'-BB' system, 4H, J = 8.4Hz, Hc); 7.27-7.14 (m, 14H, Hd); 7.08 (d, 2H, 
J = 7.6Hz, He); 6.62 (s, 2H, Hf); 4.78 (dd, 2H, J = 13.6, 6.4Hz, Hg); 4.14-4.00 (m, 4H, Hh); 3.14 (m, 4H, Hi); 
1.44 (s, 6H, H1); 1.39 (s, 18H, Hm) 
13C-NMR (CDCl3, 400Hz) δ (ppm): C3 170.5, C10 169.2, C12 167.2, C19 152.5, C28 142.2, C25 141.2, C16 
139.6, C17 138.3, 136.0, C6 135.5, 133.7, 133.1, 131.3, 130.0, 129.5, 128.4, C7 127.8, C8 127.4, C9 127.0, 







SYNTHESIS OF compound 38 
Compound protected 38 (40mg, 0.035mmol) was placed in a 25mL flask and 4M HCl solution in Dioxane 
(5mL) were added. The reaction was monitored via TLC (Rf: 0, 3: 1 AcOEt: E.Pet). The reaction mixture 
was dried. 
 
SYNTHESIS OF OtBu-Serine 41 
 
1g (9.5 mmol) of serine and t-buthyl acetate (21 mg, 72 mmol) were placed in a flask equipped with a 
stirring bar. HClO4 (0.8 mL) were added by using a dropping funnel can. After 6h, 10 mL of HCl (2M) 
were added and, consequently K2CO3 up to pH 9. The reaction mixture was extracted with DCM (60 mL) 
and the organic layer washed with H2O (40 mL, 2 times), Brine (40 mL, 2 times). At the end the extracts 
were combined, dried over anhydrous MgSO4, filtered, and evaporated. Yield: 1.1g (55%). The 
compound is a colorless oil. 
1H-NMR (CDCl3, 200Hz) δ (ppm): 3.57 (m, 2H, HA), 3.43(m, 1H, HB) 1.69 (s, 2H, HE), 1.46 (s, 9H, HD), 
1.16 (s, 9H, HC) 
 
SYNTHESIS OF compound 43 
 
Ser-OtBu (500 mg, 2.3 mmol, 1 eq) and Fmoc-Asp(OtBu)-OH (946 mg, 2.3 mmol, 1 eq) were reacted in 
a flask with DCM (12 mL) uder stirring at room temperature. At 0°C EDC HCl (490 mg, 2.75 mmol, 1.2eq) 
was added to the mixture, after 10’ HOBt (373 mg, 2.75 mmol, 1.2ew) was placed in the flask. After the 
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night via TLC a new spot Rf: 0.92 (DCM:EtOAc 3:1) was formed. The mixture was diluted with DCM and 
washed with H2O (10 mL x 2), extracted again with fresh DCM. The organic phase was dried over 
Na2SO4, filtered to obtain an orange-yellow oil. Yield: 840mg (60%)  
1H-NMR (CDCl3, 400Hz) δ (ppm): 7.77 (d, 2H, HF); 7.59 (d, 2H, HG); 7.40 (t, 2H, HE); 7.31 (t, 2H, HD); 6.01 
(d, 1H, HH); 4.63 (m, part X of a system ABX, 1H, HN); 4.53 (dt, part X of a system ABX, 1H, HR); 4.38 (d, 
part AB of a system ABX, 2H, HM); 4.23 (t, part X of a system ABX, 1H, HQ); 3.81-3.50 (Part AB of a 
system ABX, 1H, HP); 2.93-2.65 (part AB of a system ABX, 2H, HL); 1.45 (s, 18H, HA e HC); 1.15 (s, 9H, 
HB). 
 
SYNTHESIS OF compound 44 
 
In a 100 mL flask compound 43 (980mg, 1.60mmol, 1eq) was dissolved in 25mL of dry CH3CN and 2.5mL 
of DEA. The reaction was carried out under N2 atmosphere for 1.5h. TLC checking confirmed the end of 
reaction: a first spot due to fulvene (Rf: 0.92, DCM : EtOAc 50:1) and a second one associated to the 
product (Rf: 0.71).  
After the evaporation of CH3CN and DEA, a washing with Et2O occurred. Despite this procedure, 1H-NMR 
spectrum showed the presence of byproducts. The purification proceeded with a flash chromatography 
(2 cm column, DCM:EtOAc 100:1 -> EtOAc). Yield: 580mg (93%). The product was an orange-yellow oil. 
 
1H NMR (400 MHz, CDCl3) δ (ppm): 7.96 (d, 1H, HL); 4.55 (dt, part X of a system ABX, 1H, HE); 3.80-3.72 
(part AB of a system ABX, 2H, HD); 3.51 (dd, 1H, part X of a system ABX, HF); 2.70 (Part AB of a system 
ABX, 2H, HG); 1.46 (s, 9H, HC); 1.45 (s, 9H, HB); 1.14 (s, 9H, HA). 
 
SYNTHESIS OF BOC -Gly-OBn 45  
 
Gly-BOC (1.4g, 8 mmol, 1eq) and CH3CN were placed in a flask, therefore DBU (1.22g, 8 mmol, 1.22 mL, 
1.02 g/cm3, 1eq) was added. In an ice-bath benzyl bromide (1.4g, 8 mmol, 1mL, 1.4 g/cm3). After two 
days at room temperature, CH3CN was evaporated, the crude product was diluted with DCM (100 mL) 
e therefore first KHSO4 1M (2 x 75 mL) and then NaHCO3 were added and the final product extracted 
and dried over Na2SO4. The removal of residual benzyl bromide occurred after the addition of Petroleum 
Ether to the white crude product and the filtration on Buchner. Yield: 1.19g (50%) The product was a 
white solid. 
1H-NMR (CDCl3, 200Hz) δ (ppm): 7.36 (s, 5H, HA), 5.18 (s, 2H, HB), 3.96 (d, 2H, HC), 1.44 (s, 9H, HD)  
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SYNTHESIS OF H2N-Gly-OBn 46 
 
Compound 45 (1.2g, 4.3mmol, 1eq) was dissolved in 8mL of a 4M solution of HCl in dioxane. After 2h 
under stirring the end of reaction was confirmed by TLC (Rf: 0.91, EtOAc : Pet.E. 1:5). The crude product 
was dried and after the addition of Et2O a precipitate was achieved in an ice-bath. Yield: White solid 
700mg (Quantitative yield) 
1H-NMR (CDCl3, 400Hz) δ (ppm): 7.24 (s, 5H, Ha); 5.16 (bs, 2H, Hb); 4.00 (bs, 2H, Hc) 
 
SYNTHESIS OF compound 48 
 
Compound 46 (254mg, 1.54mmol, 1eq) and Fmoc-Arg-(Pbf) (47) (1g, 1.54mmol, 1eq) were dissolved in 
a flask thanks to 5 mL of DCM. Under stirring, at 0°C EDC HCl (328 mg, 1.85mmol, 1.2eq) was added. 
After 10’ HOBt (250 mg, 1.85mmol, 1.2eq) was added in the same reaction conditions. After 16h a TLC 
checking showed a new spot (Rf: 0.46, DCM: EtOAc 1:1). The crude was washed with H2O and Brine, 
dried over Na2SO4 , filtered and the solvent was evaporated.  
The purification occurred through flash chromatography column (4 cm, DCM:EtOAc 12:1 -> 1:1) 
 Yield: 805mg (66%) 
 
1H NMR (400 MHz, DMSO) δ (ppm): 8.36 (t, 1H, HZ); 7.88-7.33 (m, 13H, HF e HO); 5.10 (s, 2H, HN); 4.27-
4.17 (m, 3H, HB e HC) 4.03-3.94 (m, 1H, HD); 3.91-3.82 (m, 2H, HE); (3.00 (m, 2H, HA); 2.87 (s, 2H, HE); 
2.47 (s, 3H, HK); 2.38 (s, 3H, HH); 1.98 (s, 3H, HI); 1.60 (m, 2H, HM); 1.46 (m, 2H, HP); 1.37 (s, 6H, HL). 
 
13C-NMR (100 MHz, DMSO) δ (ppm): C19 172.85, C21 170.05, C13 157.90, C14 156.73, C29 144.34, C32 
e C43 144.26, C37 e C38 141.16, C8 137.74, C23 136.29, C5 131.88, C25 e C27 128.93, C28 e C24 128.51, 
C35 128.40, C40 128.09, C36 127.51, C39 125.80, C41 124.77, C34 120.54, C10 116.72, C33 85.96, C42 
66.31, C6 66.12, C30 60.20, C22 54.58, C18 47.11, C31 42.91, C4 41.19, C5 29.76, C20 28.73, C17 25.33, 





SYNTHESIS OF compound 49 
 
 
Compound 48 (680mg, 0.96mmol, 1eq) and 10% w/w of Pd(OH)2/C (68mg, 0.48mmol, 0.5eq) were 
placed in a 250mL flask under stirring. After the addition of 80mL of MeOH the reaction was kept under 
N2 for 10’. The substitution of nitrogen with hydrogen occurred for the night. The end of reaction was 
checked by TLC (Rf:0). A filtration through celite allows to obtain the final product. Yield: 520mg (77%). 
The product was a white solid. 
 
1H NMR (400 MHz, DMSO) δ (ppm): 7.87-7.29 (m, 8H, HF); 7.06 (s, 1H, HN); 6.59 (s, 1H, HO); 4.22 (m, 
part X of a system ABX, 1H, HB); 4.00-3.92 (part AB of a system ABX, 2H, HD); 3.75-3.67 (System ABX, 
3H, HD e HE); 3.03 (m, 2H, HG); 2.94 (d, 2H, HG); 2.47 (s, 3H, HH); 2.41 (s, 3H, HZ); 1.99 (d, 3H, HI); 1.45 
(m, 2H, HF); 1.39 (s, 3H, HM); 1.37 (s, 6H, HL) 
 
13C NMR (100 MHz, CD3OD) δ (ppm): C21 173.32, C19 172.38, C5 172.03, C14 170.40, C22 158.70, C25 
157.39, C32 157.20, C29 149.89, C36 145.00, C9 141.96, C6 141.14, C12 138.55, C28 132.69, C35 128.89, 
C27 128.33, C11 126.62, C26 125.42, C33 121.35, C8 117.53, C4 87.58, C23 66.51, C18 55.39, C34 53.11, 






SYNTHESIS OF compound 50 
 
Compound 44 (286mg, 0.74mmol, 1eq) and 49 (520mg, 0.74mmol, 1eq) were placed in a flask with 15 
mL of DCM. At 0°C EDC HCl (157mg, 0.89mmol, 1.2eq) was added and after 10’ under stirring HOBt (120 
mg, 0.89mmol, 1.2eq) was put it into the flask. TLC check displayed the end of reaction (Rf: 0.69, EtOAc 
: MeOH 10:1). The workup consisted in washing the mixture with H2O (10 mL x 2) and then Brine (10 mL 
x 2). The combined organic layers were dried over Na2SO4 and the solvent evaporated by rotavapor.  
The crude was purified by flash chromatography column ( 3 cm of diameter, DCM : EtOAc 100:1 -> 
EtOAc). Yield: 728mg (91%). The product was a white solid. 
1H-NMR (400 Hz, CD3OD) δ (ppm): 7.77-7.29 (8H, HD); 4.80 (t, part X of a system ABX, 1H, HA); 4.44 (m, 
part AB of a system ABX, 2H, HC); 4.35 (m, part X of a system ABX, 1H, HE); 4.21 (t, part X of a system 
ABX, 1H, HB); 4.02 (t, part X of a system ABX, 1H, HF); 3.81 (s, 2H, HG); 3.72-3.51 (dd, 2H, part AB of a 
system ABX, HH); 2.96 (s, 2H, HO); 2.82- 2.63 (dd, parte AB di sistema ABX, 2H, HV); 2.57 (s, 3H, HP); 
2.50 (s, 3H, HM); 2.06 (s, 3H, HN); 1.76 (m, 2H, HX); 1.66 (m, 2H, HW); 1.55 (m, 2H, HY); 1.47 (s, 3H, HS); 
1.43 (s, 9H, HL); 1.42 (s, 3H, HQ); 1.37 (s, 9H, HT); 1.14 (s, 9H, HU). 
 
13C-NMR (100 MHz, CD3OD) δ (ppm): C21 174. 17, C55 171.21, C19 170.00, C34 169.13, C28 158.45, C10 
157.23, C14 156.73, C40 e C39 143.85, C7143.76, C43 e C54 141.21, C2 137.99, C48 e C49 132.95, C3 
132.10, C5 127.38, C47 e C50 126.78, C45 e C52 124.91, C44 e C53 124.85, C8 124.60, C51 e C46 119.53, 
C13 117.02, C24 86.23, C31 81.49, C38 81.12, C41 72.97, C30 66.59, C29 61.58, C42 61.36, C15 55.03, 
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C17 53.75, C22 49.48, C1 42.54, C20 42.08, C23 36.86, C35 e C36 e C37 28.28, C25 e C26 C27 27.28, C32 




SYNTHESIS OF compound 51 
 
Compound 50 (250mg, 0.23mmol, 1eq) was dissolved in 11mL of dry CH3CN and 1.1 mL of DEA. The 
reaction proceeded for 3h, under N2 atmosphere. At the end of reaction a TLC analysis showed three 
spots DCM:MeOH 50:1: fulvene Rf: 0.92, starting material Rf: 0.5, final product Rf: 0.35.  
CH3CN and DEA were removed by using rotavapor. The workup consisted in a washing with Et2O. 1H-
NMR spectrum presented fulvene’s signals; therefore a flash chromatography column allows to achieve 
the final compound. (1 cm column diameter, DCM -> DCM:MeOH 10:1). 
 Yield: 166mg (84%). The product was a white solid. 
 
1H-NMR (CD3OD, 400Hz) δ (ppm): 4.80 (s, part X of a system ABX, 1H, HV); 4.40(t, part X of a system 
ABX, HT); 3.86-3.91 (m, 2H, HQ); 3.54-3.79 (dd, 2H, HS); 3.34 (m, 2H, HR); 3.17(s, 2H, HP); 2.99 (s, 2H, 
HN); 2.62-2.82 (part AB of a system ABX, 2H, HM); 2.57 (s, 3H, HL); 2.51 (s, 3H, HI); 2.07 (s, 3H, HH); 1.70 
(m, 2H, HG); 1.56 (m, 2H, HF); 1.45 (s, 18H, HB e HC); 1.44 (s, 6H, HE e HD); 1.17 (s, 9H, HA) 
 
13C NMR (100 MHz, CD3OD) δ (ppm): C39 176.22, C38 171.21, C37 170.20, C36 169.87, C35 169.13, C34 
158.44, C31156.71, C33 137.96, C29 133.02, C32 132.09, C30 124.59, C28 117.00, C27 86.25, C26 81.54, 
C25 81.22, C24 73.02, C23 61.40, C22 54.14, C21 53.75, C20 49.45, C18 42.58, C19 41.89, C17 37.01, 
C40 31.55, C14 27.34, C15 26.97, C12 e C11 e C10 26.94, C9 e C8 and C7 26.31, C6 e C5 e C426.28, C16 





SYNTHESIS OF compound 53 
 
Compounds 34 (166mg, 0.20mmol, 2.5eq) and 51 (49mg, 0.08mmol, 1eq) were put in a flask with 1.5mL 
of DCM. At 0°C EDC HCl(41.4 mg, 0.23mmol, 2.9eq) was added and after 10’ HOBt (31.5mg, 0.23mmol, 
2.9eq) was put into the flask. After 16h the mixture was washed with H2O and Brine. The combined 
organic layers were dried over Na2SO4 , filtered and evaporated. Flash chromatography column allows 
to purify the crude product. Rf: 0.36, DCM:MeOH 50:1 -> 10:1. 
 Yield: 2, 80mg (45%). Solid blue product. 
 
1H NMR (400 MHz, CD3OD) δ (ppm): 7.88 (Part AA’ of a system AA’-BB’, 4H, J=8Hz, HF); 7.75 (d, 2H, 
J=16Hz, HE); 7.63 (Part BB’ of a system AA’-BB’, 4H, J=8Hz, HG); 7.38 (d, 2H, J=16.0, HD); 7.27(Part AA’ 
of a system AA’-BB’, 2H, J=8Hz, HA); 7.20 (Part BB’ of a system AA’-BB’, 2H, J=8Hz, HH); 6.78(s, 2H, HC); 
4.57-4.39 (t, 2H, HK e HJ); 3.89 (dd, 2H, HI); 3.75-3.49 (dd, 2H, HL); 3.63 (t, 1H, HX); 3.21 (m, 2H, 
Hgamma); 2.93 (s, 2H, HZ); 2.89-2.66 (dd, 2H, HV); 2.57 (s, 3H, HN); 2.51 (s, 3H, HM); 2.03 (s, 3H, HO); 







SYNTHESIS OF compound 54 
 
Compound 53 (40mg, 0.02mmol, 1eq) with 80μL of H2O and 80μL of triisopropylsilane were put into a 
flask. 1.5mL of TFA was added drop by drop. After 2h at room temperature a TLC check showed a new 
spot with Rf:0. The solvent was evaporated. 
 
Purification occurred by reverse silica gel C18 column. A starting solution 1% of TFA in H2O was 
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4. Study of anticancer biological activity of biguanide 
derivative, compared to metformin activity. 
 
4.1 OBJECTIVES OF THIS CHAPTER (4) I 
As presented in our first work,1 due to the activity of metformin in cancer cells, we decided to conjugate 
this molecule to carbon nanotubes, but we didn’t exploit a covalent bond which failed in the 
intracellular release, but a system based on Metformin (Met) salts with oxidized multiwalled carbon 
nanotubes. 
4.2 INTRODUCTION: METFORMIN81 
Metformin (1,1-dimethylbiguanide), a commonly prescribed antitype II diabetes drug, belongs to the 
biguanide class of compounds, which also includes phenformin and buformin.82 The glucose and the 
insulin lowering ability of metformin, along with reduced hepatic glucose output, are shown to lower 
blood glucose levels and improve several other diseases, including polycystic ovary syndrome and 
metabolic syndrome. In past decades, several epidemiologic studies have linked metformin use with a 
decreased risk of several types of cancers, including breast, prostate, pancreatic cancer. There is also a 
change in fatty acids metabolism in patients treated with metformin, and a their weight loss is 
experienced.83 Unlike other antidiabetic drugs, metformin has therapeutic efficacy consolidated, has a 
good safety profile, is economical, can be used with others antidiabetic drugs without causing problems 
and is tolerated very well with minimal collateral effects.84 Lactic acidosis, a potential side effect of other 
members of the biguanide family, is very rare in patients treated with metformin Together these 
economical and clinical benefits of metformin support its further development and potential clinical 
implementation as an anti-cancer therapy 
 
Figure 86. Metformin chemical structure 
4.2.1 METFORMIN AS ANTICANCER DRUG 
Diabetic patients possess a higher risk of developing cancers than healthy patients, which is partly due 
to increasing levels of circulating growth factors, such as insulin or insulin growth factor 1 and 2 (IGF-1 
and 2). In this context, many retrospective analyses in type 2 diabetes patients have shown that 
metformin possesses antitumoral proprieties. Due to these studies the interest in metformin arose as 
antitumor agent.85 
The association between metformin use and reduced cancer risk in patients with diabetes was 
suggested in a pioneering observational study published in 2005 which reported a 23% decrease in 
cancer risk with metformin use. Since then, several epidemiologic studies have provided additional 





Direct and indirect effects of metformin may work to inhibit cancer. Indirectly, metformin inhibits 
glucose production in the liver and stimulates glucose uptake in the muscle, thereby enhancing insulin 
sensitivity and reducing blood glucose and insulin levels. Directly, metformin activates AMPK by 
inhibiting the complex I of the mitochondrial respiratory chain, which leads to impaired mitochondrial 
function and conditions that effectively mimic cellular energy stress, such as glucose deprivation, 
hypoxia, oxidative stress, ischemia, and muscle contraction or exercise, all of which lead to the 
activation of the AMPK axis and inhibit the mammalian target of rapamycin complex 1 (mTORC1).86 
 
However, the principal effects of metformin on cancer cells are direct effects, which predominantly 
induce mammalian target of rapamycin complex 1 (mTORC1) inhibition (Figure 89). mTORC1 is a protein 
complex composed of five different proteins. This complex is implicated in many cellular processes but 
principally in protein synthesis regulation, which is essential for cellular growth. This complex is often 




Figure 89. | Direct and indirect mechanisms of action of metformin in cancer cells. Metformin induces 
antitumorigenic effects by both indirect and direct mechanisms. In the blood circulation, metformin decreases 
glucose levels and therefore insulin levels; insulin can act as a growth factor in tumor cells. For direct effects, 
metformin acts by AMPK-dependent and independent effects. Generally, metformin induces inhibition of the 
mTORC1 pathway, which involves an essential protein complex in cellular processes, including protein synthesis and 
cell proliferation; this complex also promotes tumor cell resistance to therapies. Furthermore, metformin induces 
cell cycle arrest by p53 activation.85 
 
Moreover, the reduced incidence of liver, pancreatic, colorectal (CRC), and breast cancers in metformin 
users was reported to be 78%, 46%, 23%, and 6%, respectively, in a meta-analysis of 37 studies 
comprising 1,535,636 patients. Metformin causes a reduction in dimension of tumor, targets 
angiogenesis and metastasis in various tumor models, and inhibits tumor cell growth by targeting 
numerous metabolic pathways involved in cell proliferation in vitro. Finally, it inhibits cell proliferation 
by inducing a cell cycle arrest in G0 / G1 phase in various tumor cell line models for breast, kidney, 





Different results, demonstrate that metformin can suppress cancer cell growth by impairing cell cycle 
progression and inducing apoptosis in human cancer cells; however, the effects of metformin on cell 
cycle progression might vary depending on the cancer type and microenvironments.86 we observed that 
metformin significantly suppressed melanoma cell motility by modulating the miR-192-5p/EFEMP1 axis. 
Furthermore, metformin inhibits several genes involved in cell division.85 
 
Additionally, studies have demonstrated that the efficacy of metformin is affected by the change in the 
expression levels of membrane transporters (OCT1-4, PMAT, and MATE1-2) involved in the uptake and 
secretion of metformin. 81 
 
Due to its hydrophilicity, metformin cannot simply diffuse through cell membranes and is trans- ported 
inside the cell via uptake transporters. Metformin is a substrate for OCT1 (organic cation transporter 1), 
an uptake transporter primarily expressed in the hepatocytes. Once inside the cells, metformin 
accumulates in the mitochondrial matrix, presumably because of its positive charge and the polarization 
of the mitochondrial inner membrane 87 Metformin is a positively charged molecule and interacts with 
the mitochondrial membrane by virtue of its negative charge.88 
 
Metformin specifically inhibits the mitochondrial respiratory chain complex 1 in a range of tissues 
including 
hepatocytes, skeletal muscle, endothelial cells, pancreatic beta cells, and neurons. Inhibition of 
mitochondrial respiratory chain complex 1 induces a transient reduction in cellular energy status, which 
alters the balance between adenosine triphosphate (ATP) production and consumption, leading to an 
increase in the intracellular ratio of adenosine monophosphate (AMP) to ATP. Increased levels of AMP 
activate AMP-activated protein kinase (AMPK) by binding to regulatory sites, causing a conformational 
change in the enzyme, a process dependent on the upstream actions of the serine–threonine liver 
kinase B1 (LKB1). AMPK is a phylogenetically conserved protein kinase that monitors cellular energy 
status and protects cellular functions under energy-restricted conditions. Activation of AMPK causes 
the cell to switch from an anabolic to a catabolic state in an attempt to restore energy balance through 
phosphorylation of key metabolic enzymes and activation of transcription factors that modulate gene 
expression. In turn, activated AMPK leads to inhibition of gluconeogenesis, lipogenesis, and protein 
synthesis while stimulating fatty acid oxidation and glucose uptake in the liver.84 
 
Under stimulation with metformin, the DNA damage response pathway was reactivated, decreasing in 
cancer cell development.  In conclusion, metformin acts as a major disruptor of metabolism in cancer 
cells, induces an irregularity in energy metabolism and protein synthesis and activates the processes of 
autophagy and apoptosis.85 
 
4.2.2 METFORMIN AND MELANOMA 
As previously discussed, metformin can inhibit cancer cell proliferation and induce cancer cell death by 
many different mechanisms. In melanoma cells, it has been shown that metformin induces cell cycle 
arrest in melanoma cells in the G0-G1 phase after 24 h of treatment at 10mM. However, the molecular 
mechanism of this cell cycle arrest has not been identified in melanoma cells. Furthermore, our 
laboratory has also shown that this cell cycle arrest is responsible for autophagy (at 72 h) and apoptosis 
(at 96 h) induction by metformin in melanoma cells.85 
 
Metformin significantly suppresses the motility and growth of cancer cells melanoma by inducing a cell 
cycle arrest at the G2 / M phase and promoting cell apoptosis. The migration ability of A375 melanoma 
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cells comes significantly suppressed after treatment with a metformin concentration equal to 5 mM. 
When A375 cells are incubated with 5 mM metformin, the number of cells in the S phase and in the G2 
/ M phase increases relative to the number of cells of the control group, while the number of cells in 
the G0 / G1 phase decreases. Finally, the number of the apoptotic cell population also increases. These 
results indicate that the growth of melanoma cells can be suppressed by treatments with the 
metformin, compromising cell cycle progression and the induction of cellular apoptosis. The suppressive 
effect of metformin is dose-dependent.86 
 
AMPK induces a partial restoration of melanoma cell viability under metformin treatment, suggesting 
that AMPK plays a partial role in metformin-induced melanoma cell death. This finding also suggests 
that another AMPK independent mechanism is implicated in metformin-induced melanoma cell death. 
Metformin decreases the tumoral volume of melanoma cells. In addition, no cellular death has been 
observed in normal human cells, such as melanocytes, even if endogenous AMPK is expressed.  
Interestingly, a recent study showed that metformin can directly act not only on melanoma cells to 
induce cell death but also on the tumor microenvironment, particularly in the context of an immune 
response. The results showed that metformin activity on melanoma cells was partly due to the immune 
system and that the antitumor activity of metformin was lost on immunodeficient (NSG) mice. This 
group also showed that metformin interaction with the immune system was principally associated with 
T cells. Interestingly, metformin blocks the inflammatory pathway responsible for stem cell 
transformation and growth due to cellular metabolism disruption.85 
 
4.2.3 METFORMIN AND COMBINED THERAPY 
Drugs operate differently in cell cultures and human physiology, which raises some concerns regarding 
the applicability of the findings of drug effects in cell cultures to humans. The first concern is that the 
standard range of the therapeutic plasma level of metformin in humans is 0.465–2.5 mg/L, which results 
when an average patient with a body weight of 60 kg receives a recommended human therapeutic daily 
dose (1000–2550 mg). The dose of metformin used in this study was 1–10 mM (165–1650 mg/L), leading 
to 30- to 400-fold excess concentrations that were far in excess of the recommended therapeutic 
doses.86 
 
Thus, concerns regarding the usage of superphysiological concentrations of metformin in preclinical 
studies could be somewhat resolved by altering the expression of membrane transport proteins 
through the use of drugs, such as antibiotics and proton pump inhibitors, in combination with 
metformin to increase cellular uptake and accumulation in tumor cells. Future studies to better 
understand the role of membrane transport proteins in enhancing metformin’s potency as an anti-
cancer agent are imperative. Experimental therapeutic strategies include use of metformin in 
combination with other chemotherapy drugs and / or radiotherapy..81 
 
The use of metformin with or without radiotherapy reduces the tumor growth in different types of 
cancer such as ovarian, prostate, breast cancer and melanoma.89 
 
Similarly, metformin in combination with chemotherapeutic drugs have shown significant reductions in 
tumor and a prolonged tumor remission. In trastuzumab-resistant breast cancer cell and xenograft 
models.81 
 
Finally, several laboratory studies have shown a higher sensitivity to chemotherapy in various cancer 




4.3 RESULTS AND DISCUSSION-METFORMIN SALTS WITH CNTs  
In our ongoing study for the production of new drug delivery systems and with the final goal to produce 
nano-devices90 for the combined therapy of cancer, we have started a research activity aimed to verify 
the efficacy of metformin loaded CNT towards cancer cell lines. There are a few examples of Met 
decorated CNT in the recent literature.91,92 In all these examples, Met is covalently linked to CNT 
profiting of the nucleophilic nature of the bis-guanidine group. In particular the work of Yoo and co-
workers93 is the first one to address directly the synergetic action of Met, linked to CNT, with another 
therapeutic effect, namely the photothermal effect. Since most of the formulations of Met are 
composed by its salts with different carboxylic acids, this preliminary study is dedicated to the analysis 
of the effect of salts of Met with oxidized MWCNTs (2) (Scheme 32) onto selected cancer cell lines. Our 
aim is to verify if the action of CNT can improve Met internalization by cells and reduce the amount of 




Scheme 32. Synthesis of Met-CNTs 
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The comparison between the values reported in Figure 90 A and C reveals that the quantity of Met used 
in the experiments with 58 is around 500 times lower than that used in the experiments of Figure 90 A. 
Nevertheless, the viability MCF7 cells showed a remarkable decrease when added with 10 μg/mL of 58 
corresponding to 2.4 μg/mL of free Met. PC3 cell line showed an analogous behavior while HT29R cell 
line revealed less sensitive to 58 taking in account the intrinsic toxicity of 56 on these cells. It is well 
described that metformin inhibits mitochondrial respiration by blocking complex I of the electron 
transport chain, thus inhibiting the oxygen consumption of treated cells 95. In order to verify the 
inhibitory activity of internalized metformin, we evaluated the oxygen consumption rate of treated 
cells. While simple ox-CNT 2 (20 μg/mL) did not alter the oxygen consumption, 58 (20 μg/mL) decreased 
the oxygen consumption of about 17% (p=0.07, n=2). 
 
 
To evaluate the toxicity of the starting substrates and adducts, three different cancer cell lines, selected 
for their sensitivity to Met (55), were chosen. HT29-R 94 (colon carcinoma cell resistant to 5-fluorouracil 
(5-FU)), MCF7 83 (breast cancer cell line) and PC3 92 (human prostate cancer cell line) cells were 
incubated in the presence of growing doses of compounds and analyzed through MTT assay to assess 
the cell viability. The results are reported in Figure 90. 
Figure 90 A shows the effect on Met (55) on the selected cell lines. As expected, the toxic effect of Met 
becomes evident at millimolar concentrations: the LD50 is between 1 and 2.5mM concentration both 
for HT29R and PC3 cells. Figure 90 B shows the effect of CNT-Met 56 on the same cell lines: the toxicity 
of ox-MWCNT, although more evident for HT29R, is limited in the range of concentrations used in our 
tests and absent for PC3 cell lines. Figure 90 C shows the effect of compound CNT 3. The values reported 
on the bottom abscissa line refer to the amount of 58 used while the values on the top abscissa line 




Figure 90. MTT vitality assays of HT29R, MCF7 and PC3 cell lines incubated with different concentration of Met (A), 











Tab 4. Percentage of positive cells. For each experiment, 10000 events were analyzed. 
The same quantity of free Met (4.8 μg/ml) decreased the oxygen consumption of about 25% (p=0.02, 
n=2). In order to rationalize the toxicity effect showed by MTT tests, and to highlight any possible 
influence of Met in the internalization degree of CNT, we evaluated the uploading of both 57 and 58 
(fluorescent analogues of 2 and 3) by using flow cytometry. After incubation with CNTs, cells were 
extensively washed with PBS, detached from the plastic support by trypsin treatment, and analyzed by 
using a FACSscan apparatus (BD Biosciences). The same gating was used for the cell incubated with the 
two different CNT; ten thousand cells of each sample were analyzed. The results are reported in Table 
4. 
Unexpectedly, when HT29R cells were analyzed, after 2 h of incubation with 58 (10 μg/ml), the variation 
of the fluorescent was negligible respect to the control experiment (Table 4, entry 1) suggesting that no 
internalization of 58 occurred. On the contrary, when the experiment was repeated with 57 (still entry 
1) the increase of fluorescence was evident, confirming that 57 material is efficiently internalized (as 
already demonstrated in a previous work).90 



























































Fig. 91. Confocal microscopy analysis of MCF-7 cells incubated in the presence of A) 57 and B) 58. 
 
Even prolonging the incubation time did not improve the internalization degree of 58 (entry 2- Table 4). 
To verify that such behavior is not related to HT29R cell type, the same analysis was extended to the 
other cell lines already studied in the viability tests: MCF7 (entry 6-Table 4), and PC3 (entry 5- Table 4). 
Again, the fluorescence values registered after 2 h of incubation with 58 are negligible with respect to 
the control experiment. Finally, trying to generalize the results, cytofluorimetry analyses were 
performed also with HT29 (entries 3 and 4- Table 4), PANC-1 (entry 7) and MDA-MB-231 (entry 8) cell 
lines. All these further experiments confirmed the previous results. The viability tests have shown that 
the Met salts of CNTs have a biological activity with the cell lines tested. 
Although modest, such activity is obtained with low quantities of Met. Despite these results, the 
cytofluorimetry analyses showed that no appreciable internalization is observed, even using a larger 
pool of cell lines. 
Finally, a confocal microscopy analysis was performed on MCF- 7 cells incubated in the presence of 57 
and 58. MCF-7 cells were incubated for 20 h with 57 (Figure 90A) and 58 (Figure 90B) at the final 
concentration of 10 μg/ml. The uptake of fluorescent CNTs was evaluated through confocal microscopy. 
The image in Figure 90 shows that 57 undergoes a significant uptake from MCF-7 cells and that the 
fluorescent material is limited to the cytoplasmic region and do not enter in the nucleus, confirming 
previous results. Image 3B shows that no appreciable incorporation of 58 occurred, confirming the 
cytofluorimetric analyses results. 
Finally, the inhibition of the uptake was not evidenced when MET and 57 were added separately: a 
cytofluorimetric analysis (MCF- 7 cell culture) shown no difference with the control experiment. The 
absence of internalization of 58, appears to be an exception in the literature. Since the work by Bianco 
et al. 2 many other examples of diversely decorated CNT have been used as efficient DDS, confirming 
their general ability to cross the cellular membrane.96 The presence of cationic species on the CNT 
surface does not hamper the internalization as demonstrated by the various works present in the 
literature in which CNT functionalized with cationic polymers are efficient DDS for transfection. 
However, it has been reported that internalization of CNT can be inhibited through the use of known 




4.4 CONCLUSION METFORMIN SALTS WITH CNTs 
The salt formed by Met and ox-MWCNT shown a dose-dependent inhibitory activity towards PC3 and 
MCF7 cell cultures. Although modest, this activity is significant when considering the low amount of 
drug administered. However, quite surprising, flow cytofluorimetry and confocal microscopy analyses 
demonstrated a strong inhibition of the CNT uptake induced by the presence of Met. Although the 
mechanism of such inhibition is still not disclosed, this observation is a striking exception in the 
literature data and can help in the work for shedding light on the still debated mechanism of CNT cellular 
uptake. 
 
4.5 OBJECTIVES AND PRESPECTIVES OF THIS CHAPTER  
Due to no profitable application of salt formed by Met and ox-MWCNT, we decided to extend our 
proposal modifying the chemical structure of metformin. The final goal was to achieve a metformin 
derivative able to interact with surface of CNT. The extension of aliphatic chain may increase the 
interaction with nanostructured material through chemical-physical adsorption.  
DERIVATIVES OF METFORMIN 
 
Metformin belongs to biguanidine family. Biguanides are molecules derived from guanidine and are 
useful in diabetes treatment. Guanidine is extracted from Galega officinalis, a plant used in medicine 
for many years. Indeed, this plant was used for its antidiabetic properties before its effects on glycaemia 
were discovered in the 1920s. Since this time, many guanidine-derived compounds have been used in 
type 2 diabetes, such as buformin, phenformin, and metformin. At first, metformin was not truly 
compared with other guanidine-derived compounds because of its less important effects on insulin 
sensitivity. Other biguanides, phenformin, and buformin (Figure 92 )were widely used in diabetic 
treatments starting in 1920 until their high toxicity in patients was discovered in 1930. Afterwards, 
biguanides were no longer used in type 2 diabetes treatment until a study by French chemist Jean Sterne 
in 1957, where he showed metformin’s effects on type 2 diabetes without apparent toxicity.85 
 
 
4.6 RESULTS AND DISCUSSION-BIGUANIDE DERIVATIVE 














Scheme 33. Biguanide derivative synthesis 
Dodecylamine 61 was reacted with cyanoguanidine 62 to provide the commonly known biguanide 
structure 63. 
The reaction was carried out in DCE. The dodecylamine was added to TMSOTf. TMSOTf works like Lewis 
acid, exploiting the silylation process, it removes labile protons and decreases the basicity of the atom 
on which it acts. Cyanoguanidine increments its electrophilicity, nucleophilic attack by nitrogen atom of 
dodecylamine on the carbon involved in the triple bond is promoted. 
At the end of reaction the excess of cyanoguanidine was removed through dichloromethane-water 
extractions. After the addition of dodecylamine, the reaction proceeded overnight. Washes were then 
carried out by extracting the organic phase, dissolved in DCM, with milliQ H2O. This had the purpose of 
separating the cyanoguanidine present in excess from the created derivative. In fact, the 
cyanoguanidine remained in the aqueous phase and it was removed with a correct separation of the 
phases. 
The obtained compound is then characterized with 1H NMR, 13C NMR, ESI mass and elemental analysis 
spectra. 
 
Figure 93. 1HNMR of 63 




Figure 94. 13CNMR of 63 
Comparing 13C NMR of biguanidine derivative with the recorded spectrum of dodecylamine two new 
carbon signals around 120 ppm were revealed, suggesting the occurred reaction.  
ESI-MS analysis confirmed the peck attributable to desired compound.  
Elemental analysis evaluated an amount of nitrogen, carbon and hydrogen equal to: N:15.02%, C: 
47.78%, H:8.06%. These percentages were probably associated to the presence of crystallized water.  
 
4.6.2 IN VITRO TESTS OF BIGUANIDE DERIVATIVE AND METFORMIN  
H2524 cell line was treated with metformin (5,00 mM) and with biguanide derivative 
(25,00 μM). After 20h measures at cytometry flow were performed: 
 




                   
Figure 96. H2524 treated with metformin (5,00 mM). Flow cytometry analysis 
 
Figure 97.- H2524 treated with biguanide derivative (25,00 μM). Flow cytometry analysis. 
 













Figure 99. Cell cycle analysis: percentage of H2524 cells in G2/M phase 
  
Figure 100. Cell cycle analysis: percentage of H2524 cells in S phase 
Metformin suggested to cause accumulation in G2 / M phase (phasse concerning cell division) and a 
decrease in the S phase (synthesis phase, DNA replication occurs). Biguanide derivative caused an 
accumulation both in S phase and in the G2 / M phase.  
Based on these results the synthesized biguanidine derivative showed an action mechanism different 
from the mechanism possessed by metformin. 
In Figure 98, 99, 100 a comparison between the activity of metformin and biguanide derivative (dodecyl 
metformin) on different cell lines was showed.. 
Biguanide derivative (dodecyl metformin) posses an activity higher both for A375 Cell line, both for HOS 




















                                        
                                        
                                        
                                        
                                        
                                        























                                        
                                        
                                        
                                        
                                        
                                        























                    























Figure 101. Cell viability after metformin or biguanide derivative treatment 
To study the cytotoxic effect of biguanide derivative (dodecyl metformin) on A375 cells we determined 
the value of LD50 (Lethal Dose 50). Cell line was treated with increasing solutions of dodecyl metformin 
between 5 and 100 μM; after 48 hours of incubation we evaluated cell viability with the MTT assay. In 
the graph in Figure 101 were showed these results and compared to the activity of metformin. The dose 
A375 Cell line 




curves dependence of the two molecules established LD50 value, (an indication of the lethal toxicity of 
half of the population due to a given substance). 
The calculated LD was 41.2 ± 0.7 μM for dodecyl metformin and 4558 ± 373 μM for metformin. These 
values proved that dodecyl metformin has higher cytotoxic effect, indeed, same results in cell viability 




Figure 102. A) Determination of the LD50 value for A375 cells. After 48 hours of incubation with increasing doses of 
dodecyl metformin, cell viability was determined by the MTT assay. B): Determination of the LD50 value for A375 
cells. After 48 hours of incubation with increasing doses of metformin, cell viability was determined by the MTT 
assay. 
A concerned a solution of dodecyl metformin with a concentration of 10 μM causing the death of less 
than 10% of cells; a 20 μM concentration caused approximately 10% of cells and a 30 μM concentration 
about 20% of cells death. Solutions at 10 and 20 μM concentration were sublethal doses, not causing 
the death of a significant number of cells. 
A single dose at a concentration of 41.2 μM of dodecyl metformin caused the death of 50% of the 
treated melanoma cell population. We decided to perform an experiment by administering multiple 
times a solution of dodecyl metformin at sublethal concentrations. To study the mechanism of action 
of dodecyl metformin, the growth cell assay was performed by treating melanoma cells every 24 hours 




Figure 103. A) Graph relating to the results of the cell growth test carried out by treating cells at 0, 24, 48 and 72 
hours. The black, red and green curves indicate the absorbance trend of the cells treated respectively with a solution 
of dodecyl metformin in concentration at 0, 10 and 20 μM and subsequently stained with crystal violet. The data 
obtained were normalized compared to the control. B) Graph relating to the results of the growth test carried out 
by treating cells at 0, 24, 48 and 72 hours. The black, red and green curves indicate the absorbance trend of the cells 
treated respectively with a solution of dodecyl metformin in complete medium at 0, 10 and 20 μM and subsequently 
stained with crystal violet. The data obtained were normalized compared to the control. 
In Figures 103 A dodecyl metformin derivative 63 suggested to have no effect on cells after 24 hours of 
treatment, while a partial activity was observed at 48 hours inhibition of proliferation by cells incubated 
with 20 μM solution of biguanide derivative. A minor effect, but nevertheless still evident, was 
observed, for cell line treated with a 10 μM solution. At 72 hours of treatment, cells proliferated 
independently by the presence of dodecyl metformin. 
 
 
Figure 104. Scan of the plate containing the cells treated daily for a total of 72 hours e subsequently colored with 
crystal violet. The C wells marked belong to the control. Wells numbered 10 and 20 indicate cells treated with a 10 







Figure 105. Scan of the plate containing the cells treated daily for a total of 72 hours e subsequently colored with 
crystal violet. The C wells marked belong to the control. Wells numbered 10 and 20 indicate cells treated with a 10 
and 20 μM solution of dodecyl metformin in culture medium. 
In Figures 104 and 105 the untreated melanoma cells tend to reach the confluence and the proliferation 
was partially inhibited in the cells treated with daily doses of a 10 μM solution of dodecyl metformin. 
The inhibitory effect was higher in cells treated with daily doses of a 20 μM solution. The effect of 
dodecyl metformin on melanoma cells is dose dependent. 
The results of the proliferation test were confirmed by the results collected through cell counting 
method, showed in Figure 106. From the graph appeared the number of cells treated with a 20 μM 
solution of dodecyl metformin at 24 hours was almost equivalent to untreated cells and to a cell culture 
treated with a 10 μM solution. At 48 hours, the proliferation was still significantly lower, and then, at 
72 hours, a new increment was recorded, with an index growth close to the behavior of the other two 
cell cultures. 
 
Figure 106. Results of the cell counting method performed by treating cells at 0, 24, 48 and 72 hours. The black, red 
and green curves indicate the trend of the number of cells treated respectively with a dodecyl metformin solution in 
culture medium at 0, 10 and 20 μM. The data obtained were normalized compared to the control. 
Thanks to viability assay (Figure 106) the lethality of 50% of cell population after 48 hours of a single 
dose administration of 41,2 μM solution of dodecyl metformin was established. From cell growth assay 
(figures 104 and 105) and cell counting method confirmed that dodecyl metformin administered in 
sublethal daily doses has a partial antitumor effect, the cytotoxic effect is evident after 48 hours from 
the treatment. A dodecyl metformin solution, administered a single time with a concentration equal to 
41.2 μM or daily with a concentration equal to 20 μM, posses a partial inhibitory effect on the 
proliferation of melanoma cells that occurs after 48 hours after the treatment. After this time, the cells 
no longer respond to the treatment, proliferating undisturbed.  
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Melanoma cells treated with 20 μM solution of biguanide derivative showed a spherical shape, causing 
the phenomenon of blebbing, that is the formation and resorption of bubbles on the cell plasma 
membrane. Although the phenomenon appeared to be critical, suggesting the death of treated cells, 
quite the opposite 24h after the treatment, the cells emerged to be healthy, active in proliferation and 
quickly insensitive to additional treatment.  
For an accurate description of the phenomenon, we analyzed the A375 cells treated with dodecyl 
metformin using a confocal microscope. Cells treated with 20 μM solution of dodecyl metformin in 
culture medium were observed for 25 minutes, acquiring images every 2 seconds. A visual datum of 
blebbing phenomenon was obtained. Unfortunately, we haven’t found yet an exhaustive explication 
about the phenomenon, but we hypnotize a modification and a rearrangement of the cytoskeleton, 
which could cause a temporary resistance to biguanide derivative. 
To exclude a physical damage to the membrane, A375 cells were treated with dodecyl metformin for 1 
hour. Successively the cells were incubated with a propidium iodide (PI) solution and then analyzed 
using a flow cytometer. The PI is not membrane-permeable, this fluorescent intercalating agent may 
penetrate only inside the cells showing damages.  
The data reported in Tab 5 confirmed the impossibility of cells treated for short time with dodecyl 
metformin solutions, to incorporate significantly a higher PI amounts compared to the dose assimilated 
by the control cells.  
The same assay was repeated for cells chronically treated with dodecyl metformin. As showed in Tab 6 
also cells treated for 24h, 48h and 72h with the synthesized molecule didn’t incorporate an excess of 
PI. Therefore this type of treatment induces an evident modification of cell membrane, but any 











Tab 5. Results of the assay carried out by treating cells with dodecyl metformin, incubated with PI for 1h and 





Concentration of biguanide 
derivative solution (µM) 







0 2 488 
10 1.7 477 
20 2.7 646 
30 2 555 
40 2.3 535 
50 5.8 520 
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Time of treatment (h) Solution concentration 
of dodecyl metformin 







24 0 1.3 382 
24 10 1.8 470 
24 20 1.5 367 
48 0 1.9 275 
48 10 0.8 415 
48 20 0.8 436 
72 0 1.0 429 
72 10 1.2 410 
72 20 1.6 360 
Table 6: Results of assay carried out by chronically treating the cells with dodecyl metformin, incubated with PI for 
24, 48 and 72 hours and analyzed with a flow cytometer. 
Treated A375 cells tend to assume a spherical shape giving rise to blebbing. To determine if this 
phenomenon can promote a metastasis of tumor by causing the detachment of cells from the tissue or 
surface on which they are located, new assays were performed. A375 cells were incubated with 
increasing concentrations of dodecyl metformin for 24 hours; after this period, the cells t in the medium 
of culture, no longer adhered, were recovered and plated again, to evaluate their ability to adhere and 
proliferate. The plates containing the treated cells were stained with violet crystal to evaluate the 
quantity of detached cells (figures 107 and 108). 
 
 
Figure 107. Scan of the plate containing the treated cells. The cells are been colored with crystal violet. The wells 
marked C are the control wells, those numbered 5 and 10 indicate the cells treated with a 5 and 10 μM solution of 




Figure 108. Scan of the plate containing the treated cells. The cells were colored with crystal violet. Wells numbered 
20, 40 and 60 indicate the treated cells with a 20, 40 and 60 μM solution of dodecyl metformin respectively in 
medium culture. 
In accordance with the results obtained from the growth and proliferation assays, in the graph in Figure 
109 is shown as 24 hours of dodecyl metformin treatment didn’t cause inhibition on cells treated with 
concentrations of solution equal to 5, 10 and 20 μM. Instead, an inhibition was observed for cells treated 
with a concentration of 40 and 60 μM respectively. 
 
Figure 109. Quantification of crystal violet release by the treated cells. After staining, the cells incorporating the 
crystal violet were treated with 1 mL of DMSO for 10 minutes. Subsequently, the DMSO is recovered, and the 
absorbance measured by a spectrophotometer. The data obtained were normalized compared to the control. 
After 6 days, the plates containing the detached cells were stained with crystal violet (Figures 110 and 
111). 
 
Figure 110. Scan of the plate containing the detached cells and were plated again. The cells were stained with crystal 
violet. The wells marked C were the control, wells numbered 5 and 10 indicate the cells treated with a 5 and 10 μM 




Figure 111. Scan of the plate containing the cells that had detached and were plated again. The cells were stained 
with crystal violet. Wells numbered 20, 40 and 60 indicate cells treated with a 20, 40 and 60 μM solution of dodecyl 
metformin in medium culture. 
We added 1 mL of DMSO to each well and the plates were rocked for 10 minutes. After this time the 
absorbance of the various solutions were analyzed to spectrophotometer (Figure 112). 
 
Figure 112. Quantification of crystal violet release by the treated cells. After staining, the cells incorporating the 
crystal violet were treated with 1 mL of DMSO for 10 minutes. Subsequently, the DMSO is recovered, and the 
absorbance measured by a spectrophotometer. The data obtained were normalized compared to the control. 
The obtained results showed a progressive cell detachment of treated cells, a phenomenon dose-
dependent. At the same time, the detached cells recovered from the controls (cells untreated) tend to 
adhere and proliferate rapidly. 
However the treated cells showed a lower tendency to adhesion and proliferation. This behavior 
appeared strictly dose-dependent. The collected data suggested that the biguanidine derivative could 
act as antimetastatic agent, preventing the adhesion and proliferation of cells detached from a tumor 
mass, thus blocking metastatic dissemination. 
Since melanoma cells show a tendency to detach from the primary tumor mass, entering in the 
bloodstream or lymphatic stream, we tested the possibility of treated cells to adhere to a tissue or their 
tendency to die when suspended in the blood/lymphatic stream. The adherent cells were detached and 
plated again in presence of increasing concentrations of dodecyl metformin. To evaluate the amount of 





Figure 113. Scan the plate containing the cells that have been treated in suspension and then plated. The cells were 
stained with violet crystals. The wells marked C are the control. Wells numbered with 2.5 and 5 indicate the cells 
treated with a solution 2.5 and 5 respectively μM of dodecyl metformin in medium culture. 
 
 
Figure 114. Scan the plate containing the cells that have been treated in suspension and then plated. The cells were 
stained with crystal violet. Wells numbered 10, 20 and 30 indicate the cells treated with a 10, 20 and 30 μM solution 
of dodecyl metformin, respectively, in medium culture. 
The graph in (Figure 115) showed that dodecyl metformin caused the decrease of the adhesion of A375 
cells of about 20% at 20 μM concentrations and about 50% with a concentration of 30 μM. Quite the 
opposite, dodecyl metformin appeared to cause an increase in the cited phenomenon of about 10% at 
10 μM concentration and less than 10% at 2.5 and 5 μM concentrations.  
These assays confirmed that dodecyl metformin promoted the adhesion of melanoma cells in 
concentrations below 10 μM, instead concentration above 20 μM caused a disadvantage adhesion. 
 
 
Figure115. Quantification of the crystal violet released by the cells. After staining, the cells incorporating the crystal 
violet were treated with 1 mL of DMSO for 10 minutes. Subsequently, the DMSO was recovered, and the absorbance 




4.6.3 SYNTHESIS OF CNT-BIGUANIDE DERIVATIVE  
The collected assays demonstrated the good activity of the synthesized biguanide derivative. Our 




Figure 116. Synthesis of compound 64. 
This type of functionalization exploited the chemical-physical characteristics of the carbon nanotubes. 
This type of adsorption did not significantly disturb the structure of the CNTs, but allowed to modify its 
electronic and transport properties. 
Previously the functionalization was already used with another type of drug, doxorubicin, also studied 
as anticancer drug, biologically active in cells thanks to this functionalization. 
The decoration of CNTs with this technique allowed to verify their effective interaction with the long 
aliphatic chain present on the synthesized biguanide derivative. A phosphate buffer solution at pH 7.4 
was used to solubilize the biguanide derivative. The buffer was required to protonate the free amine of 
the biguanide derivative. By adding CNTs, the protonated amines could bind the nanostructured 
material through adsorption, preventing the interaction with the carboxylic group to form salts. 
Compound 64 was obtained after a treatment in an ultrasonic bath for 1 hour, after which the dispersion 
was filtered with buffer and H2O milliQ. This product was characterized with elemental analysis: 
 
Elemental analysis: N: 5.85%, C: 74.79%, H: 2.92% 
The loading degree of biguanide derivative was equal to 0.8 mmol/ g of material. 
4.6.4 IN VITRO ASSAYS 
Biological assays were carried out on functionalized CNTs. A population of HT29R, which is a type of 
colon cancer cells resistant to 5-FU and HT29 were used to test compound 64. The cells were incubated 
for approximately 72 hours at a temperature of 37 °C. 
 
The culture medium was initially HT29R, subsequently treated with 5-FU. To these cells were 





Figure 117. HT29R con fCNTs  
 
Figure 118. HT29R con 5-FU e fCNTs  
No differences were noticed between HT29R cells treated with 5-FU or not. A high biological activity 
even at low concentrations (such as 0.5 µg / mL) up to a mortality rate of up to 80%. 
On a population of HT29 cells, not resistant to 5-FU, functionalized CNTs were administered by 
adsorption both in a complete medium and in a starvation medium. 
 




Figure 120. HT29 with fCNTs in starvation medium 
In this biological assay, a reduction in cell viability of 80% was reported, more marked than the crystal 
violet described below. These more marked reductions could be due to MTT which was metabolized by 
mitochondrial dehydrogenases. In the presence of complete medium, a reduction in mitochondrial 
activity was observed, rather than in vitality. 
A hypothesis could be that to compensate the reduction in mitochondrial activity, the cells may be able 
to increase the speed of glycolysis. 
Crystal Violet represented another cell viability assay. The incubation lasted 48 hours and to the cells 
were administrated the crystal violet dye which enters only in alive or not damaged cells. 
 
Figure 121. HT29 with fCNTs in complete medium 
 
Figure 122. HT29 with fCNTs in starvation medium 
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Crystal violet assay showed a reduced cell viability, equal to 50% (Figure 121), MTT assay had 
provided 80% of reduction. The synthesized molecule exhibited biological activity, but if 
administered to cells grown in complete medium, no decrease in viability was observed. In 
starvation medium, quite the opposite, a reduction in viability due to the use of a medium devoid 
of factors that stimulate growth and glycolysis, was observed in both assays. Since these cells were 
forced to use more respiration to survive, the biguanide derivative appeared to have a greater effect 
with a consequent reduction in proliferation or viability. 
 
Other assays were instead performed on a population of HT29R with and without 5-FU with the 
























Figure 124. HT29R with fCNTs in starvation medium, with or without 5-FU 
The viability of resistant cells is not affected by the presence of 5-FU, as expected. These cells were 
more dependent on respiration to survive. In starvation medium, cells were very sensitive to the 
biguanide derivative, their cell viability was reduced by almost 100%, as showed in (Figure 124). 
 
4.7 CONCLUSION 
Several studies proved as patients treated with metformin for diabetes disease showed a reduced 
incidence of cancer, longer survival to tumors, less metastasis and smaller dimension of mass tumor; 
compared to patients treated with another antidiabetic drug.  
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Metformin posses direct and indirect mechanisms which allows to block the cellular cycle and to induce 
apoptosis in cancer cells with consequent reduction of cell proliferation.  
Metformin, in addition, causes metabolic alterations and changes in protein synthesis, metformin 
activates the processes of autophagy and apoptosis. 
The antidiabetic drug metformin also has anticancer properties. 
This drug allows only appreciable effect at concentrations so high as to cause serious side effects to the 
body. Consecutive studies focused on synthesize a derivative of metformin, with a higher activity, which 
allows to lower administration.  
 
The viability test showed how biguanide derivative showed same toxicity of biguanide derivative, but 
at concentrations 100 times lower. No data on the possible side effect of biguanide derivative in vivo 
were collected, but the results obtained through in vitro assays suggested that the risk of a possible 
cytotoxic effect should be lower compared to metformin administration.  
The proliferation assays showed a partial inhibitory effect of dodecyl metformin on melanoma cell 
proliferation that occurred after 48 hours of treatment. After 48 hours, the treated cells appeared 
insensitive to treatment, the cells proliferated independently from the presence of biguanide derivative. 
A single critical dose or repeated administrations of sublethal doses possessed a partial anticancer effect 
which is evident after 48 hours of 
treatment.  
The presented data promote a possible in vivo application of the molecule; many anticancer drugs are 
administered in cycles consisting of several doses every day. The partial inhibitory effect of dodecyl 
metformin on the proliferation of cancer cells could lead to a reduction in tumor volume. Future 
experiments will be performed to establish the reason why after 48h of treatment, the cells develop a 
certain resistance.  
 
Immediately after a treatment with dodecyl metformin, A375 cells were studied at confocal microscopy. 
An interesting and curious aspect was the phenomenon of blebbing which occurred immediately after 
the administration of biguanide derivative, suggesting a possible death of cells. Instead, after 24 hours, 
cells proliferated, acquiring their original form. Furthermore after about thirty minutes, the blebbing 
phenomenon blocked and A375 cells resulted insensitive to further treatment. All cells didn’t show the 
same behavior, a part of them were not characterized by this particular phenomenon. 
 
All these data confirmed that dodecyl metformin causes a physical alteration of the cell, probably 
inducing a rearrangement of the cytoskeleton that concerns the creation and reabsorption of bubbles 
by the cell membrane. The occurred phenomenon, is not permanent and irreversible. No physical 
damage is observed, as demonstrated by the assays carried out with the PI.  
Future studies will be focused on the temporary developped resistance of melanoma cells subsequent 
to the treatments, as well as the mechanism by which dodecyl metformin induces these particular 
phenomena in the cell. 
 
A375 cells were treated with biguanide derivative, therefore the detached cells were plate again. The 
tendency of treated cells to proliferate again was dose-dependent. 
Dodecyl metformin could promote melanoma cell detachment from the adhesion surface, but these 
detached cells could be not able to adhere to a new surface, or they could undergo cell death. 
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By treating melanoma cells in suspension and plating them, important effects of biguanide derivative 
were showed: dodecyl metformin has an inhibitory effect on the adhesion of cells that are in 
suspension.  
 
We can conclude that dodecyl metformin could constitute a promising antimetastatic drug. 
 
The sublethal and critical concentrations of dodecyl metformin suggest an accessible administration to 
patients, a weak inhibitory effect of cell proliferation which could lead to a tumor volume reduction and 
to an important dose-dependent inhibitory effect on metastasis. 
 
The synthesized derivative CNTs-biguanide derivative (fCNTs) showed a lower activity compared to the 
molecule of biguanide derivative.  
MTT and crystal violet assays were performed on fCNTs. The cell viability was significantly affected: on 
a population of HT29R, with a mortality up to 80% for higher concentrations, which we can also observe 
with HT29 cells in starvation medium. For the crystal violet assay, populations of HT29R were analyzed 
in complete and starvation medium. In starvation medium, cell mortality was observed up to 100% of 
the entire population. 
 
4.8 MATERIALS AND METHODS 
 
Synthesis of compound 56/58 
 
The salts 56 and 58 were produced mixing 2 or 57 (20 mg) with the same amount of free 1 in 10 ml of 
acetone under prolonged sonication (10 min). The resulting suspensions were filtered on 200 nm pore 
Teflon filters, washed repeatedly with fresh acetone and dried under vacuum for 24 h.  
The loading of Met was evaluated through elemental analysis: 56 contained 1,86 mmol/g (elemental 
analysis N, 13,02%) while 58 contained 0.56 mmol/g of material (elemental analysis N, 8.32% starting 
form compound 57  
Elemental analysis N, 4.37%). TEM analysis of 56 did not show any significant variation respect to 2.  
 
In vitro Biological Assay 
 
HT29, HT29R, PC3, PANC1, MCF/, MDA-MB-231 cell lines were routinely growth in DMEM medium 
supplemented with 10% fetal bovine serum, 100 μg/ml penicillin, 100 μg/ml streptomycin and 100 μg/ 
ml L-glutamine (Sigma-Aldrich, St. Louis, USA) in a humidified atmosphere with 5% CO2 at 37 °C. Cell 
viability was evaluated by using MTT assay (Sigma-Aldrich). Cells were incubated with 0.5 μg/ml MTT 
solution for 1 h at 37 °C. After removing cell culture medium, DMSO was added to dissolve the insoluble 
MTT-formazan salt. Results were detected at 595 nm on a microplate reader (BioRad). CNTs 
internalization was analyzed by using Flow Cytometry. Briefly, cancer cells were grown in 35mm dishes 
until 60% of confluence and treated with 10 μg/ml of fluorescent carbon nanotubes for different 
interval times at 37 °C. Then, cells were extensively washed with PBS, trypsinized and collected in DMEM 
medium. Cells were pelleted by centrifugation, and washed with PBS before flow cytometric analysis 
using a FACSCanto flow cytometer (Becton-Dickinson). The carbon nanotubes incorporation in MCF7 
cells was evaluated by using confocal microscopy. Briefly, 0.5×106 cells were plated on a glass cover 
slips and then incubated in the presence of 10 μg/ml, of BODIPY decorated carbon nanotubes containing 
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or not metformin. After 20 h, glass cover slips were extensively washed with PBS, and fixed in 3% 
paraformaldehyde for 30 min at room temperature before the analysis with the confocal fluorescence 
microscope. The analysis was made using a Leica TCS SP5 confocal scanning microscope (Leica 
Microsystems, Mannheim, Germany), equipped with an argon laser source and a Leica Plan Apo 639 oil 
immersion objective. MCF7 cells treated with Met (1), CNT 2, CNT 3 for 24 h, were trypsinized, washed 
with PBS and resuspended in complete DMEM medium at the concentration of 106 cells/ml. One ml of 
cell suspension was transferred to an airtight chamber maintained at 37 °C and oxygen consumption 
was measured using a Clark-type O2 electrode (Hansatech) Oxygen content was monitored for at least 
10 min. The rate of decrease in oxygen content, related to protein amount was taken as index of the 
respiratory capability. 
 
SYNTHESIS OF compound 63 
 
The reaction was carried out in dry DCE (40 mL). Cyanoguandine 62 (400 mg, 4.7 mmol, 2.9 eq) was 
dissolved in the solvent, under nitrogen atmosphere, then TMSOTf (0.75mL, 2.8 mmol, 1.8 eq) was 
added. After 30 'at room temperature dodecylamine 61 (367 mg, 1.6 mmol, 1eq) was put in the flask 
and then the solution was refluxed in an oil bath, under nitrogen flow at 80 ° C overnight. 
The crude product was dissolved in EtOAc (70 mL) and then extracted by washing with H2O milliQ (40 
mL x 3). The organic phase was dried on Na2SO4 and then filtered. The crude obtained (695 mg) was 
purified by chromatography column (EtOAc, hexane). Yield 86%. 
 
1H NMR( 400 mHz, CD3OD): δ 0.88 (CH3), 1.40-1.29 (m, 10H, CH2), 3.17 (1H, CH2) ppm.  
 
13C NMR(400 MHz, CD3OD): δ 14.42 (s, 1C, I), 23.97 (s, 1C, H), 27.39 (s, 1C, C), 30.47 (s, 1C, F), 32.79 (s, 
1C, D), 48.15 (s, 4C, E), 48.56 (s, 1C, G), 48.84 (s, 1C, B), 49.49 (s, 1C, A), 119.79 (s, 1C, L), 123.10 (s, 1C, 




H2524 mesothelioma cells were placed in an incubator at 37 ° C, in a humidified atmosphere with 5% 
CO2, in a culture medium, containing glucose, amino acids, fatty acids, various metals, and antibiotics. 
 




The H2524 cells, plated in P60, were treated with both solutions (3 mL) of metformin (5.00 mM), and 
with solutions (3 mL) of dodecyl metformin (25.00 μΜ), making a technical duplicate for each solution. 
After 20 h the cells were observed to verify that they were alive. Subsequently, the medium was 
aspirated in each well, washed with PBS (2 mL), aspirated again and then placed 600 μL of a hypotonic 
solution (propidium iodide (50.00 mg / mL), sodium citrate (0.1%) and NP40 Cell Lysis Buffer (0.1%)). 






We performed the proliferation assays to assess the cell proliferation capacity of melanoma treated 
with 10 and 20 μM dodecyl metformin solutions in complete medium. Melanoma cells were cultured in 
2 mL of complete medium in wells of three MultiWell 6 and two P35. The two 35mm plates were needed 
to acquire the zero time, the three MultiWells to acquire the times at 24, 48 and 72 hours. The first day 
we carried out the count on the two P35s and treated the cells present in the Multiwell, the following 
days we performed the protocol on a Multiwell and treated the remaining ones. Cells plated in the 
MultiWell wells were treated following the diagram below: 
C  10     20 
C  10 20 
 
The wells marked C are the control wells, those numbered 10 and 20 indicate the cells treated with a 
10 and 20 μM solution of dodecyl metformin in respectively complete culture. 
We sucked the soil from the wells with the vacuum pump, we made two wash with 1 mL of PBS and we 
added 1 mL of 0.5% crystal violet solution in 20% MeOH. After placing the plates in the incubator for 5 
minutes, we aspirated the violet crystal solution with a pipette and recovered it in a 50 mL falcon; we 
did a wash with 1 mL of PBS and put the plate on an oscillator for 5 minutes. We carried out two more 
washes, in the last of which we used 2 mL of PBS, and after each wash we put the plate ad swing for 5 
minutes. We added 1 mL of DMSO to the wells and put the plates on the oscillator for 10 minutes. At 
the spectrophotometer we measured the absorbance of the solutions present in the various wells, the 
blank was set with 1 mL of DMSO. We collected the measurements at a wavelength of 595 nm and an 
optical path of 1 cm. 
The crystal violet was a cellular dye that works in vivo, internalized into all cells but unable to get out of 
living cells. The function of MeOH, inside of the dye solution, was its ability to dehydrate the cells and 
to crystallize them in the temporary situation. 
DMSO (dimethyl sulfoxide) is an organic solvent capable of breaking the membrane plasma cell. The 
crystal violet inside the living cells comes into solution. The obtained values of absorbance were directly 
proportional to the quantity of dye in the solution and, therefore, to the number of live cells in the well. 
For this reason is very important that, ideally, the only dye present inside of the plate is the probes 
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found in living cells. After the application of dye repeated and careful washing were carried out to 
eliminate the dye which did not enter the cells, but which remained present inside the plate. 
Proliferation Assay: Cell Count Assay with BÜCKER ROOM 
The cell count assay was used to determine if dodecyl metformin has an inhibitory activity on cell 
proliferation at 10 and 20 μM concentrations. The cells were plated in two P35 and in two MultiWell 6, 
the diagram below was followed: 
 
C  10     20 
C  10 20 
 
The wells marked with C were the control wells, while those numbered 10 and 20 indicate cells treated 
with a 10 and 20 μM solution of biguanide derivative in complete medium. 
After 24 hours from the plating, the protocol was carried out on the two P35 and the cells present in 
the Multiwells were treated. The following days the protocol was performed on a Multiwell and the 
remaining ones were treated. 
 
After the cells washing with 1 mL of PB, for two times; 3 drops of trypsin were added in each plate and 
putting them back in the incubator for 3 minutes. When the cells detached,1 mL of complete medium 
to each plate was added. 
The cells were picked up and transferred by capillarity to Bücker's chamber. Under the optical 
microscope the cells were counted in eight quadrants belonging to the two grids, we averaged the 
counts and multiplied it by 10 000 to get the number of cells present in one milliliter of suspension. We 
then multiplied the number for the actual volume of suspension present inside the well, obtaining the 
total number of cells inside the well. 
After treating the cells with trypsin and incubating them for 3 minutes, 1 mL of complete medium was 
added to block the action of trypsin which, otherwise, it would damage cellular proteins. 
Short time (1h) PI Assay 
To verify if dodecyl metformin created immediate damage to membrane, PI assay in a short time (1 h) 
was performed. 
We plated the cells in 6 P35; after 24 hours, we vacuumed the ground and we have treated the cells in 
such a way as to have six plates containing a solution respectively 0, 10, 20, 30, 40 50 μM dodecyl 
metformin in complete medium. After 1 hour, we have washed the discs twice with 2 mL of PBS, we 
detach the cells with trypsin and we added 1 mL of complete medium. We have transferred the contents 
of each P35 into six 15 mL falcons and centrifuged for 5 minutes, then aspirated the medium on top of 
the pellet and resuspended the cells in 500 μL of an isotonic solution at concentrations below 10 mg / 
mL of propidium iodide (PI) in PBS. After about twenty minutes, we analyzed the samples on a flow 
cytometer measuring the percentage and, therefore, the number of fluorescent cells and the average 
fluorescence intensity. 
 
Long time (24h, 48h, 72h) PI Assay 
To determine if dodecyl metformin causes cell membrane damage after 24, 48 and 72 hours of 
processing PI assays were performed after these periods of time. 




C  10     20 
C  10 20 
 
The wells marked C are the control wells, those numbered 10 and 20 indicate the cells treated with a 
10 and 20 μM solution of dodecyl metformin in respectively complete culture. 
Every day we repeated PI assay protocol in a short time on a MultiWell, and the cells in the remaining 
MultiWells were treated at the same rate. 
 
Cell detachment Assay 
We performed the cell detachment assay to determine if dodecyl metformin caused the detachment of 
A375 cells from the surface to which cells were attached and if, consequently, the metastasis of 
melanoma was promoted. 
Melanoma cells were plated in two 6-inch MultiWells, waiting to reach 70% of the confluence. After 
having aspirated the culture from the wells of the MultiWell, we treated the cells following the scheme 
below: 
 
C  5     10 20 40 60 
C  5  10 20 40 60 
 
The wells marked with C are the control, those marked with 5, 10, 20, 40 and 60 indicate cells treated 
with a solution of 5, 10, 20, 40 and 60 μM of biguanide derivative in complete medium. 
After 24 hours, some cells were detached. After aspirating the cell suspensions consisting of complete 
medium and the detached cells. We centrifuged the cell suspensions for 5 minutes at 1000 rpm, we 
aspirated the medium, and the cells were dispersed again in 4 mL of complete medium. The cells were 
plated again in two 6-inch MultiWells following the pattern described above and placed them in the 
incubator. We applied the assay protocol of growth to the cells of the two starting MultiWells, or to the 
cells that remained adhered to the plates. 
Cell Adhesion Assay 
Inside the human body, suspended melanoma cells were detached from the main tumor entering into 
the bloodstream or lymphatic stream and generating metastases. We carried out the adhesion assay to 
test if dodecyl metformin may inhibit the metastasis process, thus preventing the cancer cells 
suspended in the circulation blood or lymphatic to adhere to new tissue. 
We detached A375 cells, then we created a suspension cell in complete medium in a 50 mL falcon. In 
different falcons we added 4 mL of cell suspension and a quantity of dodecyl metformin such as to 
obtain solutions with concentrations of 0, 2.5, 5, 10, 20 and 30 μM. We have added 2 mL of cell 
suspension and dodecyl metformin to the wells of the two MultiWell following the diagram below: 
C  2.5 5     10 20 30 




The wells marked with C are the control, those marked with 2.5, 5, 10, 20 and 30 indicate cells treated 
with a solution of 2.5, 5, 10, 20 and 30 μM of dodecyl metformin in complete medium. We waited for 
the check cells reached at least 80% of confluence in order to perform the assay of cell growth. 
Since the solutions of DMSO and crystal violet formed inside the wells were concentrated enough to 
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5. Artificial Sponges to promote spinal cord 
regeneration 
5.1 OBJECTIVES OF THIS CHAPTER (5) 
Spiral cord injury is a common and devastating central nervous system (CNS) insult that result in 
disruption of cord microstructure with a limited neuronal regeneration and insufficient functional 
recovery in adult mammals. After severe spiral cord injury and in response to changes in the local 
microenvironment, astrocytes, the most abundant glial cells in the CNS, transform themselves into 
reactive astrocytes as a consequence of dramatic morphological changes98 as well as massive variations 
in gene expression.99 One of the most reactive changes occurring after a spinal cord injury is the 
formation of a glial scar, a reactive cellular process whereby glial cells accumulate and surround CNS 
injury sites to seal in the wound.98–100 The glial scar plays an important role in stabilizing CNS tissue by 
re-establishing the physical and chemical integrity of the CNS and closing the blood brain barrier to 
reduce infiltration of non-CNS tissue. As a consequence, this behavior minimizes the occurrence of 
infections and the spread of cellular damage.99 However, the glial scar also creates both a physical and 
molecular barrier to regenerate injured axons, preventing the re-growth and repair of axonal 
projections. The physical presence of a dense meshwork of reactive glial cells can block advancement 
of the growth cone, while proteoglycans (PG) present in the extracellular matrix of the glial scar, can 
actively inhibit axon outgrowth101,102,102 (Figure 125). 
 
The effect of removal of chondroitin sulfate proteoglicans (CSPG) on regeneration and plasticity of 
axons. It is widely accepted that removal of these PG and in particular chondroitin sulfates (CS) could 
provide beneficial effects on axon growth, its sprouting and plasticity and, most importantly, on 
promoting the recovery its function. Bacterial chondroitinase (ChABC) and aggrecanase-1 combination 
has proved a successful enzymatic treatment for both acute spinal cord injury and, recently, for chronic 
spinal cord injury, in experimental animals. However, since prolonged treatments are necessary (thus 
increasing the risk of further traumas or infections as well as triggering immune responses), their long-
term administration require modification. Furthermore, the development of new therapeutic 
treatments can meet with important obstacles related to the process safety, biodistribution 
phenomena, thermal stability effects and - last but not least - final costs.103 It is important to note that 
a recent work involving enzymatic treatment has revealed that multiple regions of proteoglycans can 
inhibit neurite outgrowth, so chondroitinase digestion might not remove all aspects of CS that prevent 







Figure 125. The effect of removal of chondroitin sulfate proteoglicans (CSPG) on regeneration and plasticity of 
axons. 
 
The key and original hypothesis in our proposal is that it should be possible to develop an innovative 
chemical strategy for the removal of the inhibitory molecules CS implied as barriers to CNS axons 
regeneration. For this goal, we have devised “nano-sponges”, novel nanoconstructures that selectively 
soaks CS and, doing so, promotes regeneration of injured axons. 
To address this challenge, we have designed nano-devices, with the desired chemical and physical 
properties, consisting of “polycationic structures” assembled around a central backbone made of 
nanostructured carbon materials [NCM, graphene oxide (GO) and oxidized carbon nanotube (Ox-CNT)], 
thus creating what we claim “nano-sponges”. We believe that the total removal of inhibitory molecules 
may be attained if the designed device is able to soak-up them efficiently. To support our idea, it has 
recently been shown that polycationic molecules, such as chitosan, poly(L-lysine) or poly-
(ethyleneimine), are capable to bind CS thus forming polymeric “nanoparticles” that can be removed 
from glial scars.105 Since our “artificial sponges” are expected to remove proteoglycans with a similar 
action path (purely ionic interaction) and even more efficiently compared to other materials/molecules 
of the state-of the art, this would prevent the presence of “inhibitory” fragments (contrary to what 
happens with the enzymatic therapeutic strategy). Furthermore, nano-constructs will be able to bind a 
large variety of sulfated glycosaminoglycans (chondroitin, heparin, dermatan and/or keratan sulfates) 
thereby offering an all-purpose strategy regardless of their molecular structures. 
The use of nanosponges for the removal of CS can be accomplished with the use of properly 
functionalized NCMs. It has been definitely proved that functionalized NCMs with tailored surface 
groups are not toxic and can be easily excreted from organisms (in mice through kidneys).106,107 
Furthermore, NCMs are ideal supports to be chemically modified through the formation of ad-hoc C-C 
bonds or through their supramolecular decoration. The literature presents several examples of 
decoration of NCMs with policationic residues: for example, Ox-CNT have efficiently been covered with 
poly(ethyleneimine) residues,108 with PAMAM dendron,109 Chitosan110 and many others. 
Herein, we propose the functionalization of NCMs with amino groups as a first step. These functional 
groups are basic and protonated at physiological pH, affording a simple nanosponge. Another possibility 
is the use of carboxylic and azido groups which can be conveniently conceived as grafting points for the 
attachment of more complex polycationic residues [i.e. PAMAM dendrimers, poly(L-lysine), poly-
(ethyleneimine) or chitosan] through a brush like or a multidentate approach. The activity of the nano-




Finally, we propose the decoration of our nano-sponges with magnetic iron oxide (IO) nanoparticles.111 
The IO–NCM composites will stick stably to chondroitin sulfates, thereby making the 
glycosaminoglycans magnetic (Figure 126). The latter will be separated from the glial scar without 
destruction under the action of an external magnetic field.  
Recently, a similar concept has been applied in the treatment of cancer by sticking magnetic 
nanoparticles to freefloating cancer cells. This has allowed them to be captured and carried out from 
the body.100 
Finally, the activity of the new magnetic nano-devices as well as their removal from the hosting bodies 
will be studied at the National Hospital for Paraplejics in Toledo (Spain) as research partner of the 
SPIDER proposal in Spain. 
 
 
Figure 126. General structure of magnetic artificial sponges based on nanostructured carbon material. 
 
5.2 INTRODUCTION 
Chondroitin sulfate proteoglycans (CSPGs) are molecules of the extracellular matrix (ECM) that are 
widely expressed in the developing and adult central nervous system (CNS) and have a potent inhibitory 
influence on regeneration of the CNS.112 After injury to the CNS, a glial scar is formed primarily by 
reactive astrocytes, which increase expression of CSPGs in the vicinity of the disrupted blood–brain 
barrier (BBB). This increase in CSPGs halts regeneration and induces the formation of dystrophic growth 
cones.113 In addition, CSPGs located in perineuronal nets (PNNs) have an important role in preventing 
unwanted synaptic plasticity in uninjured adult animals.114 In both cases, CSPG-mediated inhibition of 
growth seems to be linked to the activation of several signaling pathways. 
Much of the inhibitory influence of CSPGs can be alleviated by administration of chondroitinase ABC 
(ChABC) — an enzyme that selectively cleaves GAG chains from the protein core. ChABC is often used 
in combination with other repair strategies to facilitate the greatest regeneration possible. In addition 
to CSPGs, several other axon guidance molecules function to inhibit regenerating axons.115 
Degenerating myelin has been identified as another chief source of inhibition after injury and has been 
the subject of several recent reviews.116 
Recent developments in our understanding of the function of the ECM after damage to the adult CNS 
were examined.  
Proteoglycans: general structure and function Proteoglycans are involved in numerous processes such 
as growth, adhesion, receptor binding, migration, barrier formation and interactions with other 
components of the ECM.117 CSPGs include aggrecan, brevican, neurocan, NG2, versican and 
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phosphacan. During development, CSPGs pattern cell migration, regulate axonal pathfinding and limit 
plasticity. 
Proteoglycans consist of a protein core to which glycosaminoglycan (GAG) side chains are bound. GAG 
chains attached to the core protein vary markedly in length and number. These variations in GAG chain 
number and degree of sulfation determine the unique functions of different proteoglycans within and 
between classes.118 
Much evidence suggests that most of the inhibitory activity of CSPGs is derived from their GAG side 




A glial scar forms after injury to the CNS and acts as a barrier to regenerating neurons (Figure 127). 
 
 
Figure 127.  Elements of typical spinal cord and dorsal root entry zone lesions. After a stab lesion to the spinal cord, 
the lesion core is devoid of neurons and astrocytes and is populated by phagocytic macrophages. Fibroblasts deposit 
basal lamina and form a barrier between the lesion core and the penumbra. Reactive astrocytes secrete inhibitory 
CSPGs, which are deposited in an increased gradient (orange to red) and are highest in the lesion core. (a,b) After 
injury, CSPGs are upregulated in the dorsal root entry zone; neurons fail to regenerate and form dystrophic, club 
endings (gray, purple). (c) Descending bulbospinal axons (dark blue) cross the midline and innervate the 
contralateral phrenic nucleus. (d) Uninjured sensory neurons (green) are capable of limited sprouting to neighboring 
regions of the denervated cuneate nucleus. (e–h) Descending motor and ascending sensory fibers (green, red, pink, 
light blue, orange) fail to regenerate after injury and form dystrophic endings. 
 
Glial scars consist mainly of reactive astrocytes, which become hypertrophic and greatly increase their 
expression of intermediate filament proteins such as vimentin and glial fibrillary acidic protein. Reactive 
astrocytes and oligodendrocyte precursor cells (OPCs) have been shown to upregulate their expression 
of scar-associated inhibitory CSPGs such as neurocan, phosphacan and versican. Interestingly, the 
expression of both growth-inhibitory and growth-promoting ECM molecules increases in reactive 
astroglia, but the inhibitory ECM components are more markedly upregulated.120 In more severe 
injuries resulting in breakdown of the meninges, connective tissue elements, such as fibroblasts, mix 
with astrocytes and other invading cells, including macrophages, in the lesion.121 
Development of the scar begins within hours of injury, and a correlation among the areas of most 
significant BBB breakdown, highest infiltration of activated macrophages and greatest glial scar 
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formation has been demonstrated.122 Reactive microglia and OPCs are recruited to the forming scar, 
where they proliferate. Immediately after injury, astrocytes undergo a process known as ‘reactive 
gliosis’. Transgenically targeted ablation of the dividing population of reactive astrocytes after spinal 
cord injury (SCI) prevents reestablishment of the BBB, resulting in an increase in lesion size, cell death, 
an exacerbated immune response and marked motor deficits.123 Thus, despite its inhibitory properties, 
the glial scar is vital to seclusion of the damaged site and to protection of the surrounding regions from 
secondary injury.  
 
The role of NG2-expressing OPCs after injury remains a matter of debate.124 It has been widely 
speculated that the NG2 molecule negatively regulates axonal growth in vivo.125 It has been reported 
that neutralizing the NG2 proteoglycan with anti-NG2 antibodies modestly enhances the regeneration 
of sensory axons after spinal cord transection in the adult rat;126 however, recent evidence indicates 
that NG2 cells themselves might not be inhibitory to growing neonatal axons but instead might act as a 
permissive substrate owing to their enhanced production of growth-promoting molecules.127 OPCs do 
not become hypertrophic or increase their expression of NG2 in lesions in which the BBB is not ruptured, 





The central role of inhibitory ECM molecules in regeneration failure has been revealed by a series of 
microtransplantation experiments.129 These studies showed that adult sensory neurons that are 
microtransplanted atraumatically into injured white matter tracts can grow through the CNS 
environment, but halt abruptly as they approach the vicinity of the lesion. Upregulation of 
proteoglycans occurs in the latter region in an increasing gradient, which is highest at the lesion core. 
In the region where the glial scar forms, the ends of severed axons form ‘dystrophic endbulbs’, which 
were first described by Ramo´n y Cajal and have long been thought to be in a permanent state of 
quiescence. 
POSSIBLE TREATMENTS 
It is widely accepted that the removal of these chondroitin sulfate could provide beneficial effects on 
axon growth and, most importantly, on promoting functional recovery. The use of ABC bacterial 
chondroitinase has proven to be an effective treatment in animal experiments, both for acute and 
conical spinal cord injuries.130 However, treatment requires repeated injections, thus increasing the risk 
of further trauma and infection, and also of causing a severe immune response. Furthermore, important 
obstacles in the development of this as a therapeutic agent are in particular safety, biodistribution, 
thermal instability and above all its high cost.103 These limitations demonstrated the need to develop 
new strategies for the removal of CSPGs inhibitor molecules. 
5.3 RESULTS AND DISCUSSION 
The first part of this project was focus on carbon nanotubes oxidation. The chemical process started 
from pristine carbon nanotubes, allowed to shorten their length, making a variety of CNTs from few 
nanometers to 2 μm.  
5.3.1 SYNTHESIS OF CNTs-PDA  
Oxidized carbon nanotubes (CNTs) were functionalized through no-covalent bonds with Dopamine 
(DOA). Dopamine, generally auto-polymerizes in basic conditions to obtain poli-dopamine (PDA) which 
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stick to CNTs. CNTs-PDA showed a higher water dispersibility compared to CNTs. The chemical 
procedure was carried out at 25°C for 24h in Tris Buffer solution. The workup consisted in 
centrifugations and filtrations. 
 
Scheme 34. Functionalization CNTs-PDA. 
FT-IR, UV-Vis, Raman spectroscopy and Transmission Electron Microscope characterized the product. 
TEM images in Figure 128 showed nanostructured materials with a good dispersibility. No significant 
difference could be found in the morphology of the materials. CNTs-PDA diameter was calculated 
around10 nm, and lengths ranging from 100 nm to 1 μm.  
 
 
Figure 128.TEM images of CNTs-PDA (A); CNTs (B). 
The functionalization of material can be confirmed by two intense bands at 3431 cm-1 and 1631 cm-1 
revealed in FT-IR spectrum (Figure 129). An attribution to two specific functional groups of these bands 




Figure 129. IR Spectrum (KBr) of CNTs-PDA 64 
A comparison in UV-Vis Absorption spectrum of CNTs-PDA and CNTs was reported in Figure 130. At 280 
nm a characteristic dopamine pick attested the formation of the product. 
 
Figure 130. UV-Vis Spectrum of CNTs (black), CNTs-PDA (red) and PDA (green).  
Raman spectroscopy analyses were performed on the sample (Figure 131). Generally, carbon 
nanomaterials showed two main bands in their Raman spectra: one at ≈1580 cm−1 (G band) related to 
sp2 graphitic domain and the second at ≈1360 cm−1 (D band) attributed to the amorphous carbon or 
deformation vibrations of a hexagonal ring.131 Raman spectra of CNTs (Figure 132) showed the D and G 
bands centered at 1302 and 1590 cm−1, respectively. The functionalization with Dopamine further 






Figure 132. Raman Spectrum of CNTs (black); CNTs-PDA (red); 
Quantitative analyses concerning the functionalization loading degree of CNTs-PDA were collected 
through elemental analyses and XPS spectroscopy. The amount of C, N and H were showed in Tab 7. 
 %C %N %H 
Elemental Analyses 79.88 1.23 0.65 
XPS 97.2 2.8 - 
Tab 7 
These measures established a loading degree of PDA in the range 134 – 306 mg/g CNTs-PDA. 
 
Figure 133 XPS spectrum CNTs-PDA 64. 
5.3.2 SYNTHESIS OF CNTs-PAAH 
CNTs were modified with a no-covalent strategy to decorate the nanostructured carbon material with 
Poly(allylamine) (PAH). PAH is a linear polymer prepared by the polymerization of allylamine. Many -
NH2 groups provide a higher water solubility. The reaction was carried out in water at 70°C for 24h, with 




Scheme 35. CNTs functionalization with PAH. 
Compound 65 was characterized through UV-Vis spectroscopy and electron transmission microscope 
(TEM). The images showed in Figure 134 are analogue to the previously presented (Figure 128), since 
obviously, any morphological changes were involved. Nanotubes appear as non-aggregated and well 
dispersed structures. 
 
Figure 134: TEM images of CNTs-PAH 65. 
The comparison of UV-Vis spectrum of samples 2 and 65 showed a 5 nm shift of λmax adsorption, due 
to the functionalization.  
 
Figure 135. UV-Vis Spectrum of compound 2 (black), 65 (red). 
Additional values were achieved thanks to TGA and XPS measures. In Figure 136 the TGA profiles 




Figure 136. TGA profile of compound 2 (black) and compound 65 (red). 
XPS measures evaluated an amount of carbon and nitrogen as presented in Tab.8, the estimated loading 
of PAH was 245 mg/g. 
 
Figure 139 XPS Spectrum of CNTs-PAH 65. 
 %C %N 
XPS of 65 94.0 6.0 
Tab 8 
5.3.3 SYNTHESIS CNTs-PEI 
A different strategy consisted in the covalent functionalization of CNTs with branched PEI 
(Polyethylenimine).  The decoration occurred through amide bonds and the formations of C-N bonds, 
derived from epoxide ring opening on CNTs surface. The reaction was carried out in water at 25°C for 
24h, EDC and NHS were exploited as activating agent for carboxyl groups. The CNTs derivative 65 was 
isolated through filtration over a 0.2 μm polycarbonate membranes followed by repeated washings 
with different solvents to remove excess reagents, while compound 66 was recovered after several 




Scheme 36. Functionalization of CNTs with PEI 66 
The confirmation of the occurred reaction was obtained by UV-Vis, Raman spectroscopy and Electron 
Transmission Microscope (TEM). As with CNTs-PAH, TEM images of 66 showed similar chemical 
behavior: any morphological changes occurred. CNTs-PAH were dispersed and coupled structures of 
length in the order of hundreds of nm and diameters about 16 nm. 
 
 
Figure 140. TEM images of CNTs-PEI 66.. 
The comparison of UV-Vis spectrum of compound 2 and 6 (Figure 141) reported a shift of λmax 
adsorption from 252 nm to 257 nm, due to the functionalization of carbon material. 
 
Figure 141.UV-Vis Spectrum of compound 2 (black), 66 (red). 
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Raman spectroscopy’s measures revealed an increased intensity of D band of CNTs-PEI compared to 
CNTs. An increment of sp3 sites due to the new C-N bonds, therefore a new hybridisation could 
represent a possible explanation. 
 
Figure 142 Raman Spectrum of CNTs 2 (black); CNTs-PEI (red) 66; 
Elemental analyses and XPS measures (Figure 143) evaluated a loading degree of branched PEI on CNTs 





Figure 143. XPS spectrum of CNTs-PEI. 
Based on these results, the value of PEI grafted on CNTs was evaluated in the range 114-150 mg/g. 
 %C %N %H 
Elemental analyses 70.91 5.16 2.46 
XPS 96.1 3.9 - 
Tab 9    
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Zeta potential analyses were exploited to evaluate the charge values for the previously synthesized 
nano-adducts (Tab 10). The desired hybrid should show a positive charge to form “polycationic 
structures” able to bind a large variety of chondroitin sulphate and chitosan sulphate.  
 
 CNTs CNTs-PDA CNTs-PAH CNTs-PEI 
Zeta potential 









Tab.10 Zeta-potential values. 
CNTs-PEI appeared to be the best choice due to their positive charge value and the better dispersibility 
in water compared to the features of the other synthesized nano-hybrids. Covalent bonds, moreover, 
allowed to have steady structures.  
An additional possibility to functionalize carbon material through covalent bonds, could occur by using 
metformin, as showed in Scheme 37. 
 
Scheme 37. Synthetic Pattern for the synthesis Met-CNTs. 
The activation of carboxyl groups on CNTs was performed by adding oxalyl chloride. Metformin was 
added to the mixture to synthesize compound 68. An evaluation of loading degree occurred thanks to 
elemental analyses: 2 mmol/g was the estimated value of metformin on CNTs-MET.  
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The two described systems CNTs-PEI and CNTs-MET were selected to propose the decoration of future 
nano-sponges with magnetic iron oxide (IO) nanoparticles, making magnetic systems. This strategy will 
allow to achieve composites which stick stably to chondroitin sulfates or chitosan sulfate.  
The chemical procedure planned the formation of magnetic iron oxide nanoparticles by adding two iron 
salts (FeCl2.5H2O, FeCl3.6H2O) to the mixture.132 CNTs-MET were directly reacted as described to 
synthesize nano-sponges as CNTs-MET-IO. Scheme 38 
 
 
Scheme 38. Total Synthetic pattern for CNTs-MET-IO 69 
A first qualitative analyses of compound 69 occurred by FT-IR technique. The spectrum reported in 




Figure 144. IR spectrum of compound 69. 
This hypothesis was confirmed by ICP-AES analysis: 28.1% was the amount of iron established on CNTs-
MET-IO by quantitative evaluation. Iron oxide nanoparticles were distinctly exhibited in TEM images 
(Figure 145). Iron oxide nanoparticles were not uniformly spread on nanostructured surface, but 
assembled in local agglomerates.    
 
Figure 145. TEM images of compound 69.  
Zeta potential measures were performed to verify the charge value of nano-sponges CNTs-MET-IO in 
MilliQ water dispersion at 0.1 mg/mL at room temperature. The results were reported in Tab 11 
 CNTs CNts-IO CNTs-MET-IO 
Zeta potential analyses 








The synthesized complexes showed a negative charge value (in red in Tab 11). Unfortunately these 
nano-hybrids were not suitable for the conclusive goal of our proposal.  
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The natural evolution of this project consisted in the design and synthesis of CNTs-IO-PEI. The first step 
to realize this system was iron oxide nanoparticles synthesis, achieved by following the previously 
mentioned chemical procedure.132 (Scheme 39)  
 
Scheme39. Synthesis of CNTs-IO 70 
Consequently the addition of branched PEI was performed by following the reaction conditions adopted 
to obtain product 66. (Scheme 36) The decision to switch the order of the two synthetic steps was due 
to the reaction temperatures. We preferred to postpone the decoration of nanostructured material 
with PEI, which occurs at room temperature, to the formation of magnetic nanoparticles which requires 
60°C. (Scheme 40) 
 
Scheme 40. Synthetic pattern to achieve CNTs-IO-PEI 71.  
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After the first step, FT-IR spectroscopy was used to confirm the presence of iron oxide nanoparticles on 
CNTs. In Figure 146 a comparison between IR spectrum of compound 2 and 70 was reported. At 581 nm 








                                                      A                                                                                 B 
Figure 146. Spectrum of compound 2 (A), Spectrum of compound 71 (B).  
ICP-AES analyses evaluated a loading degree of metal equal to 50%, therefore an improvement in 
result compared to the iron quantitative amount collected for compound 71.  
After the second reaction step, elemental analyses of CNTs-IO-PEI 71 occurred to establish the 
quantitative amount of grafted PEI equal to 10.8%.  
To prove an effectively application of compound Z as nano-sponges, the complexes were tested in 
Zeta potential analyses. The results were showed in Tab 12. 
 CNTs CNts-IO CNTs-PEI CNTs-IO-PEI 
Zeta potential analyses 










To test the real potential of the synthesized nano-sponges, the ability of polycationic nano-hybrids to 
complex chondroitin sulfate proteoglycans and chitosan sulfate molecules was evaluated. Chitosan 
sulfate groups are similar in structures to chondroitin sulfate, but with a higher number of sulfate 
groups.133 Due to the negative charges of these groups they showed an improved possibility to bind 
positively charged amino groups of PEI. The decorated carbon material was dispersed in MilliQ water at 




Scheme 41. Synthesis of compound 72. 
After numerous centrifugations to remove an excess of reagents, the compounds were characterized 
by Zeta potential measures. In Tab 13 charge values of compounds CNTs-IO-PEI complexed with 
chitosan (Ch58SA3) or chondroitin sulfates (CS-A,C or CS-E) were reported and compared to the 






Zeta potential analyses 













CS: Chondroitin sulfate ChS: Chitosan sulfate 
According to our hypothesis, Zeta potential value of CNTs-PEI-CS decreased. The new calculated 
potentials (-8.8 mV, -9.8 mV ) for the whole system suggested the occurred reaction. CNTs-PEI-Ch also 
allowed to have a negative charge value. 
A first procedure to quantify the amount of Chondroitin sulfate able to form complexes with CNTs-PEI 
was carried out according to a useful bioprotocol.134 
Spectrophotometric assays to measure the Glycosaminoglycans, such as chondroitin sulfate, content in 
biological fluids and tissue/cell extracts are valuable tools. The dye 1,9- dimethylmethylene is a thiazine 
chromotrope agent that presents a change in the absorption spectrum due to the induction of 
metachromasia when bound to sulfated GAGs enabling rapid detection of GAGs in solution. Moreover, 
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there is a window in which a linear curve may be drawn (approximately between 0.5-5 μg of GAGs) 
enabling the quantification of GAGs in solution. 
After several cycles of centrifugation and dispersion compound 72 was recovered. At the end of every 
cycle the washing water was analyzed by adopting the mentioned bio-protocol, previously explained, 
to evaluate the removed chondroitin sulfate. Comparing the total amount of chondroitin sulfate at the 
beginning of the reaction to the residue of glycosaminoglycans contained in the washing water, the 
Chondroitin sulfate grafted on CNTs was calculated. Thanks to spectrophotometric analyses Figure 147, 
Figure 148 74 mg (CS-A, C)/ g (CNTs-IO-PEI-CS A, C) were quantified. In Figure 147 the absorbances of 
four water dispersions of compound 72 at different concentrations were reported. In Figure 148 the 
absorbance measures at 535 nm of the four mentioned dispersions were correlated to different 
concentrations of chondroitin sulfate. This graph allowed to establish the amount of CS-A, C solubilized 









                                        Figure 147                                                               Figure 148 
This amount of compound was confirmed by ICP-AES analyses, which provided a result equal to 101 
mg (CS-A, C)/ g (CNTs-IO-PEI-CS A, C). 
5.4 CONCLUSION AND PERSPECTIVES 
In conclusion synthesis of nano-sponges consisting in central backbone made of oxidized carbon 
nanotubes (CNTs) assembled with “polycationic structures” (polyethylenimine branched or metformin) 
and decorated with magnetic nanoparticles were performed.  
The ability of our nano-devices (CNTs-IO-PEI) to bind chondroitin sulfate or chitosan sulfate was 
checked. 
Next step will be in vitro test to confirm the potential of nano-sponges to remove molecules of the 
extracelluar matrix that have a potent inhibitory influence on tissue regeneration of the Central Nervous 
System. 
5.5 MATERIAL AND METHODS 
SYNTHESIS OF CNTs-PDA 64 
Oxidized carbon nanotubes (2) (50 mg) were dispersed in 50 mL of Tris Buffer solution (10mM, pH 8.5) 
Dopamine (25 mg) was added. The mixture was sonicated for 10 'in an ice bath and stirred at 25 °C for 
24 h. At the end, the reaction was centrifuged at 1400 rcf for 10’. The supernatant was removed and 
the precipitate was dispersed in water and centrifuged a second time. The obtained nanotubes were 
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dried under vacuum, dispersed in 0.01 M HCl and filtered on 0.2 µm membrane, washed with MilliQ 
water up to pH 7. The solid was collected and dried, under vacuum and in an oven at 80 ° for 2 hours, 
obtaining compound 64 as black powder (37 mg). 
Elemental analysis: C 79.88%; N 1.23%; H 0.65% 
SYNTHESIS OF CNTs-PAAH 65 
Oxidized carbon nanotubes (2) (20 mg) were dispersed in 100 mL of MilliQ water and sonicated for 5. 
PAAH (82 mg) was added and the dispersion sonicated again for 15 '. KOH (100 mg) was added and the 
reaction was carried out at 70 °C for 24 h under nitrogen atmosphere. At the end the reaction was to 
cool at room temperature and centrifuged at 1400 rcf for 60 '. The supernatant was removed and the 
precipitate was filtered on polycarbonate membrane (Whatman, pore size 0.2 μm, Ø 47mm), washing 
several times with milliQ water until the pH of the filtrate resulted neutral. The solid was dried under 
vacuum and subsequently was put in an oven at 120 °C for 2 h, obtaining functionalized carbon 
nanotubes (65) as black powder (9.4 mg). 
SYNTHESIS OF CNTs-PEI 66 
CNTs or CNTs-IO (2) (50 mg) were dispersed in 250 mL of methanol, the dispersion was sonicated for 5 
'. EDC (300 mg) and NHS (300 mg) were added to activate the carboxyl groups on CNTs (2). The mixture 
was stirred at room temperature for 3 h. PEI is then added (300 mg) and the reaction is again stirred at 
room temperature for 24 h. At the end the mixture was centrifuged at 1400 rcf for 10 '. The supernatant 
was removed, the precipitate was dispersed in fresh methanol. The centrifugation operations and 
dispersion were repeated 2 more times to remove the excess of polymer. The solid was dried under 
vacuum and subsequently put in an oven at 120 °C for 2 h, obtaining the modified nanotubes (66) as 
black powder (37 mg). 
Elemental analysis (8): C 70.91%; N 5.16%; H 2.46% 
SYNTHESIS OF CNTs-MET 68 
Oxidized carbon nanotubes (2) (35 mg) were dispersed in freshly distilled oxalyl chloride (10 mL) under 
nitrogen. Then the dispersion was stirred at reflux for 24 h, after that the oxalyl chloride was accurately 
removed under vacuum. The acyl chloride CNT directly dispersed in dry DMF (9.5 mL), using an 
ultrasound bath, metformin (170 mg) was added to the dispersion and the mixture stirred at 120 °C 
under nitrogen for 40 h. CNT-MET were recovered by filtration over a 0.2 μm nylon membrane washing 
several times with DMF and methanol to remove the unreacted metformin.  
Metformin loading ranged from 1.8 to 2 mmol/g as evaluated from elemental analysis on three different 
samples. 
SYNTHESIS OF Magnetic Nanoparticles 70 
CNTs or CNTs-MET (20 mg) were dispersed in MilliQ water (5 mL). 2.5 mL of a 0.04 M aqueous solution 
of FeCl2 4(H2O) (0.103 mmol in 2.5 mL of water) and 2.5 mL of a 0.09 M aqueous solution of FeCl3 6(H2O) 
(0.218 mmol in 2.5 mL of water) were added to the flask, under stirring. A 2M aqueous solution of NaOH 
was used to obtain a dispersion with pH 11. The mixture was heated at 60°C for 4h. At the end of 
reaction the dispersion was centrifuged for 20’ at 1500 rcf. The mixture was filtered on nylon membrane 
0.2 µm pores. The recovered material was 40 mg. 
ICP: CNTs-MET-IO : Fe 28.1% 
ICP: CNTs-IO-PEI: Fe 55.2% 
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SYNTHESIS OF CHONDROITIN SULFATE/CHITOSAN SULFATE WITH CNTs-IO-PEI 72 
4.2 mg of CNTs-IO-PEI or CNTs-MET-IO were dispersed in 3 mL of MilliQ water at room temperature. 
3.4 mg of Chondroitin Sulfate or Chitosan Sulfate were added to the mixture. After 24h at room 
temperature the mixture was dialyzed for 3 days and freeze dried. 
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6. Heterogenous organo- and metal catalysis using 
phosphine oxide derivatives anchored on multiwalled 
carbon nanotubes. 
 
6.1 INTRODUCTION AND OBJECTIVES OF CHAPTER (6) 
A significant attention in the development of catalytic organophosphorus-based reactions featured last 
decade.1 Thanks to numerous studies that have been published, important progress in the use of 
phosphines-mediated reactions for organic synthesis occurred. Substituted phosphines can catalyze 
many different kind of reactions recovering theirs starting oxidation state as the end of the process, 
such as when they act as nucleophiles in wide range of transformations ranging from Michael to 
Rauhut−Currier reaction.2 However, there are several examples in which their oxidation state change 
from P(III) to P(V). This is the case of Staudinger ligation,3 Mitsunobu,4 Wittig5 and Appel6 reactions in 
which the byproduct is a phosphine oxide, which is often not easy to remove form the reaction mixture. 
In these cases, to obtain a catalytic process it is necessary to add a reduction step in which the former 
phosphine is recovered. The work of many researchers developed catalytic version of these reactions. 
First O’Brien et al presented the opportunity to evolve into a catalytic protocol the Wittig reaction.7,8 By 
using a phosphine oxide as pre-catalyst and phenyl silanes as reducing agents, they achieve different 
alkenes in presence of either aldehyde or ketone as starting materials. Ashfeld et al showed a 
preeminent strategy for amide C-N bond construction exploiting a direct traceless Staudinger ligation 
of carboxylic acids and azides based on phosphine redox catalysis.9 Inspired by the development of the 
previously mentioned Staudinger Ligation and Wittig reaction, also Mitsunobu reaction catalytic in 
phosphine was disclosed by O’Brien and coworkers7 in the patent literature, and later optimized by 
Aldrich et al.10 The same occurred with the Appel reaction.11  
All this literature production, that has largely improved the efficiency of the procedures, is focused 
on the use of phosphine as homogeneous catalysts.12 Quite the opposite, no catalyst in heterogeneous 
phase has been exploited. On the other hand, carbon nanotubes (CNTs) have already demonstrated an 
efficient support for heterogeneous catalysis both profiting of their high surface area, able to host a 
large number of catalytic species,13,14 and their inner space.15 Their easy functionalization and the large 
amount of literature produced on their applications.16,17,18,19,20 made them ideal candidate for 
combining the use of phosphorus derivatives, as active component, and CNTs as heterogeneous 
support, in a catalytic process.  Through this work we present examples of heterogeneous phosphorus-
organocatalysis to synthesize small organic molecules. This goal was obtained decorating carbon 
nanotubes with phosphine oxide derivatives. Our catalytic system consists of a physical support, made 
of multi walled carbon nanotubes (MWCNT), for triphenyl phosphine oxide or phospholane oxide 
moieties. The high surface area of carbon nanotubes, permits to incorporate a significant phosphine 
moiety, achieved thanks to easy functionalization. The phosphorus-based molecules work to promote 
the organic reactions; the nanostructured carbon material allows an easy separation of products from 
the reaction mixture and consequently a straightforward purification: at the end of the process the 
reformed phosphine oxide is not discarded but recycled. The opportunity to reuse the catalyst after the 
first cycle of reaction is one of the major advantage of heterogeneous organocatalysis, making it a 
“greener process” if compared to chemical reactions carried out in homogeneous phase, seeing as the 
amount of needed phosphine is minor. To the best of our knowledge this is one of the few 




In a previous work,23 we have shown how it is possible to covalently functionalize carbon based 
nanostructured materials using amino substituted and azido substituted phosphine derivatives to 
prepare new materials that has been preliminarily tested in a Staudinger ligation experiment. Here we 
extend the use of the catalysts to Wittig and Mitsunobu reactions and demonstrate the possibility of a 
different use of the same material in which the phosphine moieties act as ligand for Pd nanoparticles 
to afford a nanocomposite that can catalyze the Heck reaction.24 Heck reaction is a useful method for 
forming C-C bond on the double bond carbon atoms, with a wide application in organic synthesis.25 
 
6.2 RESULTS AND DISCUSSION 
The synthesis of the heterogeneous catalysts started from pristine MWCNT (1) that were oxidized using 
a HNO3/H2SO4 mixture at 100 °C for 30 min. The oxidation removed any metal impurity, shortened the 
nanotubes and improved their dispersibility in most solvent due to the insertion of oxygenated 
functional groups as shown by IR spectra. The oxidized multiwalled carbon nanotubes (Ox-MWCNTs) 2 
were used as substrate for the reaction with three different phosphine oxide derivatives: (4-
aminophenyl)diphenyl phosphine oxide (73)26; (4-azidophenyl)diphenyl phosphine oxide (74)23 and 3-
azido-1-phenylphospholane 1-oxide (75) (Figure 149). Compound 75 was synthetized for this study 
since it is an analogue of the phospholane derivatives used by O’Brien8 and Aldrich10 in their works: the 
presence of an azido allowed an easy functionalization of the CNT. The synthesis started from phosphol-
2-ene 1-oxide modifying a previous procedure.27,28,29,30  
 
 
Figure 149. Structure of starting phosphine oxides 73, 74 and of phospholane 75. 
The three compounds were used to covalently decorate the nanotubes 2 using the Tour protocol31,32 
for the amino derivative 73 (Scheme 43) to afford compound 76, while profiting of the reactivity of the 
azido group, in compound 74 and 75, towards carbon nanotube walls at high temperature33 to afford 




Scheme 42. Synthesis of 76, 77 and 78. 
The loading of the resulting materials can be evaluated using different techniques. A simple IR spectrum, 
for examples, can afford qualitative evaluation of the successful reaction based on the appearance of 
an intense band at 1140 cm-1 due to the P=O stretching.34 All the IR spectra of materials 76, 77 and 78 




Figure 150. IR spectra of 76 
 
A quantitative evaluation can also be offered by inductively coupled ion plasma atomic emission 







Compound ICP/AES P% mmol/g P 
76 1,84 0,59 
77 2,25 0,73 
78 2,09 0,67 
Tab 14. Content of phosphorus calculated using ACP-AES. 
 
The % content of nitrogen, estimated by elemental analyses, for compound 7 (1.12%), was in 
accordance with the loading degree suggested by ICP-AES. (Table 1). The synthetic approach consisting 
of nitrene cycloaddition provided a slightly higher loading both for compound 77 and 78 if compared to 
compound 76.  
The following chemical transformation was the reduction of phosphine oxides 76 and 77 to the 
corresponding phosphines (catalysts 79 and 80, Figure 151), using trichloro silane.  
 
 
Figure 151. Structure of compounds 79 and 80. 
We demonstrated the successful reduction using an XPS analysis (Figure 142), but the same qualitative 
information can be obtained from a simple IR spectrum showing the disappearance of the P=O 




Figure 152. XPS analysis of samples form the reduction reaction of compound: starting material (top), after 24 h 







Figure 153. IR spectrum of compound 80. 
 
Inspired by O’Brien and coworkers,8 who demonstrated the application of the catalytic Wittig 
methodology by using 3-methyl-1-phenylphospholane 1-oxide as catalyst, the material 78, carrying a 
similar substituent on the nanotube surface, was tested as heterogeneous organocatalyst in a Wittig 
reaction. Methyl bromoacetate (82) and benzaldehyde (81) were reacted to afford methyl cinnamate 
(83) in three repeated reaction cycles (Scheme 43) (Table 14). As base, DIPEA was preferred to Na2CO3 




Scheme 43. The Witting reaction of 81 and 82 to afford cinnamate 83 
 
The catalytic process was guaranteed by the presence of Ph2SiH2 that reduced the phospholane oxide 
to the reacting phospholane at the beginning of every reaction cycle. Comparing our system with the 
results collected by O’Brien and coworkers (methyl cinnamate was obtained up to 80% yield using 0.1 
equivalent of of phosphole), the performances of catalyst 78 is comparable for the first cycle (Table 15, 
entry 1) to the results obtained in solution considering that the reaction was conducted with an amount 
of catalysts corresponding to 0.057 equivalent of phospholane. Unluckily the catalyst efficiency 
degraded quickly in the second and third cycles. (Table 15, entry 1). The same reaction was performed 
using catalyst 79 (0.05 equivalents of phosphine substituent) with lower yields (Table 16 entry2). 
Increasing the amount of catalysts, up to 0.1 equivalent did not increase the yields, while any reduction 
did not afford any product. This adopted heterogeneous organocatalysis allows a recycle of catalyst for 
















1 78 5.7 70% 52% 25% 
2 79 5 55% 24% - 
Tab 15. Catalytic Wittig reaction: yields of methyl cinnamate (13) over the different cycles 
 
The same redox driven approach, involving phosphorus compound with different valence, could be 
applied for Mitsunobu catalytic reaction. Again, inspired by the work of Aldrich and coworkers,10 who 
used 1-phenylphospholane 1-oxide as catalyst (5%), we used catalyst 78 for the synthesis of the benzyl 
4-nitrobenzoate (86) (Scheme 44) following Aldrich’s procedure: refluxing THF in the presence of 
diisopropyl azodicarboxylate and phenyl silane as reducing agent.   
 






Cycle 1 Cycle 2 Cycle 3 
78 2 54% 40% 22% 
Tab 16. Catalytic Mitsunobu reaction: yields of benzoate 86 over the different cycles. 
 
The reaction was conducted using an amount of 78 corresponding to 2% mol of phospholane derivative 
obtaining for the first cycle a conversion of 54%, Again the efficiency of the catalyst decrease rapidly in 
the second and third cycles and the amount of catalyst was critical to obtain acceptable yields. 
Catalysts 79 and 80 were, then, used in a Staudinger Ligation reaction. Compound 80 was already used 
in our previous work. 83 Here we report a comparison of the activity of catalyst 79 and catalyst 80 in the 
Staudinger ligation reaction between benzoic acid (87) and benzyl azide (88) to obtain N-
Benzylbenzamide (89). (Scheme 45) using the same reaction conditions as reported by Ashfeld and 
coworkers:[9] refluxing toluene in the presence of phenyl silane and the catalyst (triphenyl phosphine 
(10% mol) in the case of the work of Ashfeld and catalysts 79 or 80 (1% mol of phosphorus moiety) in 
this work) 
 








Cycle 1 Cycle 2 Cycle 3 
1 79 1 75% 30% 20% 
2 80 1 69% 34% 21% 
Tab 17. Catalytic Staudinger Ligation: yields of benzamide 19 over the different cycles 
 
The results reported in Table 17 show that catalysts 79 and 80 perform very similarly and regardless of 
the different way in which the triphenylphosphine group is linked to the nanotube surface. Again, the 
catalysts efficiency decreases rapidly upon recycling in the following reaction cycles.   
Finally, adduct 80 was tested as support for Pd nanoparticles to produce a new nanocomposite (adduct 
90) in which the phosphine groups might play the role to coordinate and stabilize catalytically active 
Pd(0) nanoparticles. The nanoparticles were produced, in the presence of adduct 80, upon reduction of 
Pd acetate in hydrogen atmosphere. 
 
 
Scheme 46. Synthesis of nanocomposite 20 
 
The nanostructured material represented the carbon support for the effective catalyst: the 
nanoparticles synthesized from a palladium salt. TEM images confirmed the formation of nanoparticles 
(Figure 154). The evaluation of their diameter distribution is showed in Figure 154. ICP-plasma analysis 
estimated a loading degree of palladium 1.03 mmol/g for catalyst 20. 
 
         
Figure 154. TEM image of nanocomposite 20 (up); Size distribution of Pd(0)  nanoparticles (down).  
 
In a previous experiment Fareghi et al[24] synthetized trans-stilbene (24) (among many other 
substrates), via Heck reaction, in one cycle with 95% of yield, exploiting a catalytic system 
consisting of immobilized Pd nanoparticles on phosphine-functionalized graphene. We tested 


































and styrene (22). (Scheme 47) The results are reported in table 5 (entry 1). Comparing the amount 
of Pd used by Fareghi and coworkers24 (1.7 mol%) with our system 20 (0.92 mol%) the results are 
good. The decrease in performance recorded for the last reaction cycle can be explained with a 
significant leaching of palladium. An ICP-AES analysis showed a metal loading of 0.18 mmol/g after 
the fourth reaction cycle, suggesting a loss of 80% of the catalytic species.  
 
 






Cycle 1 Cycle 2 Cycle 3 Cycle 4 
1 92 0,97 66% 89% 90% 37 
2 93 0,12 58% 61% 61 51 
Tab 18 Catalytic Heck reaction: yields over the different cycles 
 
Better results were obtained in the synthesis of trans-cinnamic acid in which the catalyst loading could 
be lowered down to 0.12 % of active Pd species preserving acceptable yields up to the forth cycle (table 
5, entry 2).  
 
6.3 CONCLUSIONS 
The decoration of MWCNT with phosphine oxide derivatives has demonstrated a straightforward 
method to produce new nanostructured material with promising properties as catalysts. Although the 
limited efficiency of the processes study, this is, to the best of our knowledge, the first example of an 
organocatalytic processes based on phosphine oxides that has been transferred to heterogeneous 
materials.  
 
6.4 MATERIALS AND METHODS 
Materials and Methods should be described with sufficient details to allow others to replicate Materials 
MWCNTs were purchased from Sigma-Aldrich reagent, O.D. × L.= 6–9 nm × 5 μm, carbon >95%, 
CoMoCat©. All the other reagents, whose synthesis is not described, were commercially available and 
have been used without any further purification, if not specified otherwise. Rf values are referred to TLC 
on silica gel plate (0.25 mm, Merck silica gel 60 F254). NMR spectra were recorded on Varian Gemini 
200 MHz or Varian Mercury 400 MHz at room temperature. Chemical shifts were reported in parts per 
million (ppm) relative to the residual solvent peak rounded to the nearest 0.01 for proton and 0.1 for 
carbon (reference: CHCl3 [1H:7.26, 13C:77.2]. Coupling constants J were reported in Hz to the nearest 
0.01 Hz. Peak multiplicity was indicated by s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet) 
and br (broad signal). IR spectra were recorded on a Perkin-Elmer FT-IR 881 or Shimadzu FT-IR 8400s 
spectrometer. IR data are reported as frequencies in wavenumbers (cm−1). Elemental analyses were 
performed with a Thermofinnigan CHN-S Flash E1112 analyzer. ICP analysis were made using an Optima 
2000 Perkin Elmer Inductively Coupled Plasma (ICP) Dual Vision instrument after acidic mineralization. 
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TEM images were acquired at the electronic microscopic center CNR Florence (CE.M.E.) with a Philips 
CM12 with CRYO-GATAN UHRST 3500 technology, digital camera and EDAX microanalysis. 
 
Compounds 3,26 4, 6 and 7, 9 and 1023 were synthesized following published procedures. 
 
SYNTHESIS OF 3-azido-1-phenylphospholane 1-oxide 75 
 
Synthesis of this compound was accomplished by adaptation of the previously developed 
procedures.27,28  
 
SYNTHESIS OF 1-phenyl-3-benzylaminophospholane 1-oxide A 
 
In a Schlenk flask equipped with a magnetic stirrer was placed 1.78 g of phosphol-2-ene 1-oxide, 10.71 
g (100 mmol) of benzylamine, and 10 mL of water. The resulting mixture was heated at 110 °C for 72 h. 
After cooling to room temperature, the reaction mixture was extracted with chloroform (3x30 mL), the 
extracts were combined, dried over anhydrous MgSO4, filtered, and evaporated. The excess of 
benzylamine was distilled off in vacuo to give crude product in the form of two diasteroisomers in ca. 
1:2.5 ratio (31P NMR: δ 58.63 and 56.38 ppm, respectively). Final purification of this mixture on a silica 
gel column using chloroform/metanol mixture (15:1) as eluent afforded 1.36 g (48%)of pure major 
adduct as an oil. 
 
1H NMR (CDCl3) δ 1.58 (bs, 1H), 1.95-2,07 (bm, 2H), 2.07-2.36 (bm, 3H), 2.37-2.46 (m,2H),3.35-3.46 (m, 
1H), 3.89 (q, J = 13.1 Hz, 2H), 7.26-7.32 (m, 1H), 7.33-7.39 (m, 4H), 7.48-7.59 (m, 3H), 7.68-7.76 (m, 2H).  
 
13C NMR (CDCl3) δ 27.9 (d, JP-C = 65.9 Hz), 31.3 (d, JP-C = 5.5 Hz), 36.8 (d, JP-C = 67.0 Hz), 51.7, 57.2 (d, JP-C 
= 12.2 Hz), 127.1, 128.0, 128.5, 128.7 (d, JP-C = 12.5 Hz), 129.8 (d, JP-C = 11.,4 Hz),131.6 (d, JP-C = 2.7 Hz), 
134.4 (d, JP-C = 91.6 Hz), 139.8. 
 
31P NMR(CDCl3) δ 56.38 ppm. 
Elemental Anal. Calcd. for C17H20NOP: C, 71.61; H, 7.06; found C, 71.45; H, 6.99.  
The minor adduct was washed from the column in the first fraction together with unreacted phosphol-
2-ene 1-oxide and was not be separated. Considering that the double bond in phosphol-2-ene oxides is 
known to undergo attacks by the incoming reagents exclusively, or at least preferentially, from the side 
opposite to the bigger P-substituent,[29,30] the stereochemical array of the 3-amino and P-Ph 
substituents in the major adduct is tentatively assigned as anti. 
 
SYNTHESIS OF 3-azido-1-phenylphospholane 1-oxide 75 
 
A solution of sodium azide (333 mg, 5.12 mmol) in H2O (1.7 mL) and CH2Cl2 (0.5 mL) was added with a 
solution of trifluoromethanesulfonic anhydride (233 mg, 1.02 mmol) in CH2Cl2 (1 mL) at 0°C. The 
resulting suspension was stirred for 10’ at 0 °C and at room temperature for 3 h. After the addition of 5 
mL of H2O the mixture was extracted three times with CH2Cl2 (10 mL*3). The combined organic extracts 
were first washed with a saturated solution of Na2CO3, therefore stored.  
CuSO4 (0.9 mg, 0,005 mmol) and K2CO3 (106 mg, 0.77 mmol) were added to a solution of A (100 
mg, 0.512 mmol) in H2O/MeOH (7mL/18mL). The stirring solution was mixed to the previously achieved 
solution. After 19 h the reaction was completed. Rf of product 0.9 (EtOAc/MeOH 5:1). The mixture was 
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extracted five times with CH2Cl2 (15 mL). The combined organic extracts were washed with brine (35 
mL), dried over anhydrous MgSO4, filtered, and evaporated in vacuo to afford 5 as a white solid. (80 
mg, 71% yield). 
 
IR spectrum ν cm-1 2100 s, 1710 s. (see SI: Figure S3); 
 
1HNMR (400 MHz, 298K, CDCl3) δH 7.69-7.63 (m, 2H), 7.53-7.44 (m, 3H), 4.20–4.11 (m, 2H), 2.37-2.02 
(m, 7H).  
 
MS-ESI 244.0, (M+Na) 464.8 (2M+Na) 
 
SYNTHESIS OF CNTs-(PO-phospholane)-Nitrene (78) 
 
A 100 mL flask was added with CNTs (20 mg) and 40 mL of 1,2- dichlorobenzene. The mixture was kept 
in an ultrasound bath for 20 min. 3-azido-1-phenylpfospholane 1-oxide (5) (60 mg 0.27 mmol) was 
added. The dispersion was kept at 165 °C under vigorous stirring for 4.5 days. The dispersion was diluted 
with isopropanol and centrifuged for 15 min at 1500 rcf. The supernatant was removed. The precipitate 
was washed, dispersed and centrifugated (5 min in ultrasound bath and centrifugation for 15 min at 
1500 rcf) with a solution of diisopropyl ether and isopropanol 1:1. After the removal of supernatant, the 
solid was washed by cycle of dispersion in fresh methanol and centrifugation (two times). The product 
was recovered and dried to afford 66.8 mg of a black powder.  
ICP-AES: phosphorus 0.67 mmol/g.  
FTIR (KBr): 3380, 1713, 1586, 1159 and 1123 cm−1 P=O stretching. (see SI: Figure: S12). 
 
SYNTHESIS OF Pd nanocomposite (90) 
 
In a 5 mL flask, 5.2 mg (0.023 mmol) of Pd(OAc)2 were added to a dispersion of 12.9 mg of 80 in 3 mL of 
ethanol.  The mixture was kept under hydrogen atmosphere for 24 h. The reaction mixture was filtered 
through a polycarbonate membrane filter (pore diameter: 0.2 µm) and the solid washed (30 mL of 
ethanol) and dried. The product was recovered as 15.9 mg as a black powder. 
 
ICP-AES of Pd: 1.04 mmol/g.  
Procedure for the Wittig Reaction 
 
A pyrex tube equipped with a stirring bar was charged with 78 or 79 (6 mg) and 0.2 mL of dry toluene. 
After 5 minutes in an ultrasonic bath, DIPEA (10 mg, 1.2 eq), benzaldehyde (7.5 mg, 1 eq), methyl 
bromoacetate (13 mg, 1.2 eq), diphenyl silane (26 mg, 2 eq) and 0.1 mL of dry toluene were added to 
the mixture. The reaction was heated at 100°C for 24 h. The catalyst was recovered first by 
centrifugation (2 x 15 min at 1500 rcf) and dispersion with toluene 20 mL, then same procedure by using 
methanol 20 mL. The solution was evaporated under vacuum giving the crude product. After flash 
chromatography (silica) using a mixture of hexane / ethyl acetate 10 : 1 the product was achieved as 
white solid.  
 
GC-MS Spectrum (EI) retention time: 12.4’. m/z 163 (M+1) 
1H-NMR (400 MHz, 298 K, CDCl3) δ H 7.70 (d, J= 16.0 Hz, 1H), 7.53-7.51 (m, 2H), 7.38-7.36 (m, 3H) 6.44 
(d, J= 16.0 Hz, 2H). (see SI: Figure S18) 
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Procedure for the Mitsunobu Reaction 
 
A pyrex tube equipped with a stirring bar was charged with 78 (5 mg) and 0.3 mL of tetrahydrofuran. 
After 5 minutes in an ultrasonic bath, 4-nitro benzoic acid (42 mg, 1.5 eq), benzyl alcohol (18 mg, 1 eq), 
diisopropyl azodicarboxylate (38 mg, 1.1 eq), phenyl silane (27 mg, 1.5 eq) were added to the mixture. 
The reaction was heated at 80°C for 24 h. The reaction mixture was filtered through a PTFE membrane 
filter (pore diameter: 0.2 µm). The catalyst was washed with fresh tetrahydrofuran and recovered. The 
solution was evaporated under vacuum giving the crude product. After flash chromatography (silica) 
using a mixture of hexane / ethyl acetate 20 : 1 the product (benzyl 4-nitrobenzoate) was achieved as a 
yellow solid.  
 
GC-MS Spectrum (EI) retention time: 21.5’. 257 (M+1) m/z. (see SI: Figure S19)  
 




Procedure for the Staudinger Ligation 
A pyrex tube was added with 80 (5 mg) degassed dry toluene (1 mL), carboxyl acid (0.19 mmol, 1 eq), a 
solution of benzyl azide (0.19 mmol) in 0.5 mL of degassed toluene and phenylsilane (21 mg, 0.19 mmol, 
1 eq) and the reaction was stirred at 110 °C under nitrogen atmosphere for 24 h. The catalyst was 
recovered by dispersion with 20 mL of toluene and centrifugation 2 times for 15 minutes at 1500 rcf. 
The solution was evaporated under vacuum giving the crude product. The amide was recovered after 
flash chromatography (silica) using a mixture of hexane/ ethyl acetate 1:1. N-Benzylbenzamide: Rf = 
0.48.  
 
GC-MS spectrum (CI) retention time: 23.0’. m/z 212 (M+1). (see SI: Figure: S15) 1H-NMR (200 MHz, 298 
K, CDCl3) δ H 7.79 (d, J= 9.6 Hz, 2H), 7.51-7.29 (m, 8H), 6.44 (bs, 1H), 4.65 (d, J= 5.6 Hz, 2H).  
 
Procedure for Heck reaction 
 
A pyrex tube was added with catalyst 90 (3.5 mg), potassium carbonate (138 mg, 2 eq), N,N-dimethyl 
formamide (1.5 mL), alkene (1.2 eq) and iodobenzene (79 mg, 1 eq) and the reaction was stirred at 
120°C for 6 hours. The reaction mixture was diluted with 20 mL of isopropyl alcohol and centrifuged at 
1500 rcf for 15’.  The catalyst was recovered.  
After flash chromatography the product was recovered. 
 
trans-stilbene (hexane: ethyl acetate 2:1), was obtained as a white solid. 
GC-MS Spectrum (CI) retention time: 29.1’. m/z 181 (M+1).  
1H-NMR (200 MHz, 278K, CDCl3) δ H 7.53 (d, J= 6.8 Hz, 4H), 7.41-7.30 (m, 6H), 7.12 (s, 2H).  
 
trans-cinnamic acid (hexane: dichloromethane 20:1), was obtained as a white solid. 
GC-MS Spectrum (CI) retention time 15.3’. m/z 149 (M+1). 
1H-NMR (200 MHz, 298K, CDCl3) δ H 7.81 (d, J=16 Hz 1H), 7.59-7.52 (m, 2H), 7.46–7.40 (m, 3H), 6.47 (d, 
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7. Functionalization of GO with amines and phenols via 
Ball Milling 
 
7.1 OBJECTIVES OF THIS CHAPTER (7) 
The aim of this chapter was to obtain derivatives of graphene oxide through a covalent decoration with 
phenols, alcohols and amines. 
Graphene oxide was reacted with the following compounds: 
8-hydroxyquinoline (96), 4-nitrophenol (97), 4-hydroxyacetanilide (98), 4-chloro-2-
nitrophenylmethanol (99), N-ferrocenyl-1,2-diaminoethane (100). 
 
Figure 155. Molecules used in reactions with graphene oxide 
The study concerned the possibility of using nitrogenous or oxygenated nucleophiles to open epoxide 
rings, onto of graphene oxide surface. 
These reactions with amines and phenols are well known when carried out in solution. By using non-
classical reaction conditions such as, Ball Milling, no example was reported in literature.  
This technique, based on the high energy impact of spheres of various materials, allows to perform 
reactions in the solid state avoiding the use of solvents. Sometimes completely different reactivity 
results were collected from those obtained by performing the same solution responses. 
To favor the nucleophilicity of oxygenated reagents, phenols, the reaction was also carried out in the 
presence of sodium carbonate as a base. 
The interest in this type of reactions is related to the possibility to perform the reduction of graphene 
oxide derivatives to obtain functionalized reduced graphene oxide. 




7.2 INTRODUCTION OF CHAPTER 7  
7.2.1 CHEMICAL REDUCTION OF GRAPHENE OXIDE 
Different methods to reduce dispersed graphene oxide in solution are known. The most classic 
procedure involves the use of hydrazine monohydrate, which has the advantage of not reacting with 
water. This characteristic allows to react graphene oxide in aqueous dispersions, unlike reducing agents 
such as lithium aluminum hydride which give rise to side reactions with solvents. 
The reaction was carried out at 80-100 ° C. Hydrazine was added to a dispersion of graphene oxide in 
water and the precipitation of a black solid was observed, probably due to the increase in 
hydrophobicity of the material related to the decrease in polarity on the surface. 
A disadvantage of this reduction was the introduction of heteroatoms, since nitrogen tends to remain 
covalently bonded to the graphene oxide surface. 
To overcome this problematic sodium borohydride was added as reducing agent. Although this 
substrate was hydrolyzed by water, the process was slow enough to take place successfully in freshly 
prepared solutions with a large excess of NaBH4. Improvements in conductivity were observed in rGO 
films obtained with NaBH4 compared to products synthesized by using N2H4.135 
A selective effect is shown by the majority of chemical reducing reagents A single reducing agent is not 
enough to remove all the functional groups containing oxygen.136 Reductive processes consisting in 
several consecutive steps have been developed: Gao et al,137 proposed a chemical strategy which 
involves a reduction with NaBH4 followed by dehydration with sulfuric acid and annealing at high 
temperatures. The method proved particularly effective in restoring the conjugate structure of 
graphene. 
Reduction techniques concerning the use of hydrogen iodide138,139, showing high values in the C: O ratio 
of the products (about 15) and in sample conductivity (about 300 S / cm), and with ascorbic acid,140 
which provides results similar to the collected values connected with the use of hydrazine with the 
advantage of non-toxicity. 
7.2.2 THERMAL REDUCTION 
GO can also be reduced by thermal processes141: this process occurs by CO2 extrusion performed by 
heating the graphite oxide to 1050 ° C. At high-temperature gas creates enormous pressure between 
the layers (up to 130 MPa at 1000 ° C) causing their separation. However, a considerable damage to the 
GO structure, was observed, around 30% of its mass was lost, leaving vacancies and topological defects 
that affect the properties of the material. 
7.2.3 IDROTHERMAL REDUCTION 
Hydrothermal synthesis allowed the transformation of the material by using aqueous solutions at high 
temperature and pressure. 
The sample was dispersed in water (0.7 mg / mL), the suspension was brought up to pH 11 and 
transferred to an autoclave. The reaction was carried out under stirring for 6 h at 180 ° C. 
Using a sealed tube, the water can be brought to a temperature well above its boiling point thanks to 
the increase in pressure resulting from heating. 
The process was pH sensitive, as confirmed by HR-TEM, XPS and Raman studies. The acidic conditions 
led to a greater amount of defects in rGO samples, with thin sheet sizes and greater tendency to 
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aggregate. The increase in negative charge on the sheets was obtained by increasing the pH, which 
determines the repulsion between the layers.142 
7.2.4 CHEMISTRY FUNCTIONALIZATION: GO REACTIVITY WITH ALCOHOLS AND AMINES 
It is possible to covalently bind molecules to graphene oxide by exploiting the reactions which occur 
with the functional groups present on its surface (the carboxylic acids found on the sides, the epoxy 
groups and the hydroxyl groups). The ability to initiate these reactions makes graphene oxide a versatile 
precursor for a wide range of applications. Several reactions can occur simultaneously: nucleophiles 
such as amines or alcohols can react with carboxylic groups, after their activation, giving rise to the 
formation of amides and esters, and opening reactions of the epoxy ring can occur following 
nucleophilic attack. The groups more reactive are the epoxy rings. 
Amines are better nucleophiles than alcohols, reacting more effectively with the electrophilic group. 
Alcohols and phenols can be activated by carrying out the reaction in a basic environment, to 
deprotonate the hydroxyl groups making them better nucleophiles. (Figure 156) 
 
Figure 156. Reaction of epoxide rings of GO with amines and alcohols.  
7.2.5 BALL MILLING 
A "mechano-chemical reaction" is defined, by IUPAC as "a chemical reaction induced by the direct 
absorption of mechanical energy". The input can be provided by various types of mechanical action, 
including grinding. The term "ball milling" describes processes of this type performed with ball mills The 
reagents are transferred into jars containing spheres that can vary in material and size, and subjected 
to mechanical agitation. The fine grinding of the material that occurs during the process reduces the 
size of the particles down to the nanoscale, increasing the surface area of the solid. The amount of 
highly active regions on the surface of material was increased.  
The advantages of using mechanochemical techniques are numerous: the process is "green", delating 
the problem of wasting solvents, the reactions are carried out at lower temperatures compared to the 
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analogous reactions in solution, requiring less energy. No problems relating to the solubility of the 
products occurred.  
7.2.6 PARAMETERS INFLUENCING THE REACTIONS 
Several parameters influence the success of chemical reactions carried out by ball milling. The type of 
mill used, the frequency of oscillation / rotation, the reaction time, the material that constitutes jars 
and spheres, the size and number of spheres should be evaluated.143 
There are planetary ball mills, the movement gave to the jars is a rotation in the horizontal plane, and 
vibration mills, the jars are accelerated by oscillations in vertical or horizontal plane. The latter are the 
most common mills. Since the physical mechanism is different, it is difficult to compare the results 
obtained with the two different types of mill. 
The kinetic energy related to the movement of oscillation or rotation is directly proportional to the 
value of the frequency, so this parameter is fundamental. The frequency influences the reaction yield 
and the selectivity. The grade of effect of frequency depends on the type of reaction.142,143  
The reaction time is an additional parameter that may be modulated: normally the reaction yield 
increases with the time,144 unless secondary reactions occur that lead to a conversion of the products. 
The choice of material of apparatus represents another influential parameter. Some reactions show an 
increase in yield when heavier materials are used,145 others show no particular effects.146 Tungsten 
carbide, steel, zirconium, corundum and agate jars can be used. In this work steel or agate jars were 
used. It is important, of course, to choose materials that are inert towards the reagents. 
There may be problems due to abrasion of the material, which can determine the presence of 
impurities in the desired product. 
Finally, the number of spheres significantly affects the reaction. when the density of the material and 
the diameter of the spheres was constant. There is a proportionality between the yield and the number 
of spheres given the linear correlation between mass, moment of inertia and kinetic energy of the 
system. The diameter of the balls is important when the total mass is not constant 
 
                Reagents                                        Products 
                            Spheres and jars materials,  
                            Reaction time, Frequency 
Figure 157. Parameters affecting ball milling reactions 
 
7.2.7 BALL MILLING APLLICATION TO GRAPHENE DERIVATIVE 
Ball milling has been successfully used in reactions involving graphene, such as obtaining graphene 
oxide from flaked graphite and the production of graphene nanolayers: the kinetic energy generated 
during collisions is sufficient to break the bonds between the graphite layers e, also allowing the 
introduction of functional groups. 
Ball milling can be used to functionalize graphene oxide, such as to obtain functionalized GO with PEG 
for targeting cancer cells. 
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In our work, ball milling was used to covalently bind different types of nucleophiles to the graphene 
oxide substrate. This technique is useful to avoid the consumption of high volumes of solvent that would 
otherwise be necessary in order not to aggregate the graphene oxide in suspension. 
7.3 DISCUSSION AND RESULTS 
The goal of this work was the functionalization of graphene oxide with different nucleophiles and 
consecutive reduction of synthesized products. The opportunity to use the Ball milling technique allows 
to achieve a greener process compared to the reaction in liquid phase, without solvents. The solid 
phase, furthermore avoids the reaction workout, saving time and resources. 
7.3.1 FUNCTIONALIZATION OF GRAPHENE OXIDE 
The reactions were carried out through ball milling technique, the powdered samples were placed into 
steel or agate jars containing a sphere and subjecting them to mechanical stirring. The material of the 
jars and the spheres was specified for each reaction in the experimental part. Reactions ratio ratio by 
weight between the reactants was 1: 1. 
The oxygenated nucleophiles were pre-mixed with sodium carbonate for 10 minutes at 25 Hz (1500 
rpm) and then mixed with the GO at 25 Hz for 40 minutes, time required to quantitatively perform the 
reaction, without overheating the jars. The premixing with Na2CO3 promoted the deprotonation of 
phenols making them better nucleophiles, profitable to open epoxy ring. 
The amine was reacted directly with GO. 
In all reactions, about 100 mg of inert NaCl was added to the jars in order to increase the volume 
occupied. 
The samples were then subjected to several washes with suitable solvents, in order to remove both 
NaCl and the excess reagent not reacted with GO. The washes were carried out by dispersing the sample 
in the solvent, later repeated centrifuges were performed. Washing waters were checked by using UV-
vis spectroscopy to verify the absence of the unreacted starting material. The product was then filtered 
under vacuum, dispersed in MilliQ water and freeze-dried. The samples functionalized with phenols 
showed some difficulties, when washed with water quite stable dispersions were formed. A large part 
of the sample remained dispersed in the solvent. The following centrifuges, leading to a difficult 
recovery of it. 
All lyophilized samples were characterized by UV-vis, IR spectroscopy and elemental analysis. The 
results of the elemental analyses were shown below. Brackets (1) indicate the product obtained without 
























Tab 19. Elemental analyses to evaluate the loading degree on GO. 
That functionalization did not occur successfully with 4-chloro-2-nitrophenylmethanol and 4-
nitrophenol, which are obviously too weak nucleophiles. 
The GO functionalization with phenols occurred by activating the molecule in a basic environment, the 
final product exhibits greater functionalization (the nitrogen loading degree was approximately double 
in both cases). 
For GO -N-ferrocenyl-1,2-diaminoethane, the functionalization of the sample was also confirmed by the 
ICP analysis, which indicates an amount of iron equal to 33.82 µg / mg. 
The provided results can be compared with the information obtainable from the UV-vis spectra of the 
products (Figure 158) 
Sample N% C% H% 
mmol N / 
100 mg 
GO – Hydroxyquinoline 
(1) 
0,826 52,920 2,580 0,059 
GO – Hydroxyquinoline 
(2) 
1,921 51,805 1,981 0,137 
GO – 4-Nitrophenol (1) 0,000 39,322 1,535 0,000 
GO – 4-Nitrophenol (2) 0,000 33,599 1,151 0,000 
GO – 4-Hydroxyanalide 
(1) 
0,237 48,267 2,402 0,017 
GO – 4-
Hydroxycetanalide (2) 
0,438 45,455 2,065 0,031 
GO – 4-Chloro-2-
nitrobenzyl methanol (1) 
0,000 43,550 2,146 0,000 
GO – 4-Chloro-2-
nitrobenzyl methanol (1) 
0,000 37,872 1,974 0,000 
GO – N-ferrocenyl-1,2-
diaminoethane 






Figure 158. UV-vis spectrum of functionalized GO. 
The spectra of the samples pre-mixed with sodium carbonate have been reported. 
The spectrum of GO - N-ferrocenyl-1,2-diaminoethane was not carried out, since the amine does not 
show absorption peaks in the UV. 
In general, the absorption peak of GO and that of the molecules bund onto GO should be observed, 
possibly overlapping. 
Typically, GO has an absorption peak spectrum around 230 nm, which is attributed to the π – π * 
transition caused by the aromatic ring, while rGO shows a peak, shifted at 270 nm.147 
In all spectra, the peak of the GO was shifted to longer wavelengths, this could be an indication of a 
partial reduction of the GO which occurred during the functionalization process. 
The functionalization was confirmed in spectrum 1, a peak at 240 nm characteristic of hydroxyquinoline 
was clearly visible. 
In spectrum 3, a peak at 243 nm relating to hydroxyacetanilide should be observed, but it was not 
very intense and superimposed on GO curve. 
The peak relative to nitrophenol (317 nm) in spectrum 2 was not observed, elemental analysis 
confirmed that the reaction did not occur. 
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4-chloro-2-nitrophenylmethanol showed a peak at 253 nm, it was not clearly identifiable in spectrum 4. 
Elemental analysis, indicated the lack of functionalization. 
IR spectra of oxidized products (reported in methods and synthesis) showed OH, C = C and C-O 
stretching and the characteristic of graphene oxide material. Peaks relative to other molecular 
vibrations were less intense and superimposed on these. The spectra were therefore not useful in 
confirming the functionalization. 
7.3.1 THERMAL REDUCTION 
The most functionalized products, GO - hydroxyquinoline and GO - N-ferrocenyl-1,2-diaminoethane, 
were subjected to hydrothermal reduction. This method had already given good results in previous 
experiments on the reduction of GO functionalized with amines. 
A 0.7 mg / mL suspension of the sample in MilliQ water was brought to pH 11 by the addition of NaOH 
0.1 M solution and transferred to a 20 mL capacity sealed autoclave. 
The autoclave was heated to 180 ° C and the reaction was carried out for 6 hours under magnetic 
stirring. The crude product was then filtered under vacuum and washed with MilliQ water. 
Advantages of the method were undoubtedly the simplicity of the procedure and the standardization 
of the method for all samples. 
In Tab 20 the results of elemental analyses of reduced products were reported. 
Sample N% C% H% 




1,026 66,227 1,441 
0,037 
GO – Hydroxyquinoline 
(2) 
2,287 60,202 2,184 
0,163 
Tab 20. Elemental analyses of reduced products. 
Both samples, showed an increased percentage of carbon compared to the amount of carbon of the 
corresponding oxidized product. The functionalization during the process was preserved, as highlighted 
by the quantity of nitrogen, which was slightly decreased for GO - N-ferrocenyl-1,2-diaminoethane, 
while for GO - Hydroxyquinoline increased, suggesting that the percentage of oxygen on reduced 
sample had actually decreased. 
No peaks useful for characterization in UV spectra of the samples were observed, the reduced 
compounds were difficult to disperse.  
7.3.2 GO REDUCTION WITH NaBH4 
Sodium borohydride reduction was performed for all samples. To verify the effectiveness of the process, 
first the reaction was applied to no-functionalized GO. An excess of NaBH4 was added to a 0.5 mg / mL 
suspension of GO and the reaction mixture was heated at 100 ° C for 3 h. 
Characteristic peck of GO in UV measures moves from 228 nm to 273 nm, confirming the occurred 
reduction (Figure 159): 
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Figure 159. UV spectra of GO and rGO reduced with sodium borohydride. 
The procedure was then replicated on all functionalized samples. 
The method provided good results: elemental analyses revealed that the quantity of nitrogen and 
carbon has increased compared to the corresponding oxidized samples. 
Sample N% C% H% mmol N / 100 mg 
rGO 0,000 55,671 0,615 0,000 
rGO – N-ferrocenyl-
1,2-diaminoethane 
1,409 52,247 2,818 0,050 
rGO – 
Hydroxyquinoline 
2,266 60,709 2,649 0,162 
rGO – 4-
Hydroxycetanalide 
0,555 56,904 1,779 0,040 
Tab 21 
The procedure is therefore efficient for all samples, giving results comparable to the values collected 
with hydrothermal reduction. The chemical reductions performed with the addition of NaBH4, 
presented an increase in the percentage of hydrogen, if compared to the samples reduced by 
hydrothermal method. Additional OH groups were impurities generated during this reductive 
process.148 
The reduced products were difficult to disperse in water, improving slightly in basic solutions. It was 
therefore complicated to obtain information from the UV-vis spectra. Spectrum of rGO - N-ferrocenyl-




Figure 160. UV spectrum of rGO – N-ferrocenyl-1,2-diaminoethane 
In all the IR spectra of the reduction products (shown in the Experimental Part), a widened band was 
observed relating to the presence of OH groups. These groups were not totally eliminated through the 
reductive processes. However, many spectra showed a reduction in intensity of this band, in particular 
in the products obtained through hydrothermal reduction. 
XPS measures performed on samples containing N-ferrocenyl-1,2-diaminoethane. Figure 161 showed 
the XPS spectra of GO - N-ferrocenyl-1,2-diaminoethane (A), rGO - N-ferrocenyl-1,2-diaminoethane 
reduced with hydrothermal treatment (B), rGO - N-ferrocenyl-1 , 2-diaminoethane reduced with sodium 
borohydride (C). 
 
Figure 161. XPS spectra of rGO – N-ferrocenyl-1,2-diaminoethane  
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In N1s region of spectra A, B, C we observed the presence of NH2 (≃398 eV) and NH3 + (≃402 eV) groups 
due to molecules which have not reacted with GO. The main contribution was provided by the CN bond 
(≃ 400 eV), which confirmed the functionalization of GO, even after reductive processes. 
In C1s region, peaks attributable to the C-O-C epoxy bonds (≃ 287 eV) and COOH of carboxylic acids 
(≃288.6 eV) were observed in the oxidized sample. These signals were not present in the reduced 
sample, where instead we can identify those of the groups C = O (≃288.5 eV) and C-O (≃286 eV). This 
confirmed the GO reduction. 
The results therefore confirmed the data obtained from the elemental analyses and the UV-vis spectra. 
7.4 CONCLUSION AND OUTLOOKS 
This work showed the possibility to functionalize layers of graphene oxide with nucleophiles by using 
the ball milling technique. had already been obtained. Previous experiments concerning the decoration 
with amines via Ball milling demonstrated good results, but the reactivity with phenols had not been 
investigated. Despite the lower nucleophilicity compared to amines, it was possible to bind oxygenated 
nucleophiles onto GO. 
The results regarding the reduction of GO samples evidenced the success of reaction proved by 
elemental analyses, UV-vis and IR. The reductions occurred without loss of nucleophiles covalent bund 
to GO, thus maintaining the functionalization. 
Future investigations could introduce several phenols and amines on GO, furthermore different 
methods to reduce substrates may be investigated. In addition the characterization of materials could 
proceed by XPS; TEM or AFM to achieve additional information about the new modifications of material.  
7.5 MATERIAL AND METHODS 
SYNTHESIS OF GO – 8-Hydroxyquinoline 101 
 
80 mg of graphene oxide, 80 mg of 8-Hydroxyquinoline and 100 mg of NaCl were placed into a 10 mL 
steel jar containing a steel sphere. The jar was put in a ball mill and subjected to mechanical stirring for 
40 'at a frequency of 25 Hz. The product was recovered, dispersed in 80 mL of MilliQ water and divided 
into 4 50 mL Falcon tubes. It was centrifuged at 8000 rpm for 15 '. The process was repeated 7 times 
using a 1: 1 water / methanol mixture as solvent. 
The product was subsequently dialyzed in a 4: 1 water / methanol solution in order to completely 
remove the excess of unreacted phenol. 
The product was finally filtered on a polycarbonate membrane with 0.4 µm pores, dispersed in 80 mL 
of MilliQ water and freeze-dried. 
Elemental analyses CHN: N 0.83 %, C 52.92 %, H 2.58 % 
227 
 
Nitrogen loading degree: 0.06 mmol/100 mg of material 
UV-vis: the material was dispersed in methanol to achieve a 50 ppm solution, maximum absorption at 
240 nm (8-Hydroxyquinoline). 
 
Figure162. UV spectrum of compound 101 
IR spectrum (KBr): 3700-3000 (str. OH), 1620 (str. C=C aromatic groups), 1377 (str. C-O), 1060 (str. C-
OH) cm-1 
 
Figure 163. IR spectrum of compound 101. 
SYNTHESIS OF GO – 8-Hydroxyquinoline with Na2CO3 102 
 
80 mg of graphene oxide, 80 mg of 8-Hydroxyquinoline, 100 mg of NaCl, 80 mg of Na2CO3 were placed 
into a 5 mL steel jar containing a steel sphere. The jar was put in a ball mill and subjected to mechanical 
stirring for 40 'at a frequency of 25 Hz. The product was recovered, dispersed in 80 mL of MilliQ water 
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and divided into 4 50 mL Falcon tubes. It was centrifuged at 8000 rpm for 15 '. The process was repeated 
7 times using a 1: 1 water / methanol mixture as solvent. 
The product was subsequently dialyzed in a 4: 1 water / methanol solution in order to completely 
remove the excess of unreacted phenol. 
The product was finally filtered on a polycarbonate membrane with 0.4 µm pores, dispersed in 80 mL 
of MilliQ water and freeze-dried. 
Elemental analyses: nitrogen loading degree: 0.14 mmol/100 mg of material 
UV-vis: the material was dispersed in methanol to achieve a 50 ppm solution, maximum absorption at 
240 nm (8-Hydroxyquinoline). 
 
Figure 164. UV spectrum of compound 102 
IR spectrum (KBr): 3194 (str. OH), 1589 (str. C=C aromatic groups), 1375 (str. C-O), 1242 (str. C-O) cm-1 
 










Hydrothermal reduction of GO – 8-Hydroxyquinoline 103 
 
14 mg of GO - 8-Hydroxyquinoline were dispersed in 20 mL of MilliQ water and the suspension was 
brought to pH 12 with the addition of 0.1 M NaOH water solution. The mixture was placed into an 
autoclave which was heated to 180 ° C for 6 h, under stirring. 
The product was recovered and finally filtered on a nylon membrane with 0.4 µm pore. The product 
was washed several times until neutral pH of washing water, then it was freeze-dried. 
Elemental analyses: N 2.29 %, C 60.20 %, H 2.18 % 
Nitrogen loading degree: 0.16 mmol/100 mg of material 
UV-vis: the material was dispersed with difficulty in methanol, the identification of a clear peck was not 
possible.  
IR spectrum (KBr): 3500-3000 (str. OH), 1579 (str. C=C), 1238 (str. C-O) cm-1 
 
 








Chemical reduction of GO – 8-Hydroxyquinoline 104 
 
20 mg of GO - 8-Hydroxyquinoline were dispersed in22 mL of MilliQ water, of NaBH4 were added. The 
reaction was reflux (100° C) for 3 h, under stirring. After 3 h a UV spectrum was performed to confirm 
the reduction. 
The product rGO - 8-Hydroxyquinoline was recovered by vacuum filtration on a polycarbonate 
membrane with 0.4 µm pores, washed with MilliQ water and dried on vacuum.  
Elemental analyses: N 1.41%, C 52.25%, H 2.82% 
Nitrogen loading degree: 0.05 mmol/100 mg of material 
UV-vis: the material was dispersed with difficulty in methanol, the identification of a clear peck was not 
possible.  
IR Spectrum (KBr): 3700-3200 (str. OH), 1560 (str. C=C), 1236 (str. C-O) cm-1 
 









SYNTHESIS OF GO-4-Nitro phenol 105 
 
80 mg of graphene oxide, 80 mg of 4-Nitro phenol and 100 mg of NaCl were placed into a 10 mL steel 
jar containing a steel sphere. The jar was put in a ball mill and subjected to mechanical stirring for 40 
'at a frequency of 25 Hz. The product was recovered, dispersed in 80 mL of MilliQ water and divided 
into 4 50 mL Falcon tubes. It was centrifuged at 8000 rpm for 15 '. The process was repeated 5 times 
using MilliQ water as solvent.  
The functionalized material was filtered on a polycarbonate membrane with 0.4 µm pores, then 
dispersed in 80 mL of water and freeze-dried 
Elemental analyses CHN: N 0.00 %, C 39.32 %, H 1.54 % 
Nitrogen loading degree: 0.00 mmol/100 mg of material 
UV-vis: the material was dispersed in MilliQ water to achieve a solution at 50 ppm, maximum absorption 
at 238 nm (GO). 
 
Figure 168. UV spectrum of compound 105 










SYNTHESIS OFGO – 4-Nitro phenol with Na2CO3 
 
80 mg of graphene oxide, 80 mg of 8-Hydroxyquinoline, 100 mg of NaCl and 80 mg of Na2CO3 were 
placed into a 5 mL agate jar containing an agate sphere. The jar was put in a ball mill and subjected to 
mechanical stirring for 40 'at a frequency of 25 Hz. The product was recovered, dispersed in 80 mL of 
MilliQ water and divided into 4 50 mL Falcon tubes. It was centrifuged at 8000 rpm for 15 '. The 
process was repeated 5 times using a MilliQ wate as solvent. 
The product was finally filtered on a polycarbonate membrane with 0.4 µm pores, dispersed in 80 mL 
of MilliQ water and freeze-dried. 
Elemental analyses CHN: N 0.00 %, C 33.60 %, H 1.51 % 
Nitrogen loading degree: 0.00 mmol/100 mg of material 
UV-vis: the material was dispersed in MilliQ water to achieve a solution at 50 ppm, maximum absorption 




Figure 170. UV spectrum of compound 106 
 
IR spectrum (KBr): 3700 – 3000 (str. OH), 1631 (str. C=C), 1240 (str. C-O), 1072 (str. C-OH) cm-1 
 
Figure 171. IR spectrum of compound 106 
SYNTHESIS OF GO-4-Hydroxyacetanilide 107 
 
80 mg of graphene oxide, 80 mg of 4-Hydroxyacetanilide and 100 mg of NaCl were placed into a 10 mL 
agate jar containing an agate sphere. The jar was put in a ball mill and subjected to mechanical stirring 
for 40 'at a frequency of 25 Hz. The product was recovered, dispersed in 80 mL of MilliQ water and 
divided into 4 50 mL Falcon tubes. It was centrifuged at 8000 rpm for 15 '. The process was repeated 5 
times using 2-propanol as solvent.  
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The functionalized material was filtered on a polycarbonate membrane with 0.4 µm pores, then 
dispersed in 80 mL of water and freeze-dried 
Elemental analyses CHN: N 0.23 %, C 48.27 %, H 2.40 % 
Nitrogen loading degree: 0.02 mmol/100 mg of material 
UV-vis: the material was dispersed in MilliQ water to achieve a solution at 50 ppm, maximum absorption 
at 243 nm, peck overlapped to GO. 
 
Figure 172. UV spectrum of compound 107 
IR spectrum (KBr): 3400-2500 (str. OH), 1728 (str. C=O), 1610 (str. C=C), 1234 (str. C-O), 1070 (str. C-OH) 
cm1 
 











SYNTHESIS OF GO-4-Hydroxyacetanilide with Na2CO3 108 
 
80 mg of graphene oxide, 80 mg of 4-Hydroxyacetanilide, 100 mg of NaCl and 80 mg of Na2CO3 were 
placed into a 10 mL agate jar containing an agate sphere. The jar was put in a ball mill and subjected to 
mechanical stirring for 40 'at a frequency of 25 Hz. The product was recovered, dispersed in 80 mL of 
MilliQ water and divided into 4 50 mL Falcon tubes. It was centrifuged at 8000 rpm for 15 '. The process 
was repeated 5 times using a 2-propanol as solvent. 
The product was finally filtered on a polycarbonate membrane with 0.4 µm pores, dispersed in 50 mL 
of MilliQ water and freeze-dried. 
Elemental analyses CHN: N 0.44 %, C 45.46 %, H 2.07 % 
Nitrogen loading degree: 0.03 mmol/100 mg of material 
UV-vis: the material was dispersed in MilliQ water to achieve a solution at 50 ppm, maximum absorption 
at 239 nm, peck overlapped to GO. 
 
Figure 174. UV spectrum of compound 108 
 





Figure 175. IR spectrum of compound 108 
Chemical reduction of GO-4-Hydroxyacetanilide WITH NaBH4 108 
 
20 mg of GO - 4-Hydroxyacetanilide were dispersed in22 mL of MilliQ water, x of NaBH4 were added. 
The reaction was reflux (100° C) for 3 h, under stirring. After 3 h a UV spectrum was performed to 
confirm the reduction. 
The product rGO - 8-Hydroxyacetanilide was recovered by vacuum filtration on a polycarbonate 
membrane with 0.4 µm pores, washed with MilliQ water and dried on vacuum.  
Elemental analyses: N 0.56%, C 56.90%, H 1.78% 
Nitrogen loading degree: 0.04 mmol/100 mg of material 
UV-vis: the material was dispersed with difficulty in methanol, the identification of a clear peck was not 
possible.  
IR Spectrum (KBr): 3500 – 2500 (str. OH e str. NH), 1689 str. C=O, 1548-1514 (str. C=C), 1207 (str. C-O) 




Figure 176. IR spectrum of compound 109 
SYNTHESIS OF GO-4-Chloro-2-Nitro phenol 
 
80 mg of graphene oxide, 80 mg of 4-Chloro-2-Nitro phenol and 100 mg of NaCl were placed into a 10 
mL agate jar containing an agate sphere. The jar was put in a ball mill and subjected to mechanical 
stirring for 40 'at a frequency of 25 Hz. The product was recovered, dispersed in 80 mL of MilliQ water 
and divided into 4 50 mL Falcon tubes. It was centrifuged at 8000 rpm for 15 '. The process was repeated 
5 times using 2-propanol as solvent.  
The functionalized material was filtered on a polycarbonate membrane with 0.4 µm pores, then 
dispersed in 50 mL of water and freeze-dried 
Elemental analyses CHN: N 0.00 %, C 43.55 %, H 2.15 % 
Nitrogen loading degree: 0.00 mmol/100 mg of material 
UV-vis: the material was dispersed in MilliQ water to achieve a solution at 50 ppm, maximum 




Figure 177. UV spectrum of compound 110 
IR spectrum (KBr): 3600-3000 (str. OH), 1622 (str. C=C), 1240 (str. C-O), 1066 (str. C-OH) cm-1 
 
Figure 178. IR spectrum of compound 110 
SYNTHESIS OF GO-4-Chloro-2-Nitro phenol with Na2CO3 111 
 
80 mg of graphene oxide, 80 mg of 4-Chloro-2-nitro phenol, 100 mg of NaCl and 80 mg of Na2CO3 were 
placed into a 10 mL agate jar containing an agate sphere. The jar was put in a ball mill and subjected to 
mechanical stirring for 40 'at a frequency of 25 Hz. The product was recovered, dispersed in 80 mL of 
MilliQ water and divided into 4 50 mL Falcon tubes. It was centrifuged at 8000 rpm for 15 '. The process 
was repeated 5 times using a 2-propanol as solvent. 
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The product was finally filtered on a polycarbonate membrane with 0.4 µm pores, dispersed in 80 mL 
of MilliQ water and freeze-dried. 
Elemental analyses CHN: N 0.00 %, C 37.87 %, H 1.97 % 
Nitrogen loading degree: 0.00 mmol/100 mg of material 
UV-vis: the material was dispersed in MilliQ water to achieve a solution at 50 ppm, maximum absorption 
at 240 nm (GO). 
 
Figure 179. UV spectrum of compound 111 
IR spectrum (KBr): 3600-3000 (str. OH), 1631 (str. C=C), 1244 (str. C-O), 1072 (str. C-OH) cm-1 
 
Figure 180. IR spectrum of compound 111 




500 mg of ferrocene carboxhaldeyde (FcA) and 0.78 mL of ethylenediamine in 12.5 mL of anhydrous 
methanol were transferred into a 25 mL flask.  
An excess (880 mg) of NaBH4 was subsequently added to reduce the imine and the stirring was 
maintained for another 2 hours at room temperature. A control TLC was carried out to confirm the 
reaction occurred. 
Finally, 12.5 mL of HCl and 12.5 mL of H2O were added to the mixture and extracted with EtOAc (2 x 
12.5 mL) to remove the unreacted FcA. The aqueous phases were trited with a saturated solution of 
NaHCO3 and extracted with EtOAc three times (3 x 12.5 mL). The organic phase was dried over Na2SO4 
and the solvent was removed. 
The crude was purified by flash chromatographic column using as eluent first DCM: MeOH (9: 1) and 
then DCM: MeOH: NH3 (4: 1: 0.1). 
Yield: 413 mg (68%) of a yellow oil.  
The product was characterized by 1H NMR spectroscopy. 
 
1H NMR (200 MHz, CDCl3): δ 4.15 (m, 9 H, Ha, Hb, Hc), 3.53 (s, 2 H, Hd), 2.75 (m, 4 H, Hf, Hg ), 2.12 (s, 3 
He, Hh) ppm 
 
Figure 181. 1H spectrum of compound 100 
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SYNTHESIS OF GO-N-Ferrocenyl-1,2-diaminoethane 112 
 
80 mg of graphene oxide, 80 mg of 4-N-ferrocenyl-1,2-diaminoethane and 100 mg of NaCl were placed 
into a 10 mL agate jar containing an agate sphere. The jar was put in a ball mill and subjected to 
mechanical stirring for 40 'at a frequency of 25 Hz. The product was recovered and dispersed in 80 mL 
of slightly acid MilliQ water and divided into 4 50 mL Falcon tubes. It was centrifuged at 8000 rpm for 
15 '. The process was repeated 5 times using 2-propanol as solvent.  
The functionalized material was filtered on a polycarbonate membrane with 0.4 µm pores, then 
dispersed in 80 mL of water and freeze-dried 
Elemental analyses CHN: N 1.20 %, C 43.50 %, H 2.39 % 
Nitrogen loading degree: 0.04 mmol/100 mg of material 
ICP analyses: 0,02 µg/mg, Cr 0,08 µg/mg, Fe 33,82 µg/mg, S 40,1 µg/mg 
IR spectrum (KBr): 3600-3000 (str. OH e str. NH), 1620 (str. C=C), 1236 (str. C-O), 1066 (str. C-OH and 
stretching C-N) cm-1 
 






Hydrothermal reduction of GO-N-Ferrocenyl-1,2-diaminoethane 113 
 
14 mg of GO – N-Ferrocenyl-1,2-diaminoethane were dispersed in 20 mL of MilliQ water and the 
suspension was brought to pH 11 with the addition of 0.1 M NaOH water solution. The mixture was 
placed into an autoclave which was heated to 180 ° C for 6 h, under stirring. 
The product was recovered and finally filtered on a nylon membrane with 0.2 µm pores. The product 
was washed several times until neutral pH of washing water, then the material was freeze-dried. 
Elemental analyses: N 1.03 %, C 60.23 %, H 1.44 % 
Nitrogen loading degree: 0.04 mmol/100 mg of material 
IR spectrum (KBr): 3500-3000 (banda slargata relativa a str. OH e NH), 1570 (str. C=C), 1185-1082 (str. 
C-O sovrapposto a str. C-N) cm-1 
A reduction in the intensity of OH stretching was observed due to the reduction process. 
 







Chemical reduction of GO-N-Ferrocenyl-1,2-diamino ethane with NaBH4 114 
 
20 mg of GO – Ferrocenyl-1,2-diaminoethane were dispersed in22 mL of MilliQ water, x of NaBH4 were 
added. The reaction was reflux (100° C) for 3 h, under stirring. After 3 h a UV spectrum was performed 
to confirm the reduction. 
The product rGO - Ferrocenyl-1,2-diaminoethane was recovered by vacuum filtration on a 
polycarbonate membrane with 0.4 µm pores, washed with MilliQ water and dried on vacuum.  
Elemental analyses: N 1.41%, C 52.25%, H 2.82% 
Nitrogen loading degree: 0.05 mmol/100 mg of material 
UV-vis analysis of a 50 ppm suspension in MilliQ water: absorbance maximum at 260 nm (N-ferrocenyl-
1,2-diaminoethane molecule does not absorb in the UV, only the peak relative to the reduced GO was 
observed 
 
Figure 184. UV spectrum of compound 114 
IR spectrum (KBr): 3500-3000 (str. OH e NH), 1575 (str. C=C overlapped to a aend. N-H), 1220 (str. C-O 
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